[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fUzZLmoc83gvwWInKmpiceQ8LJXUmdo2KD6vAERfX6X8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":87,"rows":94},"Imperial College London",[4,6],"Imperial College London Diabetes Centre",839,false,158,30,2254153,43,598,[15,18,21,24,27,30,33,35],{"name":16,"count":17},"Asthma",39,{"name":19,"count":20},"Obesity",31,{"name":22,"count":23},"Heart Failure",22,{"name":25,"count":26},"COPD",18,{"name":28,"count":29},"Chronic Obstructive Pulmonary Disease",17,{"name":31,"count":32},"Breast Cancer",13,{"name":34,"count":32},"HIV",{"name":36,"count":37},"Healthy",11,[39,44,49,54,59,64,69,74,78,82],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03991780","Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection","2023-04-05","Fostamatinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05395195","Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)","2024-12-01","Erythropoietin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06515405","Effect of Early Hydrocortisone on Risk of Gastrointestinal Perforations in Extremely Preterm Infants","2024-12-30","Hydrocortisone",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT03850301","Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target","2025-01-31","XBD173",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT03416413","Study of Foam Sclerotherapy Versus Ambulatory Phlebectomy","2025-05-31","Foam sclerotherapy",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05318794","Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer","2025-07","Doxorubicin and Cisplatin",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06355583","Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial","2026-02-01","EBX-102",{"nctId":75,"briefTitle":76,"date":72,"intervention":77},"NCT05635344","A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia","Pembrolizumab",{"nctId":79,"briefTitle":80,"date":81,"intervention":58},"NCT07362290","TSPO Occupancy in the Human Lung","2026-02-02",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT07112352","Healthy Ageing: a Feasibility Study to Evaluate Digitally-enabled Ways to Support Healthy Ageing","2026-03-26","Smart devices with Personalised data feedback and habit coaching",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,146,168,186,204,222,240,271,296,319,394,439,476,500,525,550,575,599,626,654,681,708,731,756,790,816,841,867,885,903,926,972,1024,1056,1074,1100,1118,1136,1161,1186,1213,1238,1267,1293,1343,1384,1418,1446,1478,1502,1526,1544,1569,1593,1618,1645,1670,1688,1706,1734,1752,1777,1795,1820,1844,1870,1888,1906,1924,1950,1968,1986,2004,2027,2051,2078,2096,2114,2139,2166,2189,2207,2232,2256,2280,2306,2329,2347,2371,2397,2415,2433,2456,2484,2502,2520,2544,2562,2586,2604,2622,2648,2672,2690,2718,2751,2779,2797,2815,2833,2851,2876,2901,2919,2937,2963,2987,3012,3036,3054,3072,3098,3116,3134,3152,3176,3194,3212,3230,3254,3278,3304,3322,3348,3366,3384,3409,3433,3451,3474,3524,3557,3592,3623,3655,3673,3691,3709,3727,3751,3769,3793,3816,3840,3866,3884,3905,3928,3953,3979,3997,4021,4044,4062,4085,4120,4138,4166,4189,4212,4235,4258,4281,4304,4330,4348,4372,4390,4412,4435,4453,4478,4503,4525,4550,4573,4591,4609,4634,4652,4670,4693,4715,4738,4761,4783,4814,4832,4850,4868,4886,4904,4922,4945,4967,4985,5003,5027,5052,5075,5099,5126,5144,5168,5190,5213,5238,5267,5290,5308,5337,5355,5381,5399,5424,5442,5460,5478,5504,5522,5540,5563,5592,5610,5628,5646,5664,5682,5700,5724,5746,5769,5792,5815,5840,5858,5876,5894,5916,5938,5961,5979,6003,6021,6039,6057,6075,6093,6111,6135,6157,6180,6202,6228,6246,6264,6295,6319,6337,6355,6373,6397,6444,6497,6539,6584,6606,6635,6658,6681,6708,6734,6752,6774,6802,6827,6851,6880,6898,6916,6934,6959,6977,7000,7018,7047,7073,7096,7114,7144,7162,7180,7198,7216,7234,7252,7277,7303,7326,7344,7368,7386,7408,7431,7456,7481,7502,7528,7546,7564,7592,7610,7628,7646,7664,7682,7700,7718,7741,7763,7788,7811],{"intervention":96,"totalTrials":97,"cells":98},"Rivaroxaban",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":123,"NA":144},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":119},"NCT03996772","PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","COMPLETED",[91],"2024-05-31","2019-06-03",319,[117,118],"Atrial Fibrillation","Intracerebral Hemorrhage",[120,121,122,96],"Apixaban Oral","Dabigatran","Edoxaban",{"trials":124,"activeCount":143,"soonestReadout":130},[125],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":137},"NCT05735639","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","RECRUITING",[92],"2027-06-30","2027-12-31","2024-01-22",6660,[135,136],"Venous Thromboembolism","Varicose Veins",[138,139,140,96,141,142],"Dalteparin Sodium","Tinzaparin Sodium","Enoxaparin Sodium","Apixaban","Dabigatran Etexilate",1,{"trials":145,"activeCount":101},[],{"intervention":141,"totalTrials":97,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":160,"NA":166},{"trials":149,"activeCount":101},[],{"trials":151,"activeCount":101},[],{"trials":153,"activeCount":101},[],{"trials":155,"activeCount":101},[156],{"nctId":109,"briefTitle":110,"status":111,"phases":157,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":158,"interventions":159},[91],[117,118],[120,121,122,96],{"trials":161,"activeCount":143,"soonestReadout":130},[162],{"nctId":126,"briefTitle":127,"status":128,"phases":163,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":164,"interventions":165},[92],[135,136],[138,139,140,96,141,142],{"trials":167,"activeCount":101},[],{"intervention":138,"totalTrials":143,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":184},{"trials":171,"activeCount":101},[],{"trials":173,"activeCount":101},[],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":143,"soonestReadout":130},[180],{"nctId":126,"briefTitle":127,"status":128,"phases":181,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":182,"interventions":183},[92],[135,136],[138,139,140,96,141,142],{"trials":185,"activeCount":101},[],{"intervention":139,"totalTrials":143,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":202},{"trials":189,"activeCount":101},[],{"trials":191,"activeCount":101},[],{"trials":193,"activeCount":101},[],{"trials":195,"activeCount":101},[],{"trials":197,"activeCount":143,"soonestReadout":130},[198],{"nctId":126,"briefTitle":127,"status":128,"phases":199,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":200,"interventions":201},[92],[135,136],[138,139,140,96,141,142],{"trials":203,"activeCount":101},[],{"intervention":140,"totalTrials":143,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":220},{"trials":207,"activeCount":101},[],{"trials":209,"activeCount":101},[],{"trials":211,"activeCount":101},[],{"trials":213,"activeCount":101},[],{"trials":215,"activeCount":143,"soonestReadout":130},[216],{"nctId":126,"briefTitle":127,"status":128,"phases":217,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":218,"interventions":219},[92],[135,136],[138,139,140,96,141,142],{"trials":221,"activeCount":101},[],{"intervention":142,"totalTrials":143,"cells":223},{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":230,"PHASE4":232,"NA":238},{"trials":225,"activeCount":101},[],{"trials":227,"activeCount":101},[],{"trials":229,"activeCount":101},[],{"trials":231,"activeCount":101},[],{"trials":233,"activeCount":143,"soonestReadout":130},[234],{"nctId":126,"briefTitle":127,"status":128,"phases":235,"primaryCompletion":130,"completion":131,"start":132,"enrollment":133,"conditions":236,"interventions":237},[92],[135,136],[138,139,140,96,141,142],{"trials":239,"activeCount":101},[],{"intervention":63,"totalTrials":97,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":259},{"trials":243,"activeCount":101},[],{"trials":245,"activeCount":101},[],{"trials":247,"activeCount":101},[],{"trials":249,"activeCount":101},[],{"trials":251,"activeCount":143,"soonestReadout":62},[252],{"nctId":60,"briefTitle":61,"status":128,"phases":253,"primaryCompletion":62,"completion":254,"start":255,"enrollment":256,"conditions":257,"interventions":258},[92],"2025-06-30","2018-02-01",160,[136],[63],{"trials":260,"activeCount":101},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":270},"NCT02557542","Pilot RCT Evaluating a One Stop Vein Clinic","TERMINATED",[93],"2021-03","2015-10",3,[136],[63],{"intervention":272,"totalTrials":143,"cells":273},"Pembrolizumab 25 MG\u002FML [Keytruda]",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":292,"NA":294},{"trials":275,"activeCount":101},[],{"trials":277,"activeCount":101},[],{"trials":279,"activeCount":101},[],{"trials":281,"activeCount":143,"soonestReadout":286},[282],{"nctId":283,"briefTitle":284,"status":128,"phases":285,"primaryCompletion":286,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":291},"NCT05085028","A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)",[91],"2027-05-31","2022-06-23",1750,[290],"Lung Cancer, Nonsmall Cell",[272],{"trials":293,"activeCount":101},[],{"trials":295,"activeCount":101},[],{"intervention":48,"totalTrials":143,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":315,"NA":317},{"trials":299,"activeCount":101},[],{"trials":301,"activeCount":101},[],{"trials":303,"activeCount":101},[],{"trials":305,"activeCount":143,"soonestReadout":47},[306],{"nctId":45,"briefTitle":46,"status":128,"phases":307,"primaryCompletion":47,"completion":308,"start":309,"enrollment":310,"conditions":311,"interventions":314},[91],"2026-12-01","2022-12-31",504,[312,48,313],"Encephalopathy","Newborn Asphyxia",[48],{"trials":316,"activeCount":101},[],{"trials":318,"activeCount":101},[],{"intervention":58,"totalTrials":320,"cells":321},6,{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":323,"activeCount":101},[],{"trials":325,"activeCount":101},[],{"trials":327,"activeCount":143,"soonestReadout":333},[328],{"nctId":329,"briefTitle":330,"status":331,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT07191821","TSPO Modulation in AD","ENROLLING_BY_INVITATION",[90],"2027-03-01","2027-06-01","2025-08-08",51,[338],"Alzheimer s Disease",[58],{"trials":341,"activeCount":101},[],{"trials":343,"activeCount":101},[],{"trials":345,"activeCount":393,"soonestReadout":57},[346,354,364,375,383],{"nctId":55,"briefTitle":56,"status":128,"phases":347,"primaryCompletion":57,"completion":57,"start":348,"enrollment":349,"conditions":350,"interventions":352},[93],"2018-01-01",44,[351],"Multiple Sclerosis",[58,353],"Etifoxine",{"nctId":355,"briefTitle":356,"status":128,"phases":357,"primaryCompletion":358,"completion":358,"start":359,"enrollment":360,"conditions":361,"interventions":363},"NCT06643013","Targeting 18kDa Translocator Protein (TSPO) to Improve Brain Endothelial Cell Function in Cerebral Small Vessel Disease",[93],"2028-04","2024-10",106,[362],"Cerebral Small Vessel Disease",[58],{"nctId":365,"briefTitle":366,"status":367,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":101,"conditions":372,"interventions":374},"NCT02086240","Reproducibility of the 11C-PBR28 PET Signal","WITHDRAWN",[93],"2018-01","2018-05","2014-03",[373],"Neurodegenerative Disorders",[58],{"nctId":79,"briefTitle":80,"status":331,"phases":376,"primaryCompletion":81,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},[93],"2027-03-31","2025-09-19",16,[381],"Healthy Volunteers - Male and Female",[58],{"nctId":384,"briefTitle":385,"status":386,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":320,"conditions":390,"interventions":392},"NCT06035861","Endothelial Cell Activation and Total Pulmonary Resistance in PAH","NOT_YET_RECRUITING",[93],"2026-10-31","2026-08-01",[391],"Pulmonary Artery Hypertension",[58],4,{"intervention":77,"totalTrials":268,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":397,"activeCount":101},[],{"trials":399,"activeCount":101},[],{"trials":401,"activeCount":143,"soonestReadout":72},[402,414,423],{"nctId":403,"briefTitle":404,"status":111,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT03397654","Study of Pembrolizumab Following TACE in Primary Liver Carcinoma",[89,90],"2023-02-01","2023-03-23","2018-01-28",26,[411],"Primary Liver Carcinoma",[77,413],"Trans-arterial chemoembolization",{"nctId":75,"briefTitle":76,"status":128,"phases":415,"primaryCompletion":72,"completion":389,"start":416,"enrollment":417,"conditions":418,"interventions":422},[90],"2024-02-14",20,[419,420,421],"Gestational Trophoblastic Disease","Gestational Trophoblastic Neoplasia","Gestational Trophoblastic Tumor, Recurrent",[77],{"nctId":424,"briefTitle":425,"status":111,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":429,"conditions":430,"interventions":432},"NCT03752333","Trial of Pembrolizumab in Cancer of Unknown Primary",[90],"2025-03-31","2019-02-22",35,[431],"Cancer of Unknown Primary Site",[77],{"trials":434,"activeCount":101},[],{"trials":436,"activeCount":101},[],{"trials":438,"activeCount":101},[],{"intervention":43,"totalTrials":97,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":442,"activeCount":101},[],{"trials":444,"activeCount":101},[],{"trials":446,"activeCount":143,"soonestReadout":42},[447,456],{"nctId":40,"briefTitle":41,"status":448,"phases":449,"primaryCompletion":42,"completion":450,"start":451,"enrollment":452,"conditions":453,"interventions":455},"ACTIVE_NOT_RECRUITING",[89,90],"2025-10-15","2019-05-08",8,[454],"Renal Transplant Rejection",[43],{"nctId":457,"briefTitle":458,"status":111,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":468},"NCT04581954","Inflammatory Signal Inhibitors for COVID-19 (MATIS)",[89,90],"2022-11-30","2023-09-02","2020-10-02",185,[465,466,467],"Coronavirus","Covid19","Pneumonia",[469,43],"Ruxolitinib",{"trials":471,"activeCount":101},[],{"trials":473,"activeCount":101},[],{"trials":475,"activeCount":101},[],{"intervention":86,"totalTrials":143,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":494,"PHASE4":496,"NA":498},{"trials":479,"activeCount":101},[],{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":143,"soonestReadout":85},[484],{"nctId":83,"briefTitle":84,"status":448,"phases":485,"primaryCompletion":85,"completion":486,"start":487,"enrollment":10,"conditions":488,"interventions":493},[90],"2026-04","2025-07-28",[489,490,491,492],"Frailty","Older Adults (65 Years and Older)","Digital Health Intervention","Feasibility Studies",[86],{"trials":495,"activeCount":101},[],{"trials":497,"activeCount":101},[],{"trials":499,"activeCount":101},[],{"intervention":501,"totalTrials":143,"cells":502},"Maralixibat",{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":504,"activeCount":101},[],{"trials":506,"activeCount":101},[],{"trials":508,"activeCount":143,"soonestReadout":513},[509],{"nctId":510,"briefTitle":511,"status":386,"phases":512,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT07389031","Maralixibat for Intrahepatic Cholestasis of Pregnancy",[90],"2028-03-31","2026-04-01",28,[517],"Intrahepatic Cholestasis of Pregnancy",[501],{"trials":520,"activeCount":101},[],{"trials":522,"activeCount":101},[],{"trials":524,"activeCount":101},[],{"intervention":526,"totalTrials":143,"cells":527},"tadalafil",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":529,"activeCount":101},[],{"trials":531,"activeCount":101},[],{"trials":533,"activeCount":143,"soonestReadout":538},[534],{"nctId":535,"briefTitle":536,"status":386,"phases":537,"primaryCompletion":538,"completion":538,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT07172815","PDE5 Inhibitor for Alzheimer's Disease",[90],"2028-08","2025-09",244,[542],"Alzheimer Disease",[526],{"trials":545,"activeCount":101},[],{"trials":547,"activeCount":101},[],{"trials":549,"activeCount":101},[],{"intervention":551,"totalTrials":143,"cells":552},"Tezepelumab",{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":557,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":554,"activeCount":101},[],{"trials":556,"activeCount":101},[],{"trials":558,"activeCount":143,"soonestReadout":563},[559],{"nctId":560,"briefTitle":561,"status":448,"phases":562,"primaryCompletion":563,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":568},"NCT06230354","Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis",[90],"2026-09","2024-05-15",42,[567],"EGPA - Eosinophilic Granulomatosis With Polyangiitis",[551],{"trials":570,"activeCount":101},[],{"trials":572,"activeCount":101},[],{"trials":574,"activeCount":101},[],{"intervention":576,"totalTrials":143,"cells":577},"Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":101},[],{"trials":583,"activeCount":143,"soonestReadout":588},[584],{"nctId":585,"briefTitle":586,"status":448,"phases":587,"primaryCompletion":588,"completion":588,"start":589,"enrollment":417,"conditions":590,"interventions":592},"NCT06232564","A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs",[90],"2027-10-15","2024-07-08",[591],"Neuroendocrine Tumors",[576],{"trials":594,"activeCount":101},[],{"trials":596,"activeCount":101},[],{"trials":598,"activeCount":101},[],{"intervention":73,"totalTrials":143,"cells":600},{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":602,"activeCount":101},[],{"trials":604,"activeCount":101},[],{"trials":606,"activeCount":143,"soonestReadout":72},[607],{"nctId":70,"briefTitle":71,"status":128,"phases":608,"primaryCompletion":72,"completion":609,"start":610,"enrollment":611,"conditions":612,"interventions":619},[90],"2027-05-01","2024-05-01",50,[613,614,615,616,617,618],"Acute Lymphoblastic Leukaemia","Acute Leukemia of Ambiguous Lineage","Chronic Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome","Acute Myeloid Leukemia",[73],{"trials":621,"activeCount":101},[],{"trials":623,"activeCount":101},[],{"trials":625,"activeCount":101},[],{"intervention":627,"totalTrials":143,"cells":628},"FINGER 2.0 multidomain lifestyle-based intervention",{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":633,"PHASE3":648,"PHASE4":650,"NA":652},{"trials":630,"activeCount":101},[],{"trials":632,"activeCount":101},[],{"trials":634,"activeCount":143,"soonestReadout":639},[635],{"nctId":636,"briefTitle":637,"status":128,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":647},"NCT05109169","METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for Dementia",[90],"2027-02-28","2027-06-28","2023-01-25",600,[644,645,646],"Cognitive Decline","Cognitive Impairment","Dementia",[627],{"trials":649,"activeCount":101},[],{"trials":651,"activeCount":101},[],{"trials":653,"activeCount":101},[],{"intervention":655,"totalTrials":143,"cells":656},"Modafinil",{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":658,"activeCount":101},[],{"trials":660,"activeCount":101},[],{"trials":662,"activeCount":143,"soonestReadout":667},[663],{"nctId":664,"briefTitle":665,"status":386,"phases":666,"primaryCompletion":667,"completion":668,"start":72,"enrollment":669,"conditions":670,"interventions":674},"NCT07295834","Modafinil For Fatigue in IBD: A Feasibility Randomised Controlled Trial",[90],"2027-12-01","2028-02-01",70,[671,672,673],"Crohn Disease (CD)","Ulcerative Colitis (UC)","Fatigue",[655],{"trials":676,"activeCount":101},[],{"trials":678,"activeCount":101},[],{"trials":680,"activeCount":101},[],{"intervention":682,"totalTrials":143,"cells":683},"Standard of Care",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":685,"activeCount":101},[],{"trials":687,"activeCount":101},[],{"trials":689,"activeCount":143,"soonestReadout":694},[690],{"nctId":691,"briefTitle":692,"status":448,"phases":693,"primaryCompletion":694,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":701},"NCT03763253","Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms",[90],"2026-08-31","2027-01-31","2019-04-10",433,[699,700],"Prostate Cancer","Metastatic Prostate Cancer",[682],{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[],{"intervention":68,"totalTrials":143,"cells":709},{"EARLY_PHASE1":710,"PHASE1":712,"PHASE2":714,"PHASE3":725,"PHASE4":727,"NA":729},{"trials":711,"activeCount":101},[],{"trials":713,"activeCount":101},[],{"trials":715,"activeCount":143,"soonestReadout":67},[716],{"nctId":65,"briefTitle":66,"status":386,"phases":717,"primaryCompletion":67,"completion":718,"start":719,"enrollment":417,"conditions":720,"interventions":724},[90],"2030-07","2023-11",[721,722,723],"Gastric Cancer","Peritoneal Metastases","Chemotherapy Effect",[68],{"trials":726,"activeCount":101},[],{"trials":728,"activeCount":101},[],{"trials":730,"activeCount":101},[],{"intervention":732,"totalTrials":143,"cells":733},"Investigational Medicinal Product",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":735,"activeCount":101},[],{"trials":737,"activeCount":101},[],{"trials":739,"activeCount":143,"soonestReadout":744},[740],{"nctId":741,"briefTitle":742,"status":128,"phases":743,"primaryCompletion":744,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":749},"NCT04319367","A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs).",[90],"2027-07-31","2021-05-17",72,[748],"HIV\u002FAIDS and Infections",[732],{"trials":751,"activeCount":101},[],{"trials":753,"activeCount":101},[],{"trials":755,"activeCount":101},[],{"intervention":757,"totalTrials":97,"cells":758},"Semaglutide",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":760,"activeCount":101},[],{"trials":762,"activeCount":101},[],{"trials":764,"activeCount":143,"soonestReadout":131},[765],{"nctId":766,"briefTitle":767,"status":386,"phases":768,"primaryCompletion":131,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT07200622","Oral Semaglutide in Patients With Alzheimer's Disease",[90],"2028-12-31","2025-09-25",60,[542],[757],{"trials":775,"activeCount":101},[],{"trials":777,"activeCount":101},[],{"trials":779,"activeCount":101},[780],{"nctId":781,"briefTitle":782,"status":111,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":26,"conditions":787,"interventions":789},"NCT06118203","Semaglutide Use in Acute Pulmonary Embolism",[],"2023-03-04","2023-03-05","2022-01-02",[788],"Pulmonary Embolism",[757],{"intervention":791,"totalTrials":143,"cells":792},"Dostarlimab in Combination Antiretroviral Therapy",{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":808,"PHASE3":810,"PHASE4":812,"NA":814},{"trials":794,"activeCount":101},[],{"trials":796,"activeCount":143,"soonestReadout":801},[797],{"nctId":798,"briefTitle":799,"status":448,"phases":800,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT05646082","Preliminary Assessment of Safety and Tolerability of Dostarlimab in Combination Antiretroviral Therapy (cART) Refractory HIV Associated Kaposi Sarcoma",[89],"2026-07-30","2026-12-31","2023-05-26",15,[806],"Refractory HIV Associated Kaposi Sarcoma",[791],{"trials":809,"activeCount":101},[],{"trials":811,"activeCount":101},[],{"trials":813,"activeCount":101},[],{"trials":815,"activeCount":101},[],{"intervention":817,"totalTrials":143,"cells":818},"ASTX727",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":820,"activeCount":101},[],{"trials":822,"activeCount":143,"soonestReadout":827},[823],{"nctId":824,"briefTitle":825,"status":128,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT05178693","Lutathera and ASTX727 in Neuroendocrine Tumours",[89],"2026-06-30","2029-02-28","2022-04-25",27,[591],[817],{"trials":834,"activeCount":101},[],{"trials":836,"activeCount":101},[],{"trials":838,"activeCount":101},[],{"trials":840,"activeCount":101},[],{"intervention":842,"totalTrials":143,"cells":843},"SARS-CoV-2 Omicron EG.5.1 challenge agent 10^5 TCID50",{"EARLY_PHASE1":844,"PHASE1":846,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":845,"activeCount":101},[],{"trials":847,"activeCount":143,"soonestReadout":131},[848],{"nctId":849,"briefTitle":850,"status":386,"phases":851,"primaryCompletion":131,"completion":769,"start":852,"enrollment":853,"conditions":854,"interventions":856},"NCT07397455","Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants",[89],"2026-06-01",38,[855],"SARS-CoV-2 (COVID-19)",[842,857,858],"SARS-CoV-2 Omicron EG.5.1 challenge agent 10^6 TCID50","SARS-CoV-2 Omicron EG.5.1 challenge agent 10^4 TCID50",{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":101},[],{"trials":866,"activeCount":101},[],{"intervention":857,"totalTrials":143,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":877,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":143,"soonestReadout":131},[873],{"nctId":849,"briefTitle":850,"status":386,"phases":874,"primaryCompletion":131,"completion":769,"start":852,"enrollment":853,"conditions":875,"interventions":876},[89],[855],[842,857,858],{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":101},[],{"trials":884,"activeCount":101},[],{"intervention":858,"totalTrials":143,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":888,"activeCount":101},[],{"trials":890,"activeCount":143,"soonestReadout":131},[891],{"nctId":849,"briefTitle":850,"status":386,"phases":892,"primaryCompletion":131,"completion":769,"start":852,"enrollment":853,"conditions":893,"interventions":894},[89],[855],[842,857,858],{"trials":896,"activeCount":101},[],{"trials":898,"activeCount":101},[],{"trials":900,"activeCount":101},[],{"trials":902,"activeCount":101},[],{"intervention":904,"totalTrials":143,"cells":905},"Psilocybin 5 mg with cognitive behavioural therapy intervention",{"EARLY_PHASE1":906,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":907,"activeCount":143,"soonestReadout":694},[908],{"nctId":909,"briefTitle":910,"status":128,"phases":911,"primaryCompletion":694,"completion":388,"start":912,"enrollment":10,"conditions":913,"interventions":915},"NCT06798636","PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm",[88],"2025-10-01",[914],"Self Harm",[904],{"trials":917,"activeCount":101},[],{"trials":919,"activeCount":101},[],{"trials":921,"activeCount":101},[],{"trials":923,"activeCount":101},[],{"trials":925,"activeCount":101},[],{"intervention":927,"totalTrials":268,"cells":928},"Metformin",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":945,"PHASE4":947,"NA":960},{"trials":930,"activeCount":101},[],{"trials":932,"activeCount":101},[],{"trials":934,"activeCount":101},[935],{"nctId":936,"briefTitle":937,"status":111,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":944},"NCT03651895","Metformin to Reduce Airway Glucose in COPD Patients",[90],"2023-05-31","2023-06-01","2022-05-17",14,[28],[927],{"trials":946,"activeCount":101},[],{"trials":948,"activeCount":101},[949],{"nctId":950,"briefTitle":951,"status":952,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":956,"conditions":957,"interventions":959},"NCT02394158","Preventing Recurrent Gestational Diabetes With Metformin","UNKNOWN",[92],"2019-09-30","2015-01-27",112,[958],"Gestational Diabetes Mellitus",[927],{"trials":961,"activeCount":143,"soonestReadout":334},[962],{"nctId":963,"briefTitle":964,"status":128,"phases":965,"primaryCompletion":334,"completion":334,"start":564,"enrollment":771,"conditions":966,"interventions":969},"NCT06318442","The GAPSID Study - How GLP-1 Analogues Prevent Steroid-Induced Diabetes",[93],[967,968],"Steroid-Induced Diabetes","Steroid Induced Hyperglycemia",[970,971],"Semaglutide Oral Product","Metformin Oral",{"intervention":973,"totalTrials":268,"cells":974},"Rituximab",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":1009,"NA":1011},{"trials":976,"activeCount":101},[],{"trials":978,"activeCount":101},[],{"trials":980,"activeCount":101},[],{"trials":982,"activeCount":101},[983,996],{"nctId":984,"briefTitle":985,"status":264,"phases":986,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT01773616","Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis",[91],"2017-12","2015-04",24,[991],"Systemic Lupus Erythematosus, Lupus Nephritis",[993,973,994,995],"Oral prednisolone","Mycophenolate mofetil","Methyl prednisolone",{"nctId":997,"briefTitle":998,"status":264,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":268,"conditions":1003,"interventions":1006},"NCT03994783","Transplant Antibody-Mediated Rejection: Guiding Effective Treatments",[91],"2021-07-17","2023-01-09","2019-07-17",[1004,1005],"Kidney Transplant Rejection","Antibody-mediated Rejection",[973,1007,1008],"Methylprednisolone","Intravenous Immunoglobulin",{"trials":1010,"activeCount":101},[],{"trials":1012,"activeCount":143,"soonestReadout":1017},[1013],{"nctId":1014,"briefTitle":1015,"status":386,"phases":1016,"primaryCompletion":1017,"completion":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1023},"NCT04496037","Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant",[],"2027-07-01","2028-08-31","2020-09-01",170,[1022],"Transplant; Complication, Rejection",[973],{"intervention":53,"totalTrials":97,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1044,"NA":1046},{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":101},[],{"trials":1033,"activeCount":101},[1034],{"nctId":1035,"briefTitle":1036,"status":952,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":349,"conditions":1040,"interventions":1042},"NCT03936517","Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)",[91],"2025-02-01","2019-07-31",[1041],"Adrenal Insufficiency",[1043,53],"Prednisolone",{"trials":1045,"activeCount":101},[],{"trials":1047,"activeCount":143,"soonestReadout":52},[1048],{"nctId":50,"briefTitle":51,"status":448,"phases":1049,"primaryCompletion":52,"completion":1050,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1055},[],"2025-08-30","2024-07-30",16000,[1054],"Intestinal Perforation",[53],{"intervention":970,"totalTrials":143,"cells":1057},{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1059,"activeCount":101},[],{"trials":1061,"activeCount":101},[],{"trials":1063,"activeCount":101},[],{"trials":1065,"activeCount":101},[],{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":143,"soonestReadout":334},[1070],{"nctId":963,"briefTitle":964,"status":128,"phases":1071,"primaryCompletion":334,"completion":334,"start":564,"enrollment":771,"conditions":1072,"interventions":1073},[93],[967,968],[970,971],{"intervention":1075,"totalTrials":143,"cells":1076},"FLUENZ",{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1078,"activeCount":101},[],{"trials":1080,"activeCount":101},[],{"trials":1082,"activeCount":101},[],{"trials":1084,"activeCount":101},[],{"trials":1086,"activeCount":101},[],{"trials":1088,"activeCount":143,"soonestReadout":1093},[1089],{"nctId":1090,"briefTitle":1091,"status":128,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT06620185","GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE",[93],"2026-07-31","2025-04-16",36,[1097],"Influenza",[1075,1099],"Influenza challenge virus",{"intervention":1099,"totalTrials":143,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[],{"trials":1107,"activeCount":101},[],{"trials":1109,"activeCount":101},[],{"trials":1111,"activeCount":101},[],{"trials":1113,"activeCount":143,"soonestReadout":1093},[1114],{"nctId":1090,"briefTitle":1091,"status":128,"phases":1115,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1116,"interventions":1117},[93],[1097],[1075,1099],{"intervention":353,"totalTrials":143,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"trials":1125,"activeCount":101},[],{"trials":1127,"activeCount":101},[],{"trials":1129,"activeCount":101},[],{"trials":1131,"activeCount":143,"soonestReadout":57},[1132],{"nctId":55,"briefTitle":56,"status":128,"phases":1133,"primaryCompletion":57,"completion":57,"start":348,"enrollment":349,"conditions":1134,"interventions":1135},[93],[351],[58,353],{"intervention":1137,"totalTrials":143,"cells":1138},"Bisoprolol 2.5 mg",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1140,"activeCount":101},[],{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[],{"trials":1146,"activeCount":101},[],{"trials":1148,"activeCount":101},[],{"trials":1150,"activeCount":143,"soonestReadout":1155},[1151],{"nctId":1152,"briefTitle":1153,"status":128,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":1157,"conditions":1158,"interventions":1160},"NCT07029906","pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure",[93],"2027-12","2025-04-29",150,[1159,22],"Side-Effect",[1137],{"intervention":1162,"totalTrials":143,"cells":1163},"Rhinovirus-A16",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1165,"activeCount":101},[],{"trials":1167,"activeCount":101},[],{"trials":1169,"activeCount":101},[],{"trials":1171,"activeCount":101},[],{"trials":1173,"activeCount":101},[],{"trials":1175,"activeCount":143,"soonestReadout":377},[1176],{"nctId":1177,"briefTitle":1178,"status":128,"phases":1179,"primaryCompletion":377,"completion":377,"start":1180,"enrollment":611,"conditions":1181,"interventions":1185},"NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets",[],"2025-10-08",[1182,1183,1184],"COPD (Chronic Obstructive Pulmonary Disease)","Rhinovirus Infection","Exacerbation of COPD",[1162],{"intervention":1187,"totalTrials":143,"cells":1188},"Research genetic analysis",{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1199},{"trials":1190,"activeCount":101},[],{"trials":1192,"activeCount":101},[],{"trials":1194,"activeCount":101},[],{"trials":1196,"activeCount":101},[],{"trials":1198,"activeCount":101},[],{"trials":1200,"activeCount":143,"soonestReadout":1205},[1201],{"nctId":1202,"briefTitle":1203,"status":128,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1212},"NCT04612296","The Heart Hive - Cardiomyopathy Study",[],"2026-10-01","2027-09","2019-11-09",10000,[1210,1211],"Cardiomyopathies","Myocarditis",[1187],{"intervention":1214,"totalTrials":143,"cells":1215},"Pimonidazole hydrochloride",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1226},{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":101},[],{"trials":1221,"activeCount":101},[],{"trials":1223,"activeCount":101},[],{"trials":1225,"activeCount":101},[],{"trials":1227,"activeCount":143,"soonestReadout":1232},[1228],{"nctId":1229,"briefTitle":1230,"status":128,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},"NCT06669663","Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma",[],"2028-08-01","2024-09-01",120,[1236],"OESOPHAGO-GASTRIC CARCINOMA",[1214],{"intervention":1239,"totalTrials":143,"cells":1240},"Rhinovirus A-16 Infection",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1242,"activeCount":101},[],{"trials":1244,"activeCount":101},[],{"trials":1246,"activeCount":101},[],{"trials":1248,"activeCount":101},[],{"trials":1250,"activeCount":101},[],{"trials":1252,"activeCount":143,"soonestReadout":1257},[1253],{"nctId":1254,"briefTitle":1255,"status":128,"phases":1256,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1266},"NCT06931002","A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis",[93],"2027-04-01","2027-10-30","2024-07-24",54,[1262,1263,1264,1265,1183],"Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation","Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa","Viral Infection",[1239],{"intervention":1268,"totalTrials":143,"cells":1269},"Other",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":101},[],{"trials":1281,"activeCount":143,"soonestReadout":1286},[1282],{"nctId":1283,"briefTitle":1284,"status":128,"phases":1285,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":611,"conditions":1289,"interventions":1292},"NCT06091475","Therapy to Maintain Remission in Dilated Cardiomyopathy",[93],"2026-08-15","2026-09-15","2023-12-02",[22,1290,1210,1291],"Cardiomyopathy, Dilated","Heart Diseases",[1268],{"intervention":1294,"totalTrials":268,"cells":1295},"Raltegravir",{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1311,"PHASE3":1326,"PHASE4":1328,"NA":1341},{"trials":1297,"activeCount":101},[],{"trials":1299,"activeCount":101},[1300],{"nctId":1301,"briefTitle":1302,"status":111,"phases":1303,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":942,"conditions":1307,"interventions":1309},"NCT00982553","The Raltegravir and Ribavirin Pharmacokinetics (PK) Study",[89],"2009-11","2009-12","2009-09",[1308],"HIV Infections",[1310,1294],"Ribavirin",{"trials":1312,"activeCount":101},[1313],{"nctId":1314,"briefTitle":1315,"status":111,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":771,"conditions":1320,"interventions":1321},"NCT02336074","Research In Viral Eradication of HIV Reservoirs",[90],"2017-11-15","2023-03-31","2015-11-27",[34],[1322,1294,1323,1324,1325],"Combination Antiretroviral Therapy","Vorinostat","ChAdV63.HIVconsv","MVA.HIVconsv",{"trials":1327,"activeCount":101},[],{"trials":1329,"activeCount":101},[1330],{"nctId":1331,"briefTitle":1332,"status":111,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1338},"NCT01335620","The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age",[92],"2012-12","2011-04",19,[34],[1294,1339,1340],"Tenofovir","Emtricitabine",{"trials":1342,"activeCount":101},[],{"intervention":1344,"totalTrials":268,"cells":1345},"Maraviroc",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1369,"PHASE3":1371,"PHASE4":1373,"NA":1382},{"trials":1347,"activeCount":101},[],{"trials":1349,"activeCount":101},[1350,1358],{"nctId":1351,"briefTitle":1352,"status":111,"phases":1353,"primaryCompletion":1354,"completion":1355,"start":1306,"enrollment":32,"conditions":1356,"interventions":1357},"NCT00982878","The Maraviroc Central Nervous System (CNS) Study",[89],"2010-07","2011-02",[1308],[1344],{"nctId":1359,"briefTitle":1360,"status":111,"phases":1361,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":32,"conditions":1365,"interventions":1366},"NCT01348763","The Maraviroc Darunavir\u002FRitonavir Once Daily Pharmacokinetic Study",[89],"2012-02","2012-05","2011-10",[34],[1344,1367,1368],"Truvada","Darunavir",{"trials":1370,"activeCount":101},[],{"trials":1372,"activeCount":101},[],{"trials":1374,"activeCount":101},[1375],{"nctId":1376,"briefTitle":1377,"status":264,"phases":1378,"primaryCompletion":1379,"completion":1379,"start":1306,"enrollment":26,"conditions":1380,"interventions":1381},"NCT00981773","The St. Marys and The Mater Switch Study",[92],"2013-03",[1308],[1344,1344],{"trials":1383,"activeCount":101},[],{"intervention":1385,"totalTrials":97,"cells":1386},"Live attenuated influenza vaccine",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1416},{"trials":1388,"activeCount":101},[],{"trials":1390,"activeCount":101},[],{"trials":1392,"activeCount":101},[],{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[1397,1406],{"nctId":1398,"briefTitle":1399,"status":111,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":267,"enrollment":1402,"conditions":1403,"interventions":1405},"NCT02549365","Efficacy & Safety of Nasal Influenza Immunisation in Children",[92],"2016-04",276,[1404],"Influenza Vaccines Efficacy and Safety",[1385],{"nctId":1407,"briefTitle":1408,"status":111,"phases":1409,"primaryCompletion":1410,"completion":1410,"start":1411,"enrollment":1412,"conditions":1413,"interventions":1415},"NCT03735147","Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children",[92],"2019-04-01","2018-10-23",12,[1414],"Influenza Vaccines",[1385],{"trials":1417,"activeCount":101},[],{"intervention":1419,"totalTrials":97,"cells":1420},"prednisolone",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1433,"NA":1444},{"trials":1422,"activeCount":101},[],{"trials":1424,"activeCount":101},[],{"trials":1426,"activeCount":101},[],{"trials":1428,"activeCount":101},[1429],{"nctId":1035,"briefTitle":1036,"status":952,"phases":1430,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":349,"conditions":1431,"interventions":1432},[91],[1041],[1043,53],{"trials":1434,"activeCount":101},[1435],{"nctId":1436,"briefTitle":1437,"status":111,"phases":1438,"primaryCompletion":1439,"completion":1439,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1443},"NCT00662298","Prednisolone Pharmacokinetics in Severe Asthma",[92],"2013-01","2011-06",5,[16],[1419],{"trials":1445,"activeCount":101},[],{"intervention":1447,"totalTrials":97,"cells":1448},"Celecoxib",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1466,"NA":1476},{"trials":1450,"activeCount":101},[],{"trials":1452,"activeCount":101},[],{"trials":1454,"activeCount":101},[],{"trials":1456,"activeCount":101},[1457],{"nctId":1458,"briefTitle":1459,"status":111,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1465},"NCT02429427","European Celecoxib Trial in Primary Breast Cancer",[91],"2019-03","2005-12",2639,[31],[1447],{"trials":1467,"activeCount":101},[1468],{"nctId":1469,"briefTitle":1470,"status":111,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":349,"conditions":1474,"interventions":1475},"NCT04765644","Arginine Supplementation to Improve Cardiovascular and Endothelial Function After NSAID Treatment",[92],"2022-01-24","2021-06-10",[36],[1447],{"trials":1477,"activeCount":101},[],{"intervention":1479,"totalTrials":143,"cells":1480},"cyclodextrin",{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1487,"PHASE4":1489,"NA":1500},{"trials":1482,"activeCount":101},[],{"trials":1484,"activeCount":101},[],{"trials":1486,"activeCount":101},[],{"trials":1488,"activeCount":101},[],{"trials":1490,"activeCount":101},[1491],{"nctId":1492,"briefTitle":1493,"status":367,"phases":1494,"primaryCompletion":1495,"completion":987,"start":1496,"enrollment":101,"conditions":1497,"interventions":1499},"NCT01960621","Effect of Cyclodextrin on Sensory Nerve Activity: A Novel Anti-tussive Therapy",[92],"2017-08","2016-08",[1498],"Cough",[1479],{"trials":1501,"activeCount":101},[],{"intervention":1503,"totalTrials":143,"cells":1504},"nevirapine",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1524},{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":101},[1515],{"nctId":1516,"briefTitle":1517,"status":111,"phases":1518,"primaryCompletion":1334,"completion":1334,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1522},"NCT00540137","The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects",[92],"2007-07",21,[1308],[1503,1523],"atazanavir\u002Fritonavir",{"trials":1525,"activeCount":101},[],{"intervention":1523,"totalTrials":143,"cells":1527},{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1542},{"trials":1529,"activeCount":101},[],{"trials":1531,"activeCount":101},[],{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":101},[1538],{"nctId":1516,"briefTitle":1517,"status":111,"phases":1539,"primaryCompletion":1334,"completion":1334,"start":1519,"enrollment":1520,"conditions":1540,"interventions":1541},[92],[1308],[1503,1523],{"trials":1543,"activeCount":101},[],{"intervention":1545,"totalTrials":143,"cells":1546},"Indapamide SR 1.5mg; Perindopril 2-4mg",{"EARLY_PHASE1":1547,"PHASE1":1549,"PHASE2":1551,"PHASE3":1553,"PHASE4":1555,"NA":1567},{"trials":1548,"activeCount":101},[],{"trials":1550,"activeCount":101},[],{"trials":1552,"activeCount":101},[],{"trials":1554,"activeCount":101},[],{"trials":1556,"activeCount":101},[1557],{"nctId":1558,"briefTitle":1559,"status":952,"phases":1560,"completion":1561,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1566},"NCT00122811","The Hypertension in the Very Elderly Trial (HYVET)",[92],"2008-10","2000-11",4000,[1565],"Hypertension",[1545],{"trials":1568,"activeCount":101},[],{"intervention":1570,"totalTrials":143,"cells":1571},"Anti-hypertensive Medication -",{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1580,"NA":1591},{"trials":1573,"activeCount":101},[],{"trials":1575,"activeCount":101},[],{"trials":1577,"activeCount":101},[],{"trials":1579,"activeCount":101},[],{"trials":1581,"activeCount":101},[1582],{"nctId":1583,"briefTitle":1584,"status":111,"phases":1585,"primaryCompletion":1586,"completion":1586,"start":1587,"enrollment":1588,"conditions":1589,"interventions":1590},"NCT01669928","Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control",[92],"2015-07","2012-04",103,[1565],[1570],{"trials":1592,"activeCount":101},[],{"intervention":1594,"totalTrials":143,"cells":1595},"Methylphenidate",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1616},{"trials":1597,"activeCount":101},[],{"trials":1599,"activeCount":101},[],{"trials":1601,"activeCount":101},[],{"trials":1603,"activeCount":101},[],{"trials":1605,"activeCount":101},[1606],{"nctId":1607,"briefTitle":1608,"status":111,"phases":1609,"primaryCompletion":1610,"start":1611,"enrollment":1612,"conditions":1613,"interventions":1615},"NCT02015949","The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)",[92],"2017-01","2014-02",40,[1614],"Traumatic Brain Injury",[1594],{"trials":1617,"activeCount":101},[],{"intervention":1619,"totalTrials":143,"cells":1620},"SALBUTAMOL",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1643},{"trials":1622,"activeCount":101},[],{"trials":1624,"activeCount":101},[],{"trials":1626,"activeCount":101},[],{"trials":1628,"activeCount":101},[],{"trials":1630,"activeCount":101},[1631],{"nctId":1632,"briefTitle":1633,"status":111,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1642},"NCT01721291","Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)",[92],"2017-11-27","2012-10-01",65,[1639,1640,1641],"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","ASTHMA","HEALTHY SUBJECTS",[1619],{"trials":1644,"activeCount":101},[],{"intervention":1646,"totalTrials":143,"cells":1647},"Maloprim",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1654,"PHASE4":1656,"NA":1668},{"trials":1649,"activeCount":101},[],{"trials":1651,"activeCount":101},[],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[1658],{"nctId":1659,"briefTitle":1660,"status":111,"phases":1661,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1667},"NCT00294580","Early Childhood Malaria Prevention With Maloprim in The Gambia",[92],"2001-09","1982-04",2253,[1666],"Malaria",[1646],{"trials":1669,"activeCount":101},[],{"intervention":1339,"totalTrials":143,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1678,"PHASE4":1680,"NA":1686},{"trials":1673,"activeCount":101},[],{"trials":1675,"activeCount":101},[],{"trials":1677,"activeCount":101},[],{"trials":1679,"activeCount":101},[],{"trials":1681,"activeCount":101},[1682],{"nctId":1331,"briefTitle":1332,"status":111,"phases":1683,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1684,"interventions":1685},[92],[34],[1294,1339,1340],{"trials":1687,"activeCount":101},[],{"intervention":1340,"totalTrials":143,"cells":1689},{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1704},{"trials":1691,"activeCount":101},[],{"trials":1693,"activeCount":101},[],{"trials":1695,"activeCount":101},[],{"trials":1697,"activeCount":101},[],{"trials":1699,"activeCount":101},[1700],{"nctId":1331,"briefTitle":1332,"status":111,"phases":1701,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":1336,"conditions":1702,"interventions":1703},[92],[34],[1294,1339,1340],{"trials":1705,"activeCount":101},[],{"intervention":1707,"totalTrials":143,"cells":1708},"Iron Sucrose Solution for",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1717,"NA":1732},{"trials":1710,"activeCount":101},[],{"trials":1712,"activeCount":101},[],{"trials":1714,"activeCount":101},[],{"trials":1716,"activeCount":101},[],{"trials":1718,"activeCount":101},[1719],{"nctId":1720,"briefTitle":1721,"status":111,"phases":1722,"primaryCompletion":1723,"completion":1724,"start":1725,"enrollment":1726,"conditions":1727,"interventions":1730},"NCT03658876","Predictors of Response to Iron and Erythropoietin Stimulating Agents",[92],"2016-12-31","2017-12-31","2015-06-03",197,[1728,1729],"Renal Failure Chronic","Anemia",[1707,1731],"Epoetin Beta",{"trials":1733,"activeCount":101},[],{"intervention":1731,"totalTrials":143,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1744,"NA":1750},{"trials":1737,"activeCount":101},[],{"trials":1739,"activeCount":101},[],{"trials":1741,"activeCount":101},[],{"trials":1743,"activeCount":101},[],{"trials":1745,"activeCount":101},[1746],{"nctId":1720,"briefTitle":1721,"status":111,"phases":1747,"primaryCompletion":1723,"completion":1724,"start":1725,"enrollment":1726,"conditions":1748,"interventions":1749},[92],[1728,1729],[1707,1731],{"trials":1751,"activeCount":101},[],{"intervention":1753,"totalTrials":143,"cells":1754},"Baclofen",{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1761,"PHASE4":1763,"NA":1775},{"trials":1756,"activeCount":101},[],{"trials":1758,"activeCount":101},[],{"trials":1760,"activeCount":101},[],{"trials":1762,"activeCount":101},[],{"trials":1764,"activeCount":101},[1765],{"nctId":1766,"briefTitle":1767,"status":111,"phases":1768,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":379,"conditions":1771,"interventions":1773},"NCT05161351","Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.",[92],"2022-11-11","2021-07-23",[1772],"Addiction Opiate",[1753,1774],"Vitamin D3",{"trials":1776,"activeCount":101},[],{"intervention":1774,"totalTrials":143,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1793},{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":101},[],{"trials":1784,"activeCount":101},[],{"trials":1786,"activeCount":101},[],{"trials":1788,"activeCount":101},[1789],{"nctId":1766,"briefTitle":1767,"status":111,"phases":1790,"primaryCompletion":1769,"completion":1769,"start":1770,"enrollment":379,"conditions":1791,"interventions":1792},[92],[1772],[1753,1774],{"trials":1794,"activeCount":101},[],{"intervention":1796,"totalTrials":143,"cells":1797},"Amisulpride",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1818},{"trials":1799,"activeCount":101},[],{"trials":1801,"activeCount":101},[],{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":101},[1808],{"nctId":1809,"briefTitle":1810,"status":111,"phases":1811,"primaryCompletion":1812,"completion":1812,"start":1813,"enrollment":1814,"conditions":1815,"interventions":1817},"NCT01246232","Amisulpride Augmentation in Clozapine-unresponsive Schizophrenia",[92],"2015-03","2011-09",69,[1816],"Schizophrenia",[1796],{"trials":1819,"activeCount":101},[],{"intervention":1821,"totalTrials":143,"cells":1822},"Fosinopril",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1842},{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":101},[],{"trials":1828,"activeCount":101},[],{"trials":1830,"activeCount":101},[],{"trials":1832,"activeCount":101},[1833],{"nctId":1834,"briefTitle":1835,"status":111,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1841},"NCT01014338","Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD)",[92],"2012-09","2009-10",80,[28],[1821],{"trials":1843,"activeCount":101},[],{"intervention":1845,"totalTrials":143,"cells":1846},"Fluticasone Propionate_1.5",{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1855,"NA":1868},{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":101},[],{"trials":1852,"activeCount":101},[],{"trials":1854,"activeCount":101},[],{"trials":1856,"activeCount":101},[1857],{"nctId":1858,"briefTitle":1859,"status":111,"phases":1860,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":10,"conditions":1863,"interventions":1864},"NCT00692978","Pharmacokinetics of Inhaled Monodisperse Fluticasone Propionate",[92],"2011-07-03","2008-08",[36,16],[1845,1865,1866,1867],"Fluticasone Propionate_3","Fluticasone Propionate_6","FP From Active 250 ug MDI Inhaler",{"trials":1869,"activeCount":101},[],{"intervention":1865,"totalTrials":143,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1880,"NA":1886},{"trials":1873,"activeCount":101},[],{"trials":1875,"activeCount":101},[],{"trials":1877,"activeCount":101},[],{"trials":1879,"activeCount":101},[],{"trials":1881,"activeCount":101},[1882],{"nctId":1858,"briefTitle":1859,"status":111,"phases":1883,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":10,"conditions":1884,"interventions":1885},[92],[36,16],[1845,1865,1866,1867],{"trials":1887,"activeCount":101},[],{"intervention":1866,"totalTrials":143,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1896,"PHASE4":1898,"NA":1904},{"trials":1891,"activeCount":101},[],{"trials":1893,"activeCount":101},[],{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":101},[],{"trials":1899,"activeCount":101},[1900],{"nctId":1858,"briefTitle":1859,"status":111,"phases":1901,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":10,"conditions":1902,"interventions":1903},[92],[36,16],[1845,1865,1866,1867],{"trials":1905,"activeCount":101},[],{"intervention":1867,"totalTrials":143,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1914,"PHASE4":1916,"NA":1922},{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[],{"trials":1917,"activeCount":101},[1918],{"nctId":1858,"briefTitle":1859,"status":111,"phases":1919,"primaryCompletion":1861,"completion":1861,"start":1862,"enrollment":10,"conditions":1920,"interventions":1921},[92],[36,16],[1845,1865,1866,1867],{"trials":1923,"activeCount":101},[],{"intervention":1925,"totalTrials":143,"cells":1926},"Symbicort® total dose 400ug\u002F12ug",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1933,"PHASE4":1935,"NA":1948},{"trials":1928,"activeCount":101},[],{"trials":1930,"activeCount":101},[],{"trials":1932,"activeCount":101},[],{"trials":1934,"activeCount":101},[],{"trials":1936,"activeCount":101},[1937],{"nctId":1938,"briefTitle":1939,"status":111,"phases":1940,"primaryCompletion":1941,"completion":988,"start":1439,"enrollment":20,"conditions":1942,"interventions":1944},"NCT01787097","Effect of Symbicort ® on GR in Sputum in COPD",[92],"2014-12",[1943],"Chronic Obstructive Lung Disease",[1925,1945,1946,1947],"Symbicort® total dose 800ug\u002F24ug","Formoterol 24ug","BUD total dose 800ug",{"trials":1949,"activeCount":101},[],{"intervention":1945,"totalTrials":143,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1966},{"trials":1953,"activeCount":101},[],{"trials":1955,"activeCount":101},[],{"trials":1957,"activeCount":101},[],{"trials":1959,"activeCount":101},[],{"trials":1961,"activeCount":101},[1962],{"nctId":1938,"briefTitle":1939,"status":111,"phases":1963,"primaryCompletion":1941,"completion":988,"start":1439,"enrollment":20,"conditions":1964,"interventions":1965},[92],[1943],[1925,1945,1946,1947],{"trials":1967,"activeCount":101},[],{"intervention":1946,"totalTrials":143,"cells":1969},{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1984},{"trials":1971,"activeCount":101},[],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"trials":1979,"activeCount":101},[1980],{"nctId":1938,"briefTitle":1939,"status":111,"phases":1981,"primaryCompletion":1941,"completion":988,"start":1439,"enrollment":20,"conditions":1982,"interventions":1983},[92],[1943],[1925,1945,1946,1947],{"trials":1985,"activeCount":101},[],{"intervention":1947,"totalTrials":143,"cells":1987},{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":1994,"PHASE4":1996,"NA":2002},{"trials":1989,"activeCount":101},[],{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":101},[],{"trials":1995,"activeCount":101},[],{"trials":1997,"activeCount":101},[1998],{"nctId":1938,"briefTitle":1939,"status":111,"phases":1999,"primaryCompletion":1941,"completion":988,"start":1439,"enrollment":20,"conditions":2000,"interventions":2001},[92],[1943],[1925,1945,1946,1947],{"trials":2003,"activeCount":101},[],{"intervention":2005,"totalTrials":143,"cells":2006},"Zithromax",{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2015,"NA":2025},{"trials":2008,"activeCount":101},[],{"trials":2010,"activeCount":101},[],{"trials":2012,"activeCount":101},[],{"trials":2014,"activeCount":101},[],{"trials":2016,"activeCount":101},[2017],{"nctId":2018,"briefTitle":2019,"status":111,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":1813,"enrollment":2022,"conditions":2023,"interventions":2024},"NCT01444469","AZithromycin Against pLacebo in Exacerbations of Asthma",[92],"2014-06",199,[16],[2005],{"trials":2026,"activeCount":101},[],{"intervention":2028,"totalTrials":143,"cells":2029},"Pioglitazone",{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2034,"PHASE3":2036,"PHASE4":2038,"NA":2049},{"trials":2031,"activeCount":101},[],{"trials":2033,"activeCount":101},[],{"trials":2035,"activeCount":101},[],{"trials":2037,"activeCount":101},[],{"trials":2039,"activeCount":101},[2040],{"nctId":2041,"briefTitle":2042,"status":111,"phases":2043,"primaryCompletion":2044,"completion":2044,"start":2045,"enrollment":989,"conditions":2046,"interventions":2048},"NCT00485056","Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)",[92],"2010-04","2008-04",[2047],"Diabetes",[2028],{"trials":2050,"activeCount":101},[],{"intervention":2052,"totalTrials":143,"cells":2053},"Ceftazidime",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2060,"PHASE4":2062,"NA":2076},{"trials":2055,"activeCount":101},[],{"trials":2057,"activeCount":101},[],{"trials":2059,"activeCount":101},[],{"trials":2061,"activeCount":101},[],{"trials":2063,"activeCount":101},[2064],{"nctId":2065,"briefTitle":2066,"status":952,"phases":2067,"primaryCompletion":2068,"completion":1335,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2073},"NCT01044719","Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis",[92],"2010-10","2010-01",240,[2072],"Cystic Fibrosis",[2052,2074,2075],"Tobramycin","Meropenem",{"trials":2077,"activeCount":101},[],{"intervention":2074,"totalTrials":143,"cells":2079},{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2094},{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":101},[],{"trials":2085,"activeCount":101},[],{"trials":2087,"activeCount":101},[],{"trials":2089,"activeCount":101},[2090],{"nctId":2065,"briefTitle":2066,"status":952,"phases":2091,"primaryCompletion":2068,"completion":1335,"start":2069,"enrollment":2070,"conditions":2092,"interventions":2093},[92],[2072],[2052,2074,2075],{"trials":2095,"activeCount":101},[],{"intervention":2075,"totalTrials":143,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2112},{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":101},[],{"trials":2105,"activeCount":101},[],{"trials":2107,"activeCount":101},[2108],{"nctId":2065,"briefTitle":2066,"status":952,"phases":2109,"primaryCompletion":2068,"completion":1335,"start":2069,"enrollment":2070,"conditions":2110,"interventions":2111},[92],[2072],[2052,2074,2075],{"trials":2113,"activeCount":101},[],{"intervention":2115,"totalTrials":143,"cells":2116},"Tolterodine",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2125,"NA":2137},{"trials":2118,"activeCount":101},[],{"trials":2120,"activeCount":101},[],{"trials":2122,"activeCount":101},[],{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[2127],{"nctId":2128,"briefTitle":2129,"status":367,"phases":2130,"primaryCompletion":2069,"completion":2069,"start":2131,"enrollment":101,"conditions":2132,"interventions":2136},"NCT00523068","Pharmacological vs Surgical Treatment for Mixed Incontinence",[92],"2007-09",[2133,2134,2135],"Mixed Urinary Incontinence","Urinary Incontinence, Stress","Urinary Incontinence, Urge",[2115],{"trials":2138,"activeCount":101},[],{"intervention":2140,"totalTrials":143,"cells":2141},"Atorvastatin",{"EARLY_PHASE1":2142,"PHASE1":2144,"PHASE2":2146,"PHASE3":2148,"PHASE4":2150,"NA":2164},{"trials":2143,"activeCount":101},[],{"trials":2145,"activeCount":101},[],{"trials":2147,"activeCount":101},[],{"trials":2149,"activeCount":101},[],{"trials":2151,"activeCount":101},[2152],{"nctId":2153,"briefTitle":2154,"status":111,"phases":2155,"primaryCompletion":2156,"completion":2157,"start":2158,"enrollment":771,"conditions":2159,"interventions":2163},"NCT02668016","Self-Assessment Method for Statin Side-effects Or Nocebo",[92],"2020-10-31","2020-12-31","2016-03",[2160,2161,2162],"Adverse Effects","Cardiovascular Diseases","Hyperlipidemias",[2140],{"trials":2165,"activeCount":101},[],{"intervention":2167,"totalTrials":143,"cells":2168},"Salmeterol Xinafoate",{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2177,"NA":2187},{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[],{"trials":2174,"activeCount":101},[],{"trials":2176,"activeCount":101},[],{"trials":2178,"activeCount":101},[2179],{"nctId":2180,"briefTitle":2181,"status":952,"phases":2182,"primaryCompletion":2183,"completion":2183,"start":1770,"enrollment":989,"conditions":2184,"interventions":2185},"NCT04503460","Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma",[92],"2024-09-30",[16],[2167,2186],"Salmeterol Fluticasone",{"trials":2188,"activeCount":101},[],{"intervention":2186,"totalTrials":143,"cells":2190},{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2197,"PHASE4":2199,"NA":2205},{"trials":2192,"activeCount":101},[],{"trials":2194,"activeCount":101},[],{"trials":2196,"activeCount":101},[],{"trials":2198,"activeCount":101},[],{"trials":2200,"activeCount":101},[2201],{"nctId":2180,"briefTitle":2181,"status":952,"phases":2202,"primaryCompletion":2183,"completion":2183,"start":1770,"enrollment":989,"conditions":2203,"interventions":2204},[92],[16],[2167,2186],{"trials":2206,"activeCount":101},[],{"intervention":2208,"totalTrials":143,"cells":2209},"Rifaximin",{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2216,"PHASE4":2218,"NA":2230},{"trials":2211,"activeCount":101},[],{"trials":2213,"activeCount":101},[],{"trials":2215,"activeCount":101},[],{"trials":2217,"activeCount":101},[],{"trials":2219,"activeCount":101},[2220],{"nctId":2221,"briefTitle":2222,"status":264,"phases":2223,"primaryCompletion":1837,"completion":1837,"start":2224,"enrollment":804,"conditions":2225,"interventions":2229},"NCT01355575","Rifaximin in Fatty Liver Disease",[92],"2011-05",[2226,2227,2228],"Nonalcoholic Fatty Liver Disease","NAFLD","Nonalcoholic Steatohepatitis",[2208],{"trials":2231,"activeCount":101},[],{"intervention":2233,"totalTrials":143,"cells":2234},"Citalopram",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2254},{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"trials":2242,"activeCount":101},[],{"trials":2244,"activeCount":101},[2245],{"nctId":2246,"briefTitle":2247,"status":111,"phases":2248,"primaryCompletion":1941,"completion":2249,"start":2250,"enrollment":2251,"conditions":2252,"interventions":2253},"NCT01032083","Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia",[92],"2015-01","2011-07",62,[1816],[2233],{"trials":2255,"activeCount":101},[],{"intervention":2257,"totalTrials":143,"cells":2258},"Sodium Oxybate",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2278},{"trials":2260,"activeCount":101},[],{"trials":2262,"activeCount":101},[],{"trials":2264,"activeCount":101},[],{"trials":2266,"activeCount":101},[],{"trials":2268,"activeCount":101},[2269],{"nctId":2270,"briefTitle":2271,"status":111,"phases":2272,"primaryCompletion":2273,"completion":2273,"start":2274,"enrollment":32,"conditions":2275,"interventions":2277},"NCT02055898","SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)",[92],"2015-08","2014-04",[2276],"Chronic Fatigue Syndrome",[2257],{"trials":2279,"activeCount":101},[],{"intervention":2281,"totalTrials":143,"cells":2282},"Evolocumab",{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2304},{"trials":2284,"activeCount":101},[],{"trials":2286,"activeCount":101},[],{"trials":2288,"activeCount":101},[],{"trials":2290,"activeCount":101},[],{"trials":2292,"activeCount":101},[2293],{"nctId":2294,"briefTitle":2295,"status":264,"phases":2296,"primaryCompletion":2297,"completion":2298,"start":2299,"enrollment":1412,"conditions":2300,"interventions":2303},"NCT04073134","The CHORAL Flow Study",[92],"2022-03-27","2022-05-27","2019-09-11",[2301,2302,2162],"Coronary Artery Disease","Atherosclerosis",[2281],{"trials":2305,"activeCount":101},[],{"intervention":2307,"totalTrials":143,"cells":2308},"standard care",{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2313,"PHASE3":2315,"PHASE4":2317,"NA":2327},{"trials":2310,"activeCount":101},[],{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[],{"trials":2316,"activeCount":101},[],{"trials":2318,"activeCount":101},[2319],{"nctId":2320,"briefTitle":2321,"status":111,"phases":2322,"primaryCompletion":267,"completion":267,"start":1439,"enrollment":771,"conditions":2323,"interventions":2325},"NCT01367236","Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa",[92],[34,2324],"Impaired Cognition",[2307,2326],"novel treatment",{"trials":2328,"activeCount":101},[],{"intervention":2326,"totalTrials":143,"cells":2330},{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2335,"PHASE3":2337,"PHASE4":2339,"NA":2345},{"trials":2332,"activeCount":101},[],{"trials":2334,"activeCount":101},[],{"trials":2336,"activeCount":101},[],{"trials":2338,"activeCount":101},[],{"trials":2340,"activeCount":101},[2341],{"nctId":2320,"briefTitle":2321,"status":111,"phases":2342,"primaryCompletion":267,"completion":267,"start":1439,"enrollment":771,"conditions":2343,"interventions":2344},[92],[34,2324],[2307,2326],{"trials":2346,"activeCount":101},[],{"intervention":2348,"totalTrials":143,"cells":2349},"Administration of Live attenuated influenza vaccine",{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2358,"NA":2369},{"trials":2351,"activeCount":101},[],{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[],{"trials":2357,"activeCount":101},[],{"trials":2359,"activeCount":101},[2360],{"nctId":2361,"briefTitle":2362,"status":111,"phases":2363,"primaryCompletion":2364,"completion":2364,"start":2365,"enrollment":2366,"conditions":2367,"interventions":2368},"NCT02866942","Safety of Nasal Influenza Immunisation in Children With Asthma",[92],"2017-03","2016-10",479,[16],[2348],{"trials":2370,"activeCount":101},[],{"intervention":2372,"totalTrials":143,"cells":2373},"Epipen 0.3mg",{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2382,"NA":2395},{"trials":2375,"activeCount":101},[],{"trials":2377,"activeCount":101},[],{"trials":2379,"activeCount":101},[],{"trials":2381,"activeCount":101},[],{"trials":2383,"activeCount":101},[2384],{"nctId":2385,"briefTitle":2386,"status":111,"phases":2387,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":1412,"conditions":2390,"interventions":2392},"NCT03366298","Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers",[92],"2018-10-02","2017-11-24",[2391],"Anaphylaxis",[2372,2393,2394],"Emerade 300mcg","Emerade 500mcg",{"trials":2396,"activeCount":101},[],{"intervention":2393,"totalTrials":143,"cells":2398},{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2405,"PHASE4":2407,"NA":2413},{"trials":2400,"activeCount":101},[],{"trials":2402,"activeCount":101},[],{"trials":2404,"activeCount":101},[],{"trials":2406,"activeCount":101},[],{"trials":2408,"activeCount":101},[2409],{"nctId":2385,"briefTitle":2386,"status":111,"phases":2410,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":1412,"conditions":2411,"interventions":2412},[92],[2391],[2372,2393,2394],{"trials":2414,"activeCount":101},[],{"intervention":2394,"totalTrials":143,"cells":2416},{"EARLY_PHASE1":2417,"PHASE1":2419,"PHASE2":2421,"PHASE3":2423,"PHASE4":2425,"NA":2431},{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"trials":2422,"activeCount":101},[],{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[2427],{"nctId":2385,"briefTitle":2386,"status":111,"phases":2428,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":1412,"conditions":2429,"interventions":2430},[92],[2391],[2372,2393,2394],{"trials":2432,"activeCount":101},[],{"intervention":2434,"totalTrials":143,"cells":2435},"budesonide",{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2442,"PHASE4":2444,"NA":2454},{"trials":2437,"activeCount":101},[],{"trials":2439,"activeCount":101},[],{"trials":2441,"activeCount":101},[],{"trials":2443,"activeCount":101},[],{"trials":2445,"activeCount":101},[2446],{"nctId":2447,"briefTitle":2448,"status":367,"phases":2449,"primaryCompletion":2450,"completion":2451,"start":2045,"enrollment":101,"conditions":2452,"interventions":2453},"NCT00661973","Inhaled Corticosteroids on Airway Smooth Muscle in Asthma",[92],"2010-12","2011-03",[16],[2434],{"trials":2455,"activeCount":101},[],{"intervention":2457,"totalTrials":143,"cells":2458},"Alirocumab",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2465,"PHASE4":2467,"NA":2482},{"trials":2460,"activeCount":101},[],{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"trials":2468,"activeCount":101},[2469],{"nctId":2470,"briefTitle":2471,"status":367,"phases":2472,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":101,"conditions":2476,"interventions":2479},"NCT03750760","Early Alirocumab to Reduce LDL-C in Myocardial Infarction",[92],"2020-12","2021-12","2020-01",[2477,2478],"Myocardial Infarction","Dyslipidemias",[2457,2480,2481],"Atorvastatin 80mg","Ezetimibe 10mg",{"trials":2483,"activeCount":101},[],{"intervention":2480,"totalTrials":143,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2500},{"trials":2487,"activeCount":101},[],{"trials":2489,"activeCount":101},[],{"trials":2491,"activeCount":101},[],{"trials":2493,"activeCount":101},[],{"trials":2495,"activeCount":101},[2496],{"nctId":2470,"briefTitle":2471,"status":367,"phases":2497,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":101,"conditions":2498,"interventions":2499},[92],[2477,2478],[2457,2480,2481],{"trials":2501,"activeCount":101},[],{"intervention":2481,"totalTrials":143,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2508,"PHASE3":2510,"PHASE4":2512,"NA":2518},{"trials":2505,"activeCount":101},[],{"trials":2507,"activeCount":101},[],{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[2514],{"nctId":2470,"briefTitle":2471,"status":367,"phases":2515,"primaryCompletion":2473,"completion":2474,"start":2475,"enrollment":101,"conditions":2516,"interventions":2517},[92],[2477,2478],[2457,2480,2481],{"trials":2519,"activeCount":101},[],{"intervention":2521,"totalTrials":143,"cells":2522},"Darunavir, Ritonavir, Truvada",{"EARLY_PHASE1":2523,"PHASE1":2525,"PHASE2":2527,"PHASE3":2529,"PHASE4":2531,"NA":2542},{"trials":2524,"activeCount":101},[],{"trials":2526,"activeCount":101},[],{"trials":2528,"activeCount":101},[],{"trials":2530,"activeCount":101},[],{"trials":2532,"activeCount":101},[2533],{"nctId":2534,"briefTitle":2535,"status":264,"phases":2536,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":268,"conditions":2539,"interventions":2540},"NCT01118871","The First Failure Study",[92],"2013-05","2010-05",[34,1308],[2521,2541],"Darunavir, Ritonavir and Etravirine",{"trials":2543,"activeCount":101},[],{"intervention":2541,"totalTrials":143,"cells":2545},{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2560},{"trials":2547,"activeCount":101},[],{"trials":2549,"activeCount":101},[],{"trials":2551,"activeCount":101},[],{"trials":2553,"activeCount":101},[],{"trials":2555,"activeCount":101},[2556],{"nctId":2534,"briefTitle":2535,"status":264,"phases":2557,"primaryCompletion":2537,"completion":2537,"start":2538,"enrollment":268,"conditions":2558,"interventions":2559},[92],[34,1308],[2521,2541],{"trials":2561,"activeCount":101},[],{"intervention":2563,"totalTrials":143,"cells":2564},"1.5 microns at 50mg",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2571,"PHASE4":2573,"NA":2584},{"trials":2566,"activeCount":101},[],{"trials":2568,"activeCount":101},[],{"trials":2570,"activeCount":101},[],{"trials":2572,"activeCount":101},[],{"trials":2574,"activeCount":101},[2575],{"nctId":2576,"briefTitle":2577,"status":111,"phases":2578,"primaryCompletion":1334,"completion":1334,"start":2579,"enrollment":1520,"conditions":2580,"interventions":2581},"NCT01662778","The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma",[92],"2011-12",[16],[2563,2582,2583],"6 microns at 50mg","MDI FP",{"trials":2585,"activeCount":101},[],{"intervention":2582,"totalTrials":143,"cells":2587},{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2594,"PHASE4":2596,"NA":2602},{"trials":2589,"activeCount":101},[],{"trials":2591,"activeCount":101},[],{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[2598],{"nctId":2576,"briefTitle":2577,"status":111,"phases":2599,"primaryCompletion":1334,"completion":1334,"start":2579,"enrollment":1520,"conditions":2600,"interventions":2601},[92],[16],[2563,2582,2583],{"trials":2603,"activeCount":101},[],{"intervention":2583,"totalTrials":143,"cells":2605},{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2612,"PHASE4":2614,"NA":2620},{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":101},[],{"trials":2611,"activeCount":101},[],{"trials":2613,"activeCount":101},[],{"trials":2615,"activeCount":101},[2616],{"nctId":2576,"briefTitle":2577,"status":111,"phases":2617,"primaryCompletion":1334,"completion":1334,"start":2579,"enrollment":1520,"conditions":2618,"interventions":2619},[92],[16],[2563,2582,2583],{"trials":2621,"activeCount":101},[],{"intervention":2623,"totalTrials":143,"cells":2624},"LOLA or placebo",{"EARLY_PHASE1":2625,"PHASE1":2627,"PHASE2":2629,"PHASE3":2631,"PHASE4":2633,"NA":2646},{"trials":2626,"activeCount":101},[],{"trials":2628,"activeCount":101},[],{"trials":2630,"activeCount":101},[],{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":101},[2635],{"nctId":2636,"briefTitle":2637,"status":111,"phases":2638,"primaryCompletion":2639,"completion":2639,"start":2640,"enrollment":565,"conditions":2641,"interventions":2645},"NCT01847651","Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate",[92],"2015-06","2013-08",[2642,2643,2644],"Hepatic Encephalopathy","Minimal Hepatic Encephalopathy","Cirrhosis",[2623],{"trials":2647,"activeCount":101},[],{"intervention":2649,"totalTrials":143,"cells":2650},"Colecalciferol D3",{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2659,"NA":2670},{"trials":2652,"activeCount":101},[],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":101},[],{"trials":2660,"activeCount":101},[2661],{"nctId":2662,"briefTitle":2663,"status":367,"phases":2664,"primaryCompletion":2538,"completion":2538,"start":2665,"enrollment":101,"conditions":2666,"interventions":2668},"NCT00672763","Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease",[92],"2008-05",[2667],"Crohn's Disease",[2649,2669],"Medium chain triglycerides",{"trials":2671,"activeCount":101},[],{"intervention":2669,"totalTrials":143,"cells":2673},{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2680,"PHASE4":2682,"NA":2688},{"trials":2675,"activeCount":101},[],{"trials":2677,"activeCount":101},[],{"trials":2679,"activeCount":101},[],{"trials":2681,"activeCount":101},[],{"trials":2683,"activeCount":101},[2684],{"nctId":2662,"briefTitle":2663,"status":367,"phases":2685,"primaryCompletion":2538,"completion":2538,"start":2665,"enrollment":101,"conditions":2686,"interventions":2687},[92],[2667],[2649,2669],{"trials":2689,"activeCount":101},[],{"intervention":1007,"totalTrials":97,"cells":2691},{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2714,"NA":2716},{"trials":2693,"activeCount":101},[],{"trials":2695,"activeCount":101},[],{"trials":2697,"activeCount":101},[],{"trials":2699,"activeCount":101},[2700,2710],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2703,"primaryCompletion":2704,"completion":2704,"start":2705,"enrollment":771,"conditions":2706,"interventions":2708},"NCT00802529","Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease",[90,91],"2015-05","2009-04",[2707],"Meniere's Disease",[1007,2709],"Gentamicin",{"nctId":997,"briefTitle":998,"status":264,"phases":2711,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":268,"conditions":2712,"interventions":2713},[91],[1004,1005],[973,1007,1008],{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[],{"intervention":2719,"totalTrials":97,"cells":2720},"Guanfacine",{"EARLY_PHASE1":2721,"PHASE1":2723,"PHASE2":2725,"PHASE3":2736,"PHASE4":2747,"NA":2749},{"trials":2722,"activeCount":101},[],{"trials":2724,"activeCount":101},[],{"trials":2726,"activeCount":101},[2727],{"nctId":2728,"briefTitle":2729,"status":111,"phases":2730,"primaryCompletion":2731,"completion":2731,"start":2044,"enrollment":32,"conditions":2732,"interventions":2735},"NCT00955253","Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance",[90],"2014-03-28",[2733,2734],"Stroke","Hemispatial Neglect",[2719],{"trials":2737,"activeCount":101},[2738],{"nctId":2739,"briefTitle":2740,"status":952,"phases":2741,"primaryCompletion":2742,"completion":2742,"start":2743,"enrollment":2744,"conditions":2745,"interventions":2746},"NCT03116126","Noradrenergic Add-on Therapy With Guanfacine",[91],"2024-08-05","2019-01-04",148,[542],[2719],{"trials":2748,"activeCount":101},[],{"trials":2750,"activeCount":101},[],{"intervention":2752,"totalTrials":143,"cells":2753},"cyclophosphamide",{"EARLY_PHASE1":2754,"PHASE1":2756,"PHASE2":2758,"PHASE3":2760,"PHASE4":2775,"NA":2777},{"trials":2755,"activeCount":101},[],{"trials":2757,"activeCount":101},[],{"trials":2759,"activeCount":101},[],{"trials":2761,"activeCount":101},[2762],{"nctId":2763,"briefTitle":2764,"status":111,"phases":2765,"primaryCompletion":2766,"completion":2451,"start":2767,"enrollment":2768,"conditions":2769,"interventions":2770},"NCT00963729","Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery",[91],"2010-03","2008-09",756,[31],[2752,2771,2772,2773,2774],"docetaxel","epirubicin hydrochloride","fluorouracil","letrozole",{"trials":2776,"activeCount":101},[],{"trials":2778,"activeCount":101},[],{"intervention":2771,"totalTrials":143,"cells":2780},{"EARLY_PHASE1":2781,"PHASE1":2783,"PHASE2":2785,"PHASE3":2787,"PHASE4":2793,"NA":2795},{"trials":2782,"activeCount":101},[],{"trials":2784,"activeCount":101},[],{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[2789],{"nctId":2763,"briefTitle":2764,"status":111,"phases":2790,"primaryCompletion":2766,"completion":2451,"start":2767,"enrollment":2768,"conditions":2791,"interventions":2792},[91],[31],[2752,2771,2772,2773,2774],{"trials":2794,"activeCount":101},[],{"trials":2796,"activeCount":101},[],{"intervention":2772,"totalTrials":143,"cells":2798},{"EARLY_PHASE1":2799,"PHASE1":2801,"PHASE2":2803,"PHASE3":2805,"PHASE4":2811,"NA":2813},{"trials":2800,"activeCount":101},[],{"trials":2802,"activeCount":101},[],{"trials":2804,"activeCount":101},[],{"trials":2806,"activeCount":101},[2807],{"nctId":2763,"briefTitle":2764,"status":111,"phases":2808,"primaryCompletion":2766,"completion":2451,"start":2767,"enrollment":2768,"conditions":2809,"interventions":2810},[91],[31],[2752,2771,2772,2773,2774],{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"intervention":2773,"totalTrials":143,"cells":2816},{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2829,"NA":2831},{"trials":2818,"activeCount":101},[],{"trials":2820,"activeCount":101},[],{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[2825],{"nctId":2763,"briefTitle":2764,"status":111,"phases":2826,"primaryCompletion":2766,"completion":2451,"start":2767,"enrollment":2768,"conditions":2827,"interventions":2828},[91],[31],[2752,2771,2772,2773,2774],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[],{"intervention":2774,"totalTrials":143,"cells":2834},{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2841,"PHASE4":2847,"NA":2849},{"trials":2836,"activeCount":101},[],{"trials":2838,"activeCount":101},[],{"trials":2840,"activeCount":101},[],{"trials":2842,"activeCount":101},[2843],{"nctId":2763,"briefTitle":2764,"status":111,"phases":2844,"primaryCompletion":2766,"completion":2451,"start":2767,"enrollment":2768,"conditions":2845,"interventions":2846},[91],[31],[2752,2771,2772,2773,2774],{"trials":2848,"activeCount":101},[],{"trials":2850,"activeCount":101},[],{"intervention":2852,"totalTrials":143,"cells":2853},"Doxycycline",{"EARLY_PHASE1":2854,"PHASE1":2856,"PHASE2":2858,"PHASE3":2860,"PHASE4":2872,"NA":2874},{"trials":2855,"activeCount":101},[],{"trials":2857,"activeCount":101},[],{"trials":2859,"activeCount":101},[],{"trials":2861,"activeCount":101},[2862],{"nctId":2863,"briefTitle":2864,"status":111,"phases":2865,"primaryCompletion":2866,"completion":2866,"start":2867,"enrollment":2868,"conditions":2869,"interventions":2871},"NCT02305940","Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients",[91],"2017-07-12","2014-07",222,[2870],"Chronic Obstructive Pulmonary Disease (COPD)",[2852],{"trials":2873,"activeCount":101},[],{"trials":2875,"activeCount":101},[],{"intervention":2877,"totalTrials":143,"cells":2878},"Handihaler-Tiotropium 18 mcg untrained",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2897,"NA":2899},{"trials":2880,"activeCount":101},[],{"trials":2882,"activeCount":101},[],{"trials":2884,"activeCount":101},[],{"trials":2886,"activeCount":101},[2887],{"nctId":2888,"briefTitle":2889,"status":111,"phases":2890,"primaryCompletion":348,"completion":348,"start":2891,"enrollment":349,"conditions":2892,"interventions":2894},"NCT02683668","Airway Effects of Tiotropium in Patients With COPD",[91],"2016-02-01",[25,2893],"LUNG DISEASES, OBSTRUCTIVE",[2877,2895,2896],"Handihaler-Tiotropium 18 mcg trained","Respimat-Tiotropium 5 mcg trained",{"trials":2898,"activeCount":101},[],{"trials":2900,"activeCount":101},[],{"intervention":2895,"totalTrials":143,"cells":2902},{"EARLY_PHASE1":2903,"PHASE1":2905,"PHASE2":2907,"PHASE3":2909,"PHASE4":2915,"NA":2917},{"trials":2904,"activeCount":101},[],{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[],{"trials":2910,"activeCount":101},[2911],{"nctId":2888,"briefTitle":2889,"status":111,"phases":2912,"primaryCompletion":348,"completion":348,"start":2891,"enrollment":349,"conditions":2913,"interventions":2914},[91],[25,2893],[2877,2895,2896],{"trials":2916,"activeCount":101},[],{"trials":2918,"activeCount":101},[],{"intervention":2896,"totalTrials":143,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2933,"NA":2935},{"trials":2922,"activeCount":101},[],{"trials":2924,"activeCount":101},[],{"trials":2926,"activeCount":101},[],{"trials":2928,"activeCount":101},[2929],{"nctId":2888,"briefTitle":2889,"status":111,"phases":2930,"primaryCompletion":348,"completion":348,"start":2891,"enrollment":349,"conditions":2931,"interventions":2932},[91],[25,2893],[2877,2895,2896],{"trials":2934,"activeCount":101},[],{"trials":2936,"activeCount":101},[],{"intervention":2938,"totalTrials":143,"cells":2939},"Sildenafil 100mg",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2946,"PHASE4":2959,"NA":2961},{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"trials":2945,"activeCount":101},[],{"trials":2947,"activeCount":101},[2948],{"nctId":2949,"briefTitle":2950,"status":2951,"phases":2952,"primaryCompletion":2953,"completion":2954,"start":2955,"enrollment":10,"conditions":2956,"interventions":2958},"NCT04052269","Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)","SUSPENDED",[91],"2021-10-30","2022-10-30","2019-06-21",[2957],"Glaucoma",[2938],{"trials":2960,"activeCount":101},[],{"trials":2962,"activeCount":101},[],{"intervention":2964,"totalTrials":143,"cells":2965},"ciclosporin",{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2972,"PHASE4":2983,"NA":2985},{"trials":2967,"activeCount":101},[],{"trials":2969,"activeCount":101},[],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[2974],{"nctId":2975,"briefTitle":2976,"status":111,"phases":2977,"primaryCompletion":2069,"completion":2069,"start":2978,"enrollment":2979,"conditions":2980,"interventions":2982},"NCT00773292","Ciclosporin in HTLV-1 Associated Myelopathy\u002F Tropical Spastic Paraparesis (HAM\u002FTSP)",[90,91],"2006-08",7,[2981],"HTLV I Associated Myelopathy",[2964],{"trials":2984,"activeCount":101},[],{"trials":2986,"activeCount":101},[],{"intervention":2988,"totalTrials":143,"cells":2989},"Zidovudine\u002Flamivudine",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":3008,"NA":3010},{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[2998],{"nctId":2999,"briefTitle":3000,"status":111,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":379,"conditions":3004,"interventions":3006},"NCT00272480","Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial",[90,91],"2002-07-30","1999-11-08",[3005],"HTLV-I-associated Myelopathy",[2988,3007],"Placebos",{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"intervention":3013,"totalTrials":143,"cells":3014},"Polypill: Red Heart Pill",{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3021,"PHASE4":3032,"NA":3034},{"trials":3016,"activeCount":101},[],{"trials":3018,"activeCount":101},[],{"trials":3020,"activeCount":101},[],{"trials":3022,"activeCount":101},[3023],{"nctId":3024,"briefTitle":3025,"status":367,"phases":3026,"primaryCompletion":3027,"completion":1837,"start":1355,"enrollment":101,"conditions":3028,"interventions":3030},"NCT01326676","Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial",[91],"2012-07",[3029],"Cardiovascular Disease",[3013,3031],"Usual medication",{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"intervention":3031,"totalTrials":143,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3044,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":101},[],{"trials":3041,"activeCount":101},[],{"trials":3043,"activeCount":101},[],{"trials":3045,"activeCount":101},[3046],{"nctId":3024,"briefTitle":3025,"status":367,"phases":3047,"primaryCompletion":3027,"completion":1837,"start":1355,"enrollment":101,"conditions":3048,"interventions":3049},[91],[3029],[3013,3031],{"trials":3051,"activeCount":101},[],{"trials":3053,"activeCount":101},[],{"intervention":2709,"totalTrials":143,"cells":3055},{"EARLY_PHASE1":3056,"PHASE1":3058,"PHASE2":3060,"PHASE3":3062,"PHASE4":3068,"NA":3070},{"trials":3057,"activeCount":101},[],{"trials":3059,"activeCount":101},[],{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[3064],{"nctId":2701,"briefTitle":2702,"status":111,"phases":3065,"primaryCompletion":2704,"completion":2704,"start":2705,"enrollment":771,"conditions":3066,"interventions":3067},[90,91],[2707],[1007,2709],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"intervention":3073,"totalTrials":143,"cells":3074},"Iluvien 0.19 MG Drug Implant",{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3081,"PHASE4":3094,"NA":3096},{"trials":3076,"activeCount":101},[],{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":101},[],{"trials":3082,"activeCount":101},[3083],{"nctId":3084,"briefTitle":3085,"status":367,"phases":3086,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":101,"conditions":3090,"interventions":3092},"NCT03784443","Combined Ranibizumab and Iluvien for Diabetic Macular Oedema",[90,91],"2022-09-01","2023-09-01","2019-09-01",[3091,2047],"Diabetic Macular Edema",[3073,3093],"Ranibizumab Injection [Lucentis]",{"trials":3095,"activeCount":101},[],{"trials":3097,"activeCount":101},[],{"intervention":3093,"totalTrials":143,"cells":3099},{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3106,"PHASE4":3112,"NA":3114},{"trials":3101,"activeCount":101},[],{"trials":3103,"activeCount":101},[],{"trials":3105,"activeCount":101},[],{"trials":3107,"activeCount":101},[3108],{"nctId":3084,"briefTitle":3085,"status":367,"phases":3109,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":101,"conditions":3110,"interventions":3111},[90,91],[3091,2047],[3073,3093],{"trials":3113,"activeCount":101},[],{"trials":3115,"activeCount":101},[],{"intervention":121,"totalTrials":143,"cells":3117},{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3124,"PHASE4":3130,"NA":3132},{"trials":3119,"activeCount":101},[],{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":101},[3126],{"nctId":109,"briefTitle":110,"status":111,"phases":3127,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":3128,"interventions":3129},[91],[117,118],[120,121,122,96],{"trials":3131,"activeCount":101},[],{"trials":3133,"activeCount":101},[],{"intervention":122,"totalTrials":143,"cells":3135},{"EARLY_PHASE1":3136,"PHASE1":3138,"PHASE2":3140,"PHASE3":3142,"PHASE4":3148,"NA":3150},{"trials":3137,"activeCount":101},[],{"trials":3139,"activeCount":101},[],{"trials":3141,"activeCount":101},[],{"trials":3143,"activeCount":101},[3144],{"nctId":109,"briefTitle":110,"status":111,"phases":3145,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":3146,"interventions":3147},[91],[117,118],[120,121,122,96],{"trials":3149,"activeCount":101},[],{"trials":3151,"activeCount":101},[],{"intervention":3153,"totalTrials":143,"cells":3154},"Genistein",{"EARLY_PHASE1":3155,"PHASE1":3157,"PHASE2":3159,"PHASE3":3161,"PHASE4":3172,"NA":3174},{"trials":3156,"activeCount":101},[],{"trials":3158,"activeCount":101},[],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[3163],{"nctId":3164,"briefTitle":3165,"status":111,"phases":3166,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":3169,"conditions":3170,"interventions":3171},"NCT00287690","Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease",[90,91],"2003-08-18","1999-10",71,[2301],[3153],{"trials":3173,"activeCount":101},[],{"trials":3175,"activeCount":101},[],{"intervention":993,"totalTrials":143,"cells":3177},{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3184,"PHASE4":3190,"NA":3192},{"trials":3179,"activeCount":101},[],{"trials":3181,"activeCount":101},[],{"trials":3183,"activeCount":101},[],{"trials":3185,"activeCount":101},[3186],{"nctId":984,"briefTitle":985,"status":264,"phases":3187,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":3188,"interventions":3189},[91],[991],[993,973,994,995],{"trials":3191,"activeCount":101},[],{"trials":3193,"activeCount":101},[],{"intervention":994,"totalTrials":143,"cells":3195},{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3202,"PHASE4":3208,"NA":3210},{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[],{"trials":3203,"activeCount":101},[3204],{"nctId":984,"briefTitle":985,"status":264,"phases":3205,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":3206,"interventions":3207},[91],[991],[993,973,994,995],{"trials":3209,"activeCount":101},[],{"trials":3211,"activeCount":101},[],{"intervention":995,"totalTrials":143,"cells":3213},{"EARLY_PHASE1":3214,"PHASE1":3216,"PHASE2":3218,"PHASE3":3220,"PHASE4":3226,"NA":3228},{"trials":3215,"activeCount":101},[],{"trials":3217,"activeCount":101},[],{"trials":3219,"activeCount":101},[],{"trials":3221,"activeCount":101},[3222],{"nctId":984,"briefTitle":985,"status":264,"phases":3223,"primaryCompletion":987,"completion":987,"start":988,"enrollment":989,"conditions":3224,"interventions":3225},[91],[991],[993,973,994,995],{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[],{"intervention":3231,"totalTrials":143,"cells":3232},"Subcutaneous Alutard SQ grass pollen",{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3239,"PHASE4":3250,"NA":3252},{"trials":3234,"activeCount":101},[],{"trials":3236,"activeCount":101},[],{"trials":3238,"activeCount":101},[],{"trials":3240,"activeCount":101},[3241],{"nctId":3242,"briefTitle":3243,"status":111,"phases":3244,"completion":3245,"start":3246,"enrollment":349,"conditions":3247,"interventions":3249},"NCT00135642","Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and Asthma",[91],"1998-10","1996-02",[3248],"Rhinitis, Allergic, Seasonal",[3231],{"trials":3251,"activeCount":101},[],{"trials":3253,"activeCount":101},[],{"intervention":3255,"totalTrials":143,"cells":3256},"Ciprofloxacin",{"EARLY_PHASE1":3257,"PHASE1":3259,"PHASE2":3261,"PHASE3":3263,"PHASE4":3274,"NA":3276},{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[3265],{"nctId":3266,"briefTitle":3267,"status":111,"phases":3268,"primaryCompletion":3269,"completion":3269,"start":3270,"enrollment":3271,"conditions":3272,"interventions":3273},"NCT02300220","Targeted Retreatment of COPD Exacerbations",[91],"2019-01-22","2014-05-05",144,[2870],[3255],{"trials":3275,"activeCount":101},[],{"trials":3277,"activeCount":101},[],{"intervention":3279,"totalTrials":143,"cells":3280},"N-acetyl cysteine",{"EARLY_PHASE1":3281,"PHASE1":3283,"PHASE2":3285,"PHASE3":3287,"PHASE4":3300,"NA":3302},{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":101},[],{"trials":3286,"activeCount":101},[],{"trials":3288,"activeCount":101},[3289],{"nctId":3290,"briefTitle":3291,"status":952,"phases":3292,"primaryCompletion":3293,"completion":3294,"start":3295,"enrollment":565,"conditions":3296,"interventions":3299},"NCT03069300","N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis",[91],"2022-04-01","2025-06-01","2015-10-01",[3297,3298],"Alcoholic Hepatitis","Infection",[3279],{"trials":3301,"activeCount":101},[],{"trials":3303,"activeCount":101},[],{"intervention":1008,"totalTrials":143,"cells":3305},{"EARLY_PHASE1":3306,"PHASE1":3308,"PHASE2":3310,"PHASE3":3312,"PHASE4":3318,"NA":3320},{"trials":3307,"activeCount":101},[],{"trials":3309,"activeCount":101},[],{"trials":3311,"activeCount":101},[],{"trials":3313,"activeCount":101},[3314],{"nctId":997,"briefTitle":998,"status":264,"phases":3315,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":268,"conditions":3316,"interventions":3317},[91],[1004,1005],[973,1007,1008],{"trials":3319,"activeCount":101},[],{"trials":3321,"activeCount":101},[],{"intervention":3323,"totalTrials":143,"cells":3324},"Nebulised Bupivacaine intraperitoneally",{"EARLY_PHASE1":3325,"PHASE1":3327,"PHASE2":3329,"PHASE3":3331,"PHASE4":3344,"NA":3346},{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[],{"trials":3330,"activeCount":101},[],{"trials":3332,"activeCount":101},[3333],{"nctId":3334,"briefTitle":3335,"status":111,"phases":3336,"primaryCompletion":3337,"completion":3337,"start":3338,"enrollment":1839,"conditions":3339,"interventions":3341},"NCT00180687","Clinical Trial of the Use of Intraperitoneal Local Anaesthetic",[91],"2005-09","2004-10",[3340],"Pain, Postoperative",[3323,3342,3343],"Normal Saline","Injected Bupivacaine intraperitoneally",{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[],{"intervention":3342,"totalTrials":143,"cells":3349},{"EARLY_PHASE1":3350,"PHASE1":3352,"PHASE2":3354,"PHASE3":3356,"PHASE4":3362,"NA":3364},{"trials":3351,"activeCount":101},[],{"trials":3353,"activeCount":101},[],{"trials":3355,"activeCount":101},[],{"trials":3357,"activeCount":101},[3358],{"nctId":3334,"briefTitle":3335,"status":111,"phases":3359,"primaryCompletion":3337,"completion":3337,"start":3338,"enrollment":1839,"conditions":3360,"interventions":3361},[91],[3340],[3323,3342,3343],{"trials":3363,"activeCount":101},[],{"trials":3365,"activeCount":101},[],{"intervention":3343,"totalTrials":143,"cells":3367},{"EARLY_PHASE1":3368,"PHASE1":3370,"PHASE2":3372,"PHASE3":3374,"PHASE4":3380,"NA":3382},{"trials":3369,"activeCount":101},[],{"trials":3371,"activeCount":101},[],{"trials":3373,"activeCount":101},[],{"trials":3375,"activeCount":101},[3376],{"nctId":3334,"briefTitle":3335,"status":111,"phases":3377,"primaryCompletion":3337,"completion":3337,"start":3338,"enrollment":1839,"conditions":3378,"interventions":3379},[91],[3340],[3323,3342,3343],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"intervention":3385,"totalTrials":143,"cells":3386},"Gardasill 9™ vaccine",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3393,"PHASE4":3405,"NA":3407},{"trials":3388,"activeCount":101},[],{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[],{"trials":3394,"activeCount":101},[3395],{"nctId":3396,"briefTitle":3397,"status":111,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":3401,"conditions":3402,"interventions":3404},"NCT03979014","Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia",[91],"2025-09-05","2019-11-01",1099,[3403],"Neoplasia",[3385],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"intervention":3410,"totalTrials":143,"cells":3411},"polypill",{"EARLY_PHASE1":3412,"PHASE1":3414,"PHASE2":3416,"PHASE3":3418,"PHASE4":3429,"NA":3431},{"trials":3413,"activeCount":101},[],{"trials":3415,"activeCount":101},[],{"trials":3417,"activeCount":101},[],{"trials":3419,"activeCount":101},[3420],{"nctId":3421,"briefTitle":3422,"status":111,"phases":3423,"primaryCompletion":3027,"completion":1837,"start":3424,"enrollment":3425,"conditions":3426,"interventions":3427},"NCT01057537","UMPIRE - Use of a Multidrug Pill In Reducing Cardiovascular Events",[91],"2010-06",2004,[2161],[3410,3428],"Usual cardiovascular medications",{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":101},[],{"intervention":3428,"totalTrials":143,"cells":3434},{"EARLY_PHASE1":3435,"PHASE1":3437,"PHASE2":3439,"PHASE3":3441,"PHASE4":3447,"NA":3449},{"trials":3436,"activeCount":101},[],{"trials":3438,"activeCount":101},[],{"trials":3440,"activeCount":101},[],{"trials":3442,"activeCount":101},[3443],{"nctId":3421,"briefTitle":3422,"status":111,"phases":3444,"primaryCompletion":3027,"completion":1837,"start":3424,"enrollment":3425,"conditions":3445,"interventions":3446},[91],[2161],[3410,3428],{"trials":3448,"activeCount":101},[],{"trials":3450,"activeCount":101},[],{"intervention":3452,"totalTrials":143,"cells":3453},"Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).",{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3458,"PHASE3":3460,"PHASE4":3470,"NA":3472},{"trials":3455,"activeCount":101},[],{"trials":3457,"activeCount":101},[],{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[3462],{"nctId":3463,"briefTitle":3464,"status":111,"phases":3465,"primaryCompletion":3466,"completion":1561,"start":3467,"enrollment":26,"conditions":3468,"interventions":3469},"NCT00135629","Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever",[91],"2008-01","2002-10",[3248],[3452],{"trials":3471,"activeCount":101},[],{"trials":3473,"activeCount":101},[],{"intervention":3475,"totalTrials":268,"cells":3476},"Saline",{"EARLY_PHASE1":3477,"PHASE1":3492,"PHASE2":3504,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3478,"activeCount":101},[3479],{"nctId":3480,"briefTitle":3481,"status":952,"phases":3482,"primaryCompletion":3483,"completion":3484,"start":2273,"enrollment":3485,"conditions":3486,"interventions":3489},"NCT02690987","Gut Hormones in Obesity, Nicotine and Alcohol Dependence",[88],"2019-08-21","2020-08",95,[19,3487,3488],"Smoking Cessation","Alcoholism",[3490,3491,3475],"Exenatide","Desacyl ghrelin",{"trials":3493,"activeCount":101},[3494],{"nctId":3495,"briefTitle":3496,"status":111,"phases":3497,"primaryCompletion":3498,"completion":3498,"start":3499,"enrollment":1412,"conditions":3500,"interventions":3502},"NCT01590108","The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects",[89],"2014-09","2012-03",[3501],"Idiopathic Pulmonary Arterial Hypertension",[3503,3475],"(Pyr1)apelin-13",{"trials":3505,"activeCount":101},[3506],{"nctId":3507,"briefTitle":3508,"status":111,"phases":3509,"primaryCompletion":3510,"completion":3510,"start":3511,"enrollment":3512,"conditions":3513,"interventions":3516},"NCT01447628","IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients",[90],"2017-12-22","2011-03-29",56,[3514,3515],"Pulmonary Arterial Hypertension","Iron Deficiency",[3475,3517],"Ferinject or CosmoFer",{"trials":3519,"activeCount":101},[],{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[],{"intervention":3525,"totalTrials":97,"cells":3526},"Simvastatin",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3551,"PHASE4":3553,"NA":3555},{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":101},[],{"trials":3532,"activeCount":101},[3533,3542],{"nctId":3534,"briefTitle":3535,"status":111,"phases":3536,"primaryCompletion":3537,"completion":3537,"start":3466,"enrollment":3538,"conditions":3539,"interventions":3541},"NCT00647348","Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis",[90],"2011-11",140,[3540],"Secondary Progressive Multiple Sclerosis",[3525],{"nctId":3543,"briefTitle":3544,"status":111,"phases":3545,"primaryCompletion":1561,"completion":3546,"start":3547,"enrollment":565,"conditions":3548,"interventions":3550},"NCT00180713","Simvastatin as a Treatment for Pulmonary Hypertension",[89,90],"2009-05","2005-10",[3549],"Pulmonary Hypertension",[3525],{"trials":3552,"activeCount":101},[],{"trials":3554,"activeCount":101},[],{"trials":3556,"activeCount":101},[],{"intervention":3558,"totalTrials":97,"cells":3559},"0.9% saline",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3573,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3561,"activeCount":101},[],{"trials":3563,"activeCount":101},[3564],{"nctId":3565,"briefTitle":3566,"status":111,"phases":3567,"primaryCompletion":3568,"completion":3568,"start":1587,"enrollment":3569,"conditions":3570,"interventions":3571},"NCT01515319","Safety and Pharmacokinetic Study of Y242 in Adult Subjects",[89],"2013-02",68,[19],[3572,3558],"Y242",{"trials":3574,"activeCount":101},[3575],{"nctId":3576,"briefTitle":3577,"status":111,"phases":3578,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":3581,"conditions":3582,"interventions":3584},"NCT00655928","Modulation of Lung Injury Complicating Lung Resection",[90],"2009-07","2007-08",52,[3583],"Acute Lung Injury",[3585,3558],"N-acetylcysteine",{"trials":3587,"activeCount":101},[],{"trials":3589,"activeCount":101},[],{"trials":3591,"activeCount":101},[],{"intervention":3593,"totalTrials":97,"cells":3594},"pGM169\u002FGL67A",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3617,"PHASE4":3619,"NA":3621},{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":101},[],{"trials":3600,"activeCount":101},[3601,3609],{"nctId":3602,"briefTitle":3603,"status":111,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":1363,"enrollment":3606,"conditions":3607,"interventions":3608},"NCT01621867","Repeated Application of Gene Therapy in CF Patients",[90],"2014-05",130,[2072],[3593],{"nctId":3610,"briefTitle":3611,"status":111,"phases":3612,"primaryCompletion":3613,"completion":2450,"start":3614,"enrollment":429,"conditions":3615,"interventions":3616},"NCT00789867","Single Dose of pGM169\u002FGL67A in CF Patients",[89,90],"2009-08","2008-11",[2072],[3593],{"trials":3618,"activeCount":101},[],{"trials":3620,"activeCount":101},[],{"trials":3622,"activeCount":101},[],{"intervention":3624,"totalTrials":97,"cells":3625},"Irosustat",{"EARLY_PHASE1":3626,"PHASE1":3628,"PHASE2":3630,"PHASE3":3649,"PHASE4":3651,"NA":3653},{"trials":3627,"activeCount":101},[],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[3632,3640],{"nctId":3633,"briefTitle":3634,"status":264,"phases":3635,"primaryCompletion":2867,"completion":1941,"start":3636,"enrollment":32,"conditions":3637,"interventions":3639},"NCT01662726","A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth",[90],"2012-08",[3638],"Breast Neoplasms",[3624],{"nctId":3641,"briefTitle":3642,"status":111,"phases":3643,"primaryCompletion":1941,"completion":1941,"start":3644,"enrollment":830,"conditions":3645,"interventions":3648},"NCT01785992","A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.",[90],"2012-10",[3646,3647],"Locally Advanced Breast Cancer","Metastatic Breast Cancer",[3624],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[],{"trials":3654,"activeCount":101},[],{"intervention":1322,"totalTrials":143,"cells":3656},{"EARLY_PHASE1":3657,"PHASE1":3659,"PHASE2":3661,"PHASE3":3667,"PHASE4":3669,"NA":3671},{"trials":3658,"activeCount":101},[],{"trials":3660,"activeCount":101},[],{"trials":3662,"activeCount":101},[3663],{"nctId":1314,"briefTitle":1315,"status":111,"phases":3664,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":771,"conditions":3665,"interventions":3666},[90],[34],[1322,1294,1323,1324,1325],{"trials":3668,"activeCount":101},[],{"trials":3670,"activeCount":101},[],{"trials":3672,"activeCount":101},[],{"intervention":1323,"totalTrials":143,"cells":3674},{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3685,"PHASE4":3687,"NA":3689},{"trials":3676,"activeCount":101},[],{"trials":3678,"activeCount":101},[],{"trials":3680,"activeCount":101},[3681],{"nctId":1314,"briefTitle":1315,"status":111,"phases":3682,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":771,"conditions":3683,"interventions":3684},[90],[34],[1322,1294,1323,1324,1325],{"trials":3686,"activeCount":101},[],{"trials":3688,"activeCount":101},[],{"trials":3690,"activeCount":101},[],{"intervention":1324,"totalTrials":143,"cells":3692},{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[3699],{"nctId":1314,"briefTitle":1315,"status":111,"phases":3700,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":771,"conditions":3701,"interventions":3702},[90],[34],[1322,1294,1323,1324,1325],{"trials":3704,"activeCount":101},[],{"trials":3706,"activeCount":101},[],{"trials":3708,"activeCount":101},[],{"intervention":1325,"totalTrials":143,"cells":3710},{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3715,"PHASE3":3721,"PHASE4":3723,"NA":3725},{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[3717],{"nctId":1314,"briefTitle":1315,"status":111,"phases":3718,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":771,"conditions":3719,"interventions":3720},[90],[34],[1322,1294,1323,1324,1325],{"trials":3722,"activeCount":101},[],{"trials":3724,"activeCount":101},[],{"trials":3726,"activeCount":101},[],{"intervention":3728,"totalTrials":143,"cells":3729},"perindopril arginine",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3745,"PHASE4":3747,"NA":3749},{"trials":3731,"activeCount":101},[],{"trials":3733,"activeCount":101},[],{"trials":3735,"activeCount":101},[3736],{"nctId":3737,"briefTitle":3738,"status":111,"phases":3739,"primaryCompletion":988,"completion":988,"start":1813,"enrollment":3740,"conditions":3741,"interventions":3743},"NCT01118520","AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)",[90],224,[3742],"Abdominal Aortic Aneurysm",[3728,3744],"amlodipine 5mgs",{"trials":3746,"activeCount":101},[],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[],{"intervention":3744,"totalTrials":143,"cells":3752},{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3763,"PHASE4":3765,"NA":3767},{"trials":3754,"activeCount":101},[],{"trials":3756,"activeCount":101},[],{"trials":3758,"activeCount":101},[3759],{"nctId":3737,"briefTitle":3738,"status":111,"phases":3760,"primaryCompletion":988,"completion":988,"start":1813,"enrollment":3740,"conditions":3761,"interventions":3762},[90],[3742],[3728,3744],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"trials":3768,"activeCount":101},[],{"intervention":3770,"totalTrials":143,"cells":3771},"NK3R antagonist - AZD4901",{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3787,"PHASE4":3789,"NA":3791},{"trials":3773,"activeCount":101},[],{"trials":3775,"activeCount":101},[],{"trials":3777,"activeCount":101},[3778],{"nctId":3779,"briefTitle":3780,"status":111,"phases":3781,"primaryCompletion":3782,"completion":3782,"start":2891,"enrollment":3783,"conditions":3784,"interventions":3786},"NCT02668185","Neuropeptide Treatment for Hot Flushes During the Menopause",[90],"2017-01-01",37,[3785],"Menopausal Flushing",[3770],{"trials":3788,"activeCount":101},[],{"trials":3790,"activeCount":101},[],{"trials":3792,"activeCount":101},[],{"intervention":3794,"totalTrials":143,"cells":3795},"Study drug administration",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3810,"PHASE4":3812,"NA":3814},{"trials":3797,"activeCount":101},[],{"trials":3799,"activeCount":101},[],{"trials":3801,"activeCount":101},[3802],{"nctId":3803,"briefTitle":3804,"status":111,"phases":3805,"completion":3806,"start":3807,"enrollment":1612,"conditions":3808,"interventions":3809},"NCT00278083","TNF-alpha Directed Therapy in Asthma",[90],"2004-04","2001-10",[16],[3794],{"trials":3811,"activeCount":101},[],{"trials":3813,"activeCount":101},[],{"trials":3815,"activeCount":101},[],{"intervention":3817,"totalTrials":143,"cells":3818},"AAV1\u002FSERCA2a",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3834,"PHASE4":3836,"NA":3838},{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"trials":3824,"activeCount":101},[3825],{"nctId":3826,"briefTitle":3827,"status":264,"phases":3828,"primaryCompletion":3829,"completion":3829,"start":2867,"enrollment":1441,"conditions":3830,"interventions":3833},"NCT00534703","Investigation of the Safety and Feasibility of AAV1\u002FSERCA2a Gene Transfer in Patients With Chronic Heart Failure",[90],"2015-09",[3831,3832],"Chronic Heart Failure","Patients That Have Received a Left Ventricular Assist Device",[3817],{"trials":3835,"activeCount":101},[],{"trials":3837,"activeCount":101},[],{"trials":3839,"activeCount":101},[],{"intervention":3841,"totalTrials":143,"cells":3842},"Grazax",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3860,"PHASE4":3862,"NA":3864},{"trials":3844,"activeCount":101},[],{"trials":3846,"activeCount":101},[],{"trials":3848,"activeCount":101},[3849],{"nctId":3850,"briefTitle":3851,"status":111,"phases":3852,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":3855,"conditions":3856,"interventions":3858},"NCT02005627","Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study",[90],"2017-03-01","2013-09-01",46,[3857],"Allergic Rhinitis",[3841,3859],"Grazax Placebo",{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"trials":3865,"activeCount":101},[],{"intervention":3859,"totalTrials":143,"cells":3867},{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3878,"PHASE4":3880,"NA":3882},{"trials":3869,"activeCount":101},[],{"trials":3871,"activeCount":101},[],{"trials":3873,"activeCount":101},[3874],{"nctId":3850,"briefTitle":3851,"status":111,"phases":3875,"primaryCompletion":3853,"completion":3853,"start":3854,"enrollment":3855,"conditions":3876,"interventions":3877},[90],[3857],[3841,3859],{"trials":3879,"activeCount":101},[],{"trials":3881,"activeCount":101},[],{"trials":3883,"activeCount":101},[],{"intervention":3885,"totalTrials":143,"cells":3886},"Infliximab",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3899,"PHASE4":3901,"NA":3903},{"trials":3888,"activeCount":101},[],{"trials":3890,"activeCount":101},[],{"trials":3892,"activeCount":101},[3893],{"nctId":3894,"briefTitle":3895,"status":264,"phases":3896,"primaryCompletion":2451,"completion":2451,"start":1561,"enrollment":268,"conditions":3897,"interventions":3898},"NCT00823641","The HAM Infliximab Study",[90],[3005],[3885],{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"intervention":3906,"totalTrials":143,"cells":3907},"Autologous Expanded CD34+ Haemopoietic cells",{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3912,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3909,"activeCount":101},[],{"trials":3911,"activeCount":101},[],{"trials":3913,"activeCount":101},[3914],{"nctId":3915,"briefTitle":3916,"status":111,"phases":3917,"primaryCompletion":2705,"completion":2705,"start":3918,"enrollment":1441,"conditions":3919,"interventions":3921},"NCT00655707","A Phase I\u002FII Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency",[89,90],"2006-01",[3920],"Liver Disease",[3906],{"trials":3923,"activeCount":101},[],{"trials":3925,"activeCount":101},[],{"trials":3927,"activeCount":101},[],{"intervention":3929,"totalTrials":143,"cells":3930},"MitoQ Compound",{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3935,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3932,"activeCount":101},[],{"trials":3934,"activeCount":101},[],{"trials":3936,"activeCount":101},[3937],{"nctId":3938,"briefTitle":3939,"status":111,"phases":3940,"primaryCompletion":3941,"completion":3941,"start":3942,"enrollment":3943,"conditions":3944,"interventions":3946},"NCT05410873","Examining the Effects of Mitochondrial Oxidative Stress in DCM",[90],"2024-06-19","2022-07-26",53,[3945],"Dilated Cardiomyopathy",[3929],{"trials":3948,"activeCount":101},[],{"trials":3950,"activeCount":101},[],{"trials":3952,"activeCount":101},[],{"intervention":3954,"totalTrials":143,"cells":3955},"20% Human albumin solution",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3960,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3957,"activeCount":101},[],{"trials":3959,"activeCount":101},[],{"trials":3961,"activeCount":101},[3962],{"nctId":3963,"briefTitle":3964,"status":264,"phases":3965,"primaryCompletion":2224,"completion":2224,"start":3966,"enrollment":3967,"conditions":3968,"interventions":3971},"NCT00773110","Study of Albumin to Reduce Inflammation Following Surgery",[90],"2008-12",232,[3969,3970],"Systemic Inflammatory Response Syndrome","Cardiopulmonary Bypass",[3954,3972],"Gelofusin",{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":101},[],{"intervention":3972,"totalTrials":143,"cells":3980},{"EARLY_PHASE1":3981,"PHASE1":3983,"PHASE2":3985,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3982,"activeCount":101},[],{"trials":3984,"activeCount":101},[],{"trials":3986,"activeCount":101},[3987],{"nctId":3963,"briefTitle":3964,"status":264,"phases":3988,"primaryCompletion":2224,"completion":2224,"start":3966,"enrollment":3967,"conditions":3989,"interventions":3990},[90],[3969,3970],[3954,3972],{"trials":3992,"activeCount":101},[],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[],{"intervention":3998,"totalTrials":143,"cells":3999},"PP1420",{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4001,"activeCount":101},[],{"trials":4003,"activeCount":101},[],{"trials":4005,"activeCount":101},[4006],{"nctId":4007,"briefTitle":4008,"status":264,"phases":4009,"primaryCompletion":4010,"completion":4010,"start":4011,"enrollment":4012,"conditions":4013,"interventions":4014},"NCT02221765","Safety, Tolerability and Efficacy Study of PP1420 in HV",[89,90],"2016-05","2014-08",49,[19],[3998],{"trials":4016,"activeCount":101},[],{"trials":4018,"activeCount":101},[],{"trials":4020,"activeCount":101},[],{"intervention":4022,"totalTrials":143,"cells":4023},"Deferiprone 20mg",{"EARLY_PHASE1":4024,"PHASE1":4026,"PHASE2":4028,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[],{"trials":4029,"activeCount":101},[4030],{"nctId":4031,"briefTitle":4032,"status":111,"phases":4033,"primaryCompletion":3498,"completion":1941,"start":1362,"enrollment":23,"conditions":4034,"interventions":4036},"NCT01539837","A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease",[90],[4035],"Parkinson's Disease",[4022,4037],"Deferiprone 30mg",{"trials":4039,"activeCount":101},[],{"trials":4041,"activeCount":101},[],{"trials":4043,"activeCount":101},[],{"intervention":4037,"totalTrials":143,"cells":4045},{"EARLY_PHASE1":4046,"PHASE1":4048,"PHASE2":4050,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4047,"activeCount":101},[],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[4052],{"nctId":4031,"briefTitle":4032,"status":111,"phases":4053,"primaryCompletion":3498,"completion":1941,"start":1362,"enrollment":23,"conditions":4054,"interventions":4055},[90],[4035],[4022,4037],{"trials":4057,"activeCount":101},[],{"trials":4059,"activeCount":101},[],{"trials":4061,"activeCount":101},[],{"intervention":4063,"totalTrials":143,"cells":4064},"Abatacept",{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4069,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4066,"activeCount":101},[],{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[4071],{"nctId":4072,"briefTitle":4073,"status":264,"phases":4074,"primaryCompletion":3614,"completion":3614,"start":4075,"enrollment":2979,"conditions":4076,"interventions":4078},"NCT00482066","Abatacept in ANCA Associated Vasculitis",[90],"2007-11",[4077],"ANCA-associated Vasculitis",[4063],{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[],{"intervention":4086,"totalTrials":143,"cells":4087},"Paclitaxel",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[],{"trials":4093,"activeCount":101},[4094],{"nctId":4095,"briefTitle":4096,"status":111,"phases":4097,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":4100,"conditions":4101,"interventions":4112},"NCT03648489","Dual mTorc Inhibition in advanCed\u002FRecurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)",[90],"2023-11-30","2018-09-21",134,[4102,4103,4104,4105,4106,4107,4108,4109,4110,4111],"Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinosarcoma","Ovarian Serous Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Clear Cell Adenocarcinoma","Fallopian Tube Cancer","Fallopian Tube Neoplasms","Primary Peritoneal Carcinoma","Primary Peritoneal Serous Adenocarcinoma",[4086,4113],"TAK228",{"trials":4115,"activeCount":101},[],{"trials":4117,"activeCount":101},[],{"trials":4119,"activeCount":101},[],{"intervention":4113,"totalTrials":143,"cells":4121},{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4126,"PHASE3":4132,"PHASE4":4134,"NA":4136},{"trials":4123,"activeCount":101},[],{"trials":4125,"activeCount":101},[],{"trials":4127,"activeCount":101},[4128],{"nctId":4095,"briefTitle":4096,"status":111,"phases":4129,"primaryCompletion":4098,"completion":4098,"start":4099,"enrollment":4100,"conditions":4130,"interventions":4131},[90],[4102,4103,4104,4105,4106,4107,4108,4109,4110,4111],[4086,4113],{"trials":4133,"activeCount":101},[],{"trials":4135,"activeCount":101},[],{"trials":4137,"activeCount":101},[],{"intervention":4139,"totalTrials":143,"cells":4140},"Lutathera",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4160,"PHASE4":4162,"NA":4164},{"trials":4142,"activeCount":101},[],{"trials":4144,"activeCount":101},[],{"trials":4146,"activeCount":101},[4147],{"nctId":4148,"briefTitle":4149,"status":264,"phases":4150,"primaryCompletion":4151,"completion":4151,"start":4152,"enrollment":143,"conditions":4153,"interventions":4159},"NCT05987176","Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases",[90],"2025-10-21","2024-08-02",[4154,4155,591,4156,4157,4158],"Neuroendocrine Tumor G1 (NET G1)\u002FCarcinoid","Neuroendocrine Tumor Grade 2","Liver Metastases","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Neoplasm",[4139],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[],{"trials":4165,"activeCount":101},[],{"intervention":4167,"totalTrials":143,"cells":4168},"Apremilast",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4183,"PHASE4":4185,"NA":4187},{"trials":4170,"activeCount":101},[],{"trials":4172,"activeCount":101},[],{"trials":4174,"activeCount":101},[4175],{"nctId":4176,"briefTitle":4177,"status":111,"phases":4178,"primaryCompletion":4179,"completion":4179,"start":3613,"enrollment":853,"conditions":4180,"interventions":4182},"NCT00944658","Spondylitis Trial of Apremilast for Better Rheumatic Therapy",[90],"2011-01",[4181],"Ankylosing Spondylitis",[4167],{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[],{"trials":4188,"activeCount":101},[],{"intervention":4190,"totalTrials":143,"cells":4191},"Canakinumab 150mg\u002Fml solution for",{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4196,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4193,"activeCount":101},[],{"trials":4195,"activeCount":101},[],{"trials":4197,"activeCount":101},[4198],{"nctId":4199,"briefTitle":4200,"status":111,"phases":4201,"primaryCompletion":1318,"completion":1318,"start":4202,"enrollment":4203,"conditions":4204,"interventions":4205},"NCT03775109","IL-1 Signal Inhibition in Alcoholic Hepatitis",[90],"2019-02-12",55,[3297],[4190],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[],{"intervention":4213,"totalTrials":143,"cells":4214},"Donepezil",{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4216,"activeCount":101},[],{"trials":4218,"activeCount":101},[],{"trials":4220,"activeCount":101},[4221],{"nctId":4222,"briefTitle":4223,"status":367,"phases":4224,"primaryCompletion":4225,"completion":3605,"start":3537,"enrollment":101,"conditions":4226,"interventions":4228},"NCT01442766","Donepezil Trial for Motor Recovery in Acute Stroke",[89,90],"2013-11",[4227],"Acute Stroke",[4213],{"trials":4230,"activeCount":101},[],{"trials":4232,"activeCount":101},[],{"trials":4234,"activeCount":101},[],{"intervention":4236,"totalTrials":143,"cells":4237},"Melatonin",{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4242,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4239,"activeCount":101},[],{"trials":4241,"activeCount":101},[],{"trials":4243,"activeCount":101},[4244],{"nctId":4245,"briefTitle":4246,"status":111,"phases":4247,"primaryCompletion":1355,"completion":1355,"start":2538,"enrollment":26,"conditions":4248,"interventions":4251},"NCT00649961","Melatonin As A Novel Neuroprotectant In Preterm Infants- Dosage Study",[90],[4249,4250],"Premature Birth","Brain Injury",[4236],{"trials":4253,"activeCount":101},[],{"trials":4255,"activeCount":101},[],{"trials":4257,"activeCount":101},[],{"intervention":4259,"totalTrials":143,"cells":4260},"[18F]-FET-βAG-TOCA",{"EARLY_PHASE1":4261,"PHASE1":4263,"PHASE2":4265,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[4267],{"nctId":4268,"briefTitle":4269,"status":111,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":3512,"conditions":4273,"interventions":4274},"NCT06456723","Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.",[89,90],"2018-10-17","2014-05-14",[591],[4259],{"trials":4276,"activeCount":101},[],{"trials":4278,"activeCount":101},[],{"trials":4280,"activeCount":101},[],{"intervention":4282,"totalTrials":143,"cells":4283},"AZD4547 \u002F anastrozole or letrozole",{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4288,"PHASE3":4298,"PHASE4":4300,"NA":4302},{"trials":4285,"activeCount":101},[],{"trials":4287,"activeCount":101},[],{"trials":4289,"activeCount":101},[4290],{"nctId":4291,"briefTitle":4292,"status":111,"phases":4293,"primaryCompletion":4294,"completion":4295,"start":3027,"enrollment":3581,"conditions":4296,"interventions":4297},"NCT01791985","AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)",[89,90],"2016-11","2018-12",[31],[4282],{"trials":4299,"activeCount":101},[],{"trials":4301,"activeCount":101},[],{"trials":4303,"activeCount":101},[],{"intervention":4305,"totalTrials":143,"cells":4306},"Ipilimumab",{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4311,"PHASE3":4324,"PHASE4":4326,"NA":4328},{"trials":4308,"activeCount":101},[],{"trials":4310,"activeCount":101},[],{"trials":4312,"activeCount":101},[4313],{"nctId":4314,"briefTitle":4315,"status":952,"phases":4316,"primaryCompletion":3088,"completion":4317,"start":4318,"enrollment":4319,"conditions":4320,"interventions":4322},"NCT03682276","Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma",[89,90],"2023-12-01","2019-03-01",32,[4321],"Hepatocellular Carcinoma",[4305,4323],"Nivolumab",{"trials":4325,"activeCount":101},[],{"trials":4327,"activeCount":101},[],{"trials":4329,"activeCount":101},[],{"intervention":4323,"totalTrials":143,"cells":4331},{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4342,"PHASE4":4344,"NA":4346},{"trials":4333,"activeCount":101},[],{"trials":4335,"activeCount":101},[],{"trials":4337,"activeCount":101},[4338],{"nctId":4314,"briefTitle":4315,"status":952,"phases":4339,"primaryCompletion":3088,"completion":4317,"start":4318,"enrollment":4319,"conditions":4340,"interventions":4341},[89,90],[4321],[4305,4323],{"trials":4343,"activeCount":101},[],{"trials":4345,"activeCount":101},[],{"trials":4347,"activeCount":101},[],{"intervention":4349,"totalTrials":143,"cells":4350},"Qutenza",{"EARLY_PHASE1":4351,"PHASE1":4353,"PHASE2":4355,"PHASE3":4366,"PHASE4":4368,"NA":4370},{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":101},[4357],{"nctId":4358,"briefTitle":4359,"status":111,"phases":4360,"primaryCompletion":3027,"completion":3027,"start":4361,"enrollment":37,"conditions":4362,"interventions":4364},"NCT01393795","Qutenza®-Remodulin® in Pulmonary Arterial Hypertension Patients",[90],"2011-08",[3549,4363],"Pain",[4349,4365],"Tegaderm",{"trials":4367,"activeCount":101},[],{"trials":4369,"activeCount":101},[],{"trials":4371,"activeCount":101},[],{"intervention":4365,"totalTrials":143,"cells":4373},{"EARLY_PHASE1":4374,"PHASE1":4376,"PHASE2":4378,"PHASE3":4384,"PHASE4":4386,"NA":4388},{"trials":4375,"activeCount":101},[],{"trials":4377,"activeCount":101},[],{"trials":4379,"activeCount":101},[4380],{"nctId":4358,"briefTitle":4359,"status":111,"phases":4381,"primaryCompletion":3027,"completion":3027,"start":4361,"enrollment":37,"conditions":4382,"interventions":4383},[90],[3549,4363],[4349,4365],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":101},[],{"intervention":4391,"totalTrials":143,"cells":4392},"Low dose steroids",{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4397,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4394,"activeCount":101},[],{"trials":4396,"activeCount":101},[],{"trials":4398,"activeCount":101},[4399],{"nctId":4400,"briefTitle":4401,"status":367,"phases":4402,"primaryCompletion":3547,"completion":3547,"start":3547,"enrollment":101,"conditions":4403,"interventions":4405},"NCT00180778","Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss",[89,90],[4404],"Antiphospholipid Syndrome",[4391],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"intervention":4413,"totalTrials":143,"cells":4414},"Darbepoetin Alfa",{"EARLY_PHASE1":4415,"PHASE1":4417,"PHASE2":4419,"PHASE3":4429,"PHASE4":4431,"NA":4433},{"trials":4416,"activeCount":101},[],{"trials":4418,"activeCount":101},[],{"trials":4420,"activeCount":101},[4421],{"nctId":4422,"briefTitle":4423,"status":952,"phases":4424,"primaryCompletion":1233,"completion":1233,"start":4425,"enrollment":1157,"conditions":4426,"interventions":4428},"NCT04432662","Darbepoetin in Neonatal Encephalopathy Trial",[90],"2021-05-28",[4427],"Neonatal Encephalopathy",[4413],{"trials":4430,"activeCount":101},[],{"trials":4432,"activeCount":101},[],{"trials":4434,"activeCount":101},[],{"intervention":413,"totalTrials":143,"cells":4436},{"EARLY_PHASE1":4437,"PHASE1":4439,"PHASE2":4441,"PHASE3":4447,"PHASE4":4449,"NA":4451},{"trials":4438,"activeCount":101},[],{"trials":4440,"activeCount":101},[],{"trials":4442,"activeCount":101},[4443],{"nctId":403,"briefTitle":404,"status":111,"phases":4444,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":4445,"interventions":4446},[89,90],[411],[77,413],{"trials":4448,"activeCount":101},[],{"trials":4450,"activeCount":101},[],{"trials":4452,"activeCount":101},[],{"intervention":4454,"totalTrials":143,"cells":4455},"Liraglutide Pen Injector [Victoza]",{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4460,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4457,"activeCount":101},[],{"trials":4459,"activeCount":101},[],{"trials":4461,"activeCount":101},[4462],{"nctId":4463,"briefTitle":4464,"status":367,"phases":4465,"primaryCompletion":4466,"completion":4467,"start":4468,"enrollment":101,"conditions":4469,"interventions":4471},"NCT03371862","Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)",[90],"2020-08-06","2020-09-30","2017-10-20",[4470],"Short Bowel Syndrome",[4454],{"trials":4473,"activeCount":101},[],{"trials":4475,"activeCount":101},[],{"trials":4477,"activeCount":101},[],{"intervention":4479,"totalTrials":143,"cells":4480},"Warfarin",{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4497,"PHASE4":4499,"NA":4501},{"trials":4482,"activeCount":101},[],{"trials":4484,"activeCount":101},[],{"trials":4486,"activeCount":101},[4487],{"nctId":4488,"briefTitle":4489,"status":111,"phases":4490,"primaryCompletion":4491,"completion":4492,"start":4493,"enrollment":942,"conditions":4494,"interventions":4496},"NCT00180674","Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection",[90],"2006-09","2006-10","2005-08",[4495],"Liver Fibrosis",[4479],{"trials":4498,"activeCount":101},[],{"trials":4500,"activeCount":101},[],{"trials":4502,"activeCount":101},[],{"intervention":4504,"totalTrials":143,"cells":4505},"GTU®-MultiHIV B Clade Vaccine",{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4510,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4507,"activeCount":101},[],{"trials":4509,"activeCount":101},[],{"trials":4511,"activeCount":101},[4512],{"nctId":4513,"briefTitle":4514,"status":111,"phases":4515,"primaryCompletion":4516,"completion":4516,"start":1586,"enrollment":10,"conditions":4517,"interventions":4518},"NCT02457689","The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo",[89,90],"2016-07",[34],[4504],{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":101},[],{"trials":4524,"activeCount":101},[],{"intervention":4526,"totalTrials":143,"cells":4527},"Liraglutide",{"EARLY_PHASE1":4528,"PHASE1":4530,"PHASE2":4532,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4529,"activeCount":101},[],{"trials":4531,"activeCount":101},[],{"trials":4533,"activeCount":101},[4534],{"nctId":4535,"briefTitle":4536,"status":952,"phases":4537,"primaryCompletion":4538,"completion":4538,"start":4539,"enrollment":4540,"conditions":4541,"interventions":4543},"NCT01843075","Evaluating Liraglutide in Alzheimer's Disease",[90],"2019-12","2014-01",204,[4542],"Alzheimer's Disease",[4526],{"trials":4545,"activeCount":101},[],{"trials":4547,"activeCount":101},[],{"trials":4549,"activeCount":101},[],{"intervention":4551,"totalTrials":143,"cells":4552},"Fluticasone Propionate",{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4554,"activeCount":101},[],{"trials":4556,"activeCount":101},[],{"trials":4558,"activeCount":101},[4559],{"nctId":4560,"briefTitle":4561,"status":111,"phases":4562,"primaryCompletion":3580,"completion":3580,"start":4563,"enrollment":4012,"conditions":4564,"interventions":4565},"NCT00241631","Enhancement of in-Vitro GC Function in Patients With COPD",[90],"2006-04",[25],[4551,4566],"Theophylline",{"trials":4568,"activeCount":101},[],{"trials":4570,"activeCount":101},[],{"trials":4572,"activeCount":101},[],{"intervention":4566,"totalTrials":143,"cells":4574},{"EARLY_PHASE1":4575,"PHASE1":4577,"PHASE2":4579,"PHASE3":4585,"PHASE4":4587,"NA":4589},{"trials":4576,"activeCount":101},[],{"trials":4578,"activeCount":101},[],{"trials":4580,"activeCount":101},[4581],{"nctId":4560,"briefTitle":4561,"status":111,"phases":4582,"primaryCompletion":3580,"completion":3580,"start":4563,"enrollment":4012,"conditions":4583,"interventions":4584},[90],[25],[4551,4566],{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":101},[],{"trials":4590,"activeCount":101},[],{"intervention":3517,"totalTrials":143,"cells":4592},{"EARLY_PHASE1":4593,"PHASE1":4595,"PHASE2":4597,"PHASE3":4603,"PHASE4":4605,"NA":4607},{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[4599],{"nctId":3507,"briefTitle":3508,"status":111,"phases":4600,"primaryCompletion":3510,"completion":3510,"start":3511,"enrollment":3512,"conditions":4601,"interventions":4602},[90],[3514,3515],[3475,3517],{"trials":4604,"activeCount":101},[],{"trials":4606,"activeCount":101},[],{"trials":4608,"activeCount":101},[],{"intervention":4610,"totalTrials":143,"cells":4611},"Beclometasone",{"EARLY_PHASE1":4612,"PHASE1":4614,"PHASE2":4616,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4613,"activeCount":101},[],{"trials":4615,"activeCount":101},[],{"trials":4617,"activeCount":101},[4618],{"nctId":4619,"briefTitle":4620,"status":111,"phases":4621,"primaryCompletion":4622,"completion":4622,"start":4623,"enrollment":771,"conditions":4624,"interventions":4625},"NCT02517099","Preschool Wheeze: Inflammation\u002FInfection Guided Management",[90],"2018-08-17","2015-06-05",[16],[4610,4626,4627],"Co-amoxiclav","Azithromycin",{"trials":4629,"activeCount":101},[],{"trials":4631,"activeCount":101},[],{"trials":4633,"activeCount":101},[],{"intervention":4626,"totalTrials":143,"cells":4635},{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4646,"PHASE4":4648,"NA":4650},{"trials":4637,"activeCount":101},[],{"trials":4639,"activeCount":101},[],{"trials":4641,"activeCount":101},[4642],{"nctId":4619,"briefTitle":4620,"status":111,"phases":4643,"primaryCompletion":4622,"completion":4622,"start":4623,"enrollment":771,"conditions":4644,"interventions":4645},[90],[16],[4610,4626,4627],{"trials":4647,"activeCount":101},[],{"trials":4649,"activeCount":101},[],{"trials":4651,"activeCount":101},[],{"intervention":4627,"totalTrials":143,"cells":4653},{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4664,"PHASE4":4666,"NA":4668},{"trials":4655,"activeCount":101},[],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[4660],{"nctId":4619,"briefTitle":4620,"status":111,"phases":4661,"primaryCompletion":4622,"completion":4622,"start":4623,"enrollment":771,"conditions":4662,"interventions":4663},[90],[16],[4610,4626,4627],{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[],{"trials":4669,"activeCount":101},[],{"intervention":4671,"totalTrials":143,"cells":4672},"Imatinib Mesylate",{"EARLY_PHASE1":4673,"PHASE1":4675,"PHASE2":4677,"PHASE3":4687,"PHASE4":4689,"NA":4691},{"trials":4674,"activeCount":101},[],{"trials":4676,"activeCount":101},[],{"trials":4678,"activeCount":101},[4679],{"nctId":4680,"briefTitle":4681,"status":952,"phases":4682,"primaryCompletion":4683,"completion":4683,"start":4684,"enrollment":29,"conditions":4685,"interventions":4686},"NCT04416750","Positioning Imatinib for Pulmonary Arterial Hypertension",[90],"2024-07-01","2021-01-20",[3514],[4671],{"trials":4688,"activeCount":101},[],{"trials":4690,"activeCount":101},[],{"trials":4692,"activeCount":101},[],{"intervention":4694,"totalTrials":143,"cells":4695},"Indocyanine green",{"EARLY_PHASE1":4696,"PHASE1":4698,"PHASE2":4700,"PHASE3":4709,"PHASE4":4711,"NA":4713},{"trials":4697,"activeCount":101},[],{"trials":4699,"activeCount":101},[],{"trials":4701,"activeCount":101},[4702],{"nctId":4703,"briefTitle":4704,"status":111,"phases":4705,"primaryCompletion":3829,"completion":267,"start":2537,"enrollment":10,"conditions":4706,"interventions":4708},"NCT01662752","Lymphatic Mapping for Sentinel Node Identification and Analysis",[90],[4707],"Colorectal Cancer",[4694],{"trials":4710,"activeCount":101},[],{"trials":4712,"activeCount":101},[],{"trials":4714,"activeCount":101},[],{"intervention":4716,"totalTrials":143,"cells":4717},"Eribulin",{"EARLY_PHASE1":4718,"PHASE1":4720,"PHASE2":4722,"PHASE3":4732,"PHASE4":4734,"NA":4736},{"trials":4719,"activeCount":101},[],{"trials":4721,"activeCount":101},[],{"trials":4723,"activeCount":101},[4724],{"nctId":4725,"briefTitle":4726,"status":264,"phases":4727,"primaryCompletion":4728,"completion":4728,"start":4729,"enrollment":452,"conditions":4730,"interventions":4731},"NCT02681523","ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.",[90],"2018-07-24","2015-10-28",[31],[4716],{"trials":4733,"activeCount":101},[],{"trials":4735,"activeCount":101},[],{"trials":4737,"activeCount":101},[],{"intervention":4739,"totalTrials":143,"cells":4740},"Infusion of autologous CD34+ stem cells into middle cerebral artery",{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":101},[4747],{"nctId":4748,"briefTitle":4749,"status":111,"phases":4750,"primaryCompletion":3027,"completion":1334,"start":2131,"enrollment":1441,"conditions":4751,"interventions":4754},"NCT00535197","Autologous Bone Marrow Stem Cells in Ischemic Stroke.",[89,90],[4752,4753],"Stroke, Acute","Infarction, Middle Cerebral Artery",[4739],{"trials":4756,"activeCount":101},[],{"trials":4758,"activeCount":101},[],{"trials":4760,"activeCount":101},[],{"intervention":4762,"totalTrials":143,"cells":4763},"Mesenchymal stem cells",{"EARLY_PHASE1":4764,"PHASE1":4766,"PHASE2":4768,"PHASE3":4777,"PHASE4":4779,"NA":4781},{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":101},[],{"trials":4769,"activeCount":101},[4770],{"nctId":4771,"briefTitle":4772,"status":111,"phases":4773,"primaryCompletion":4774,"completion":4774,"start":1439,"enrollment":1520,"conditions":4775,"interventions":4776},"NCT01606215","Stem Cells in Rapidly Evolving Active Multiple Sclerosis",[89,90],"2019-08",[351],[4762],{"trials":4778,"activeCount":101},[],{"trials":4780,"activeCount":101},[],{"trials":4782,"activeCount":101},[],{"intervention":4784,"totalTrials":143,"cells":4785},"Kisspeptin 1.6nmol\u002Fkg",{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4808,"PHASE4":4810,"NA":4812},{"trials":4787,"activeCount":101},[],{"trials":4789,"activeCount":101},[],{"trials":4791,"activeCount":101},[4792],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4795,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4799,"interventions":4801},"NCT01667406","The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment",[90],"2016-10-11","2012-06-01",175,[4800],"Infertility",[4784,4802,4803,4804,4805,4806,4807],"Kisspeptin 3.2nmol\u002Fkg","Kisspeptin 6.4nmol\u002Fkg","Kisspeptin 9.6nmol\u002Fkg","Kisspeptin 12.8nmol\u002Fkg","Kisspeptin 9.6 nmol\u002Fkg double","Kisspeptin 9.6 nmol\u002Fkg + saline",{"trials":4809,"activeCount":101},[],{"trials":4811,"activeCount":101},[],{"trials":4813,"activeCount":101},[],{"intervention":4802,"totalTrials":143,"cells":4815},{"EARLY_PHASE1":4816,"PHASE1":4818,"PHASE2":4820,"PHASE3":4826,"PHASE4":4828,"NA":4830},{"trials":4817,"activeCount":101},[],{"trials":4819,"activeCount":101},[],{"trials":4821,"activeCount":101},[4822],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4823,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4824,"interventions":4825},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4827,"activeCount":101},[],{"trials":4829,"activeCount":101},[],{"trials":4831,"activeCount":101},[],{"intervention":4803,"totalTrials":143,"cells":4833},{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4844,"PHASE4":4846,"NA":4848},{"trials":4835,"activeCount":101},[],{"trials":4837,"activeCount":101},[],{"trials":4839,"activeCount":101},[4840],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4841,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4842,"interventions":4843},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4845,"activeCount":101},[],{"trials":4847,"activeCount":101},[],{"trials":4849,"activeCount":101},[],{"intervention":4804,"totalTrials":143,"cells":4851},{"EARLY_PHASE1":4852,"PHASE1":4854,"PHASE2":4856,"PHASE3":4862,"PHASE4":4864,"NA":4866},{"trials":4853,"activeCount":101},[],{"trials":4855,"activeCount":101},[],{"trials":4857,"activeCount":101},[4858],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4859,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4860,"interventions":4861},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4863,"activeCount":101},[],{"trials":4865,"activeCount":101},[],{"trials":4867,"activeCount":101},[],{"intervention":4805,"totalTrials":143,"cells":4869},{"EARLY_PHASE1":4870,"PHASE1":4872,"PHASE2":4874,"PHASE3":4880,"PHASE4":4882,"NA":4884},{"trials":4871,"activeCount":101},[],{"trials":4873,"activeCount":101},[],{"trials":4875,"activeCount":101},[4876],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4877,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4878,"interventions":4879},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4881,"activeCount":101},[],{"trials":4883,"activeCount":101},[],{"trials":4885,"activeCount":101},[],{"intervention":4806,"totalTrials":143,"cells":4887},{"EARLY_PHASE1":4888,"PHASE1":4890,"PHASE2":4892,"PHASE3":4898,"PHASE4":4900,"NA":4902},{"trials":4889,"activeCount":101},[],{"trials":4891,"activeCount":101},[],{"trials":4893,"activeCount":101},[4894],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4895,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4896,"interventions":4897},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4899,"activeCount":101},[],{"trials":4901,"activeCount":101},[],{"trials":4903,"activeCount":101},[],{"intervention":4807,"totalTrials":143,"cells":4905},{"EARLY_PHASE1":4906,"PHASE1":4908,"PHASE2":4910,"PHASE3":4916,"PHASE4":4918,"NA":4920},{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[4912],{"nctId":4793,"briefTitle":4794,"status":111,"phases":4913,"primaryCompletion":4796,"completion":4796,"start":4797,"enrollment":4798,"conditions":4914,"interventions":4915},[90],[4800],[4784,4802,4803,4804,4805,4806,4807],{"trials":4917,"activeCount":101},[],{"trials":4919,"activeCount":101},[],{"trials":4921,"activeCount":101},[],{"intervention":4923,"totalTrials":143,"cells":4924},"Capivasertib",{"EARLY_PHASE1":4925,"PHASE1":4927,"PHASE2":4929,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4926,"activeCount":101},[],{"trials":4928,"activeCount":101},[],{"trials":4930,"activeCount":101},[4931],{"nctId":4932,"briefTitle":4933,"status":367,"phases":4934,"primaryCompletion":4935,"completion":4935,"start":1038,"enrollment":101,"conditions":4936,"interventions":4938},"NCT06613516","Effect of Capivasertib on ctDNA in ER Positive Breast Cancer",[90],"2025-09-16",[31,4937],"Oestrogen Receptor Positive Breast Cancer",[4923],{"trials":4940,"activeCount":101},[],{"trials":4942,"activeCount":101},[],{"trials":4944,"activeCount":101},[],{"intervention":4946,"totalTrials":143,"cells":4947},"nicotinamide",{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4952,"PHASE3":4961,"PHASE4":4963,"NA":4965},{"trials":4949,"activeCount":101},[],{"trials":4951,"activeCount":101},[],{"trials":4953,"activeCount":101},[4954],{"nctId":4955,"briefTitle":4956,"status":952,"phases":4957,"primaryCompletion":2639,"completion":987,"start":4958,"enrollment":1612,"conditions":4959,"interventions":4960},"NCT01589809","Effect of Nicotinamide in Friedreich's Ataxia",[90],"2012-06",[373],[4946],{"trials":4962,"activeCount":101},[],{"trials":4964,"activeCount":101},[],{"trials":4966,"activeCount":101},[],{"intervention":469,"totalTrials":143,"cells":4968},{"EARLY_PHASE1":4969,"PHASE1":4971,"PHASE2":4973,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4970,"activeCount":101},[],{"trials":4972,"activeCount":101},[],{"trials":4974,"activeCount":101},[4975],{"nctId":457,"briefTitle":458,"status":111,"phases":4976,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":4977,"interventions":4978},[89,90],[465,466,467],[469,43],{"trials":4980,"activeCount":101},[],{"trials":4982,"activeCount":101},[],{"trials":4984,"activeCount":101},[],{"intervention":3585,"totalTrials":143,"cells":4986},{"EARLY_PHASE1":4987,"PHASE1":4989,"PHASE2":4991,"PHASE3":4997,"PHASE4":4999,"NA":5001},{"trials":4988,"activeCount":101},[],{"trials":4990,"activeCount":101},[],{"trials":4992,"activeCount":101},[4993],{"nctId":3576,"briefTitle":3577,"status":111,"phases":4994,"primaryCompletion":3579,"completion":3579,"start":3580,"enrollment":3581,"conditions":4995,"interventions":4996},[90],[3583],[3585,3558],{"trials":4998,"activeCount":101},[],{"trials":5000,"activeCount":101},[],{"trials":5002,"activeCount":101},[],{"intervention":5004,"totalTrials":143,"cells":5005},"Probenecid",{"EARLY_PHASE1":5006,"PHASE1":5008,"PHASE2":5010,"PHASE3":5021,"PHASE4":5023,"NA":5025},{"trials":5007,"activeCount":101},[],{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[5012],{"nctId":5013,"briefTitle":5014,"status":111,"phases":5015,"primaryCompletion":5016,"completion":5016,"start":5017,"enrollment":1520,"conditions":5018,"interventions":5020},"NCT05082909","Addition of Probenecid to Penicillin-V Therapy",[89,90],"2022-07-07","2021-12-21",[5019],"Infection, Bacterial",[5004],{"trials":5022,"activeCount":101},[],{"trials":5024,"activeCount":101},[],{"trials":5026,"activeCount":101},[],{"intervention":5028,"totalTrials":143,"cells":5029},"OC459",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5034,"PHASE3":5046,"PHASE4":5048,"NA":5050},{"trials":5031,"activeCount":101},[],{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[5036],{"nctId":5037,"briefTitle":5038,"status":111,"phases":5039,"primaryCompletion":5040,"completion":5040,"start":2249,"enrollment":349,"conditions":5041,"interventions":5045},"NCT02660489","Effect of OC459 on the Response to Rhinovirus Challenge in Asthma",[90],"2018-02",[16,5042,5043,5044],"Rhinovirus","Picornaviridae Infections","Common Cold",[5028],{"trials":5047,"activeCount":101},[],{"trials":5049,"activeCount":101},[],{"trials":5051,"activeCount":101},[],{"intervention":5053,"totalTrials":143,"cells":5054},"Solithromycin",{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5069,"PHASE4":5071,"NA":5073},{"trials":5056,"activeCount":101},[],{"trials":5058,"activeCount":101},[],{"trials":5060,"activeCount":101},[5061],{"nctId":5062,"briefTitle":5063,"status":264,"phases":5064,"primaryCompletion":5065,"completion":5065,"start":1586,"enrollment":320,"conditions":5066,"interventions":5068},"NCT02628769","A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease",[90],"2017-01-05",[5067],"Pulmonary Disease, Chronic Obstructive",[5053],{"trials":5070,"activeCount":101},[],{"trials":5072,"activeCount":101},[],{"trials":5074,"activeCount":101},[],{"intervention":5076,"totalTrials":143,"cells":5077},"Testosterone undecanoate",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5093,"PHASE4":5095,"NA":5097},{"trials":5079,"activeCount":101},[],{"trials":5081,"activeCount":101},[],{"trials":5083,"activeCount":101},[5084],{"nctId":5085,"briefTitle":5086,"status":111,"phases":5087,"primaryCompletion":5088,"completion":5088,"start":5089,"enrollment":515,"conditions":5090,"interventions":5092},"NCT00239590","Testosterone and Myocardial Perfusion in Coronary Heart Disease (CHD)",[90],"2004-04-24","2001-06",[5091],"Coronary Heart Disease",[5076],{"trials":5094,"activeCount":101},[],{"trials":5096,"activeCount":101},[],{"trials":5098,"activeCount":101},[],{"intervention":5100,"totalTrials":143,"cells":5101},"Psilocybin + Placebo",{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5106,"PHASE3":5120,"PHASE4":5122,"NA":5124},{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[],{"trials":5107,"activeCount":101},[5108],{"nctId":5109,"briefTitle":5110,"status":111,"phases":5111,"primaryCompletion":5112,"completion":5113,"start":5114,"enrollment":5115,"conditions":5116,"interventions":5118},"NCT03429075","Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms",[90],"2020-04-17","2020-10-17","2019-01-07",59,[5117],"Depressive Disorder, Major",[5100,5119],"Psilocybin + Escitalopram",{"trials":5121,"activeCount":101},[],{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[],{"intervention":5119,"totalTrials":143,"cells":5127},{"EARLY_PHASE1":5128,"PHASE1":5130,"PHASE2":5132,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5129,"activeCount":101},[],{"trials":5131,"activeCount":101},[],{"trials":5133,"activeCount":101},[5134],{"nctId":5109,"briefTitle":5110,"status":111,"phases":5135,"primaryCompletion":5112,"completion":5113,"start":5114,"enrollment":5115,"conditions":5136,"interventions":5137},[90],[5117],[5100,5119],{"trials":5139,"activeCount":101},[],{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"intervention":5145,"totalTrials":143,"cells":5146},"AVI-4658",{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5151,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5148,"activeCount":101},[],{"trials":5150,"activeCount":101},[],{"trials":5152,"activeCount":101},[5153],{"nctId":5154,"briefTitle":5155,"status":111,"phases":5156,"primaryCompletion":3966,"completion":5157,"start":5158,"enrollment":2979,"conditions":5159,"interventions":5161},"NCT00159250","Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy",[89,90],"2009-03-31","2007-10-26",[5160],"Duchenne Muscular Dystrophy",[5145],{"trials":5163,"activeCount":101},[],{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"intervention":5169,"totalTrials":143,"cells":5170},"Axitinib",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":101},[],{"trials":5176,"activeCount":101},[5177],{"nctId":5178,"briefTitle":5179,"status":111,"phases":5180,"primaryCompletion":428,"completion":428,"start":5181,"enrollment":3581,"conditions":5182,"interventions":5183},"NCT04355156","Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer",[90],"2012-09-17",[4707],[5169],{"trials":5185,"activeCount":101},[],{"trials":5187,"activeCount":101},[],{"trials":5189,"activeCount":101},[],{"intervention":5191,"totalTrials":143,"cells":5192},"Rosuvastatin",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5207,"PHASE4":5209,"NA":5211},{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":101},[5199],{"nctId":5200,"briefTitle":5201,"status":111,"phases":5202,"primaryCompletion":3605,"completion":2021,"start":1354,"enrollment":5203,"conditions":5204,"interventions":5206},"NCT01170585","A Trial of Rosuvastatin in Systemic Lupus Erythematosus",[90],33,[2302,5205],"Systemic Lupus Erythematosus",[5191],{"trials":5208,"activeCount":101},[],{"trials":5210,"activeCount":101},[],{"trials":5212,"activeCount":101},[],{"intervention":5214,"totalTrials":143,"cells":5215},"Y14",{"EARLY_PHASE1":5216,"PHASE1":5218,"PHASE2":5230,"PHASE3":5232,"PHASE4":5234,"NA":5236},{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[5220],{"nctId":5221,"briefTitle":5222,"status":111,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":5226,"conditions":5227,"interventions":5229},"NCT03673111","Study of the Gut Hormone Analogue Y14 in Adult Subjects",[89],"2019-02-13","2017-04-10",77,[5228,19],"Diabetes Mellitus",[5214],{"trials":5231,"activeCount":101},[],{"trials":5233,"activeCount":101},[],{"trials":5235,"activeCount":101},[],{"trials":5237,"activeCount":101},[],{"intervention":5239,"totalTrials":143,"cells":5240},"LACTIN-V",{"EARLY_PHASE1":5241,"PHASE1":5243,"PHASE2":5259,"PHASE3":5261,"PHASE4":5263,"NA":5265},{"trials":5242,"activeCount":101},[],{"trials":5244,"activeCount":101},[5245],{"nctId":5246,"briefTitle":5247,"status":952,"phases":5248,"primaryCompletion":5249,"completion":5249,"start":5250,"enrollment":771,"conditions":5251,"interventions":5258},"NCT03992534","The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth",[89],"2021-10-01","2019-09-16",[5252,5253,5254,5255,5256,5257],"Preterm Labor","Preterm Birth","Preterm Premature Rupture of Membrane","Cervical Incompetence","Miscarriage in Second Trimester","Miscarriage in Third Trimester",[5239],{"trials":5260,"activeCount":101},[],{"trials":5262,"activeCount":101},[],{"trials":5264,"activeCount":101},[],{"trials":5266,"activeCount":101},[],{"intervention":5268,"totalTrials":143,"cells":5269},"Autologous CD34+ stem cells",{"EARLY_PHASE1":5270,"PHASE1":5272,"PHASE2":5282,"PHASE3":5284,"PHASE4":5286,"NA":5288},{"trials":5271,"activeCount":101},[],{"trials":5273,"activeCount":101},[5274],{"nctId":5275,"briefTitle":5276,"status":111,"phases":5277,"primaryCompletion":2537,"completion":2537,"start":3614,"enrollment":2979,"conditions":5278,"interventions":5281},"NCT00788827","Autologous Adult Stem Cells to Patients With Type 1 Diabetes and a Successful Renal Transplant",[89],[5279,5280],"Type 1 Diabetes","Type 2 Diabetes",[5268],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"trials":5289,"activeCount":101},[],{"intervention":3503,"totalTrials":143,"cells":5291},{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5300,"PHASE3":5302,"PHASE4":5304,"NA":5306},{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[5296],{"nctId":3495,"briefTitle":3496,"status":111,"phases":5297,"primaryCompletion":3498,"completion":3498,"start":3499,"enrollment":1412,"conditions":5298,"interventions":5299},[89],[3501],[3503,3475],{"trials":5301,"activeCount":101},[],{"trials":5303,"activeCount":101},[],{"trials":5305,"activeCount":101},[],{"trials":5307,"activeCount":101},[],{"intervention":5309,"totalTrials":143,"cells":5310},"MRx0518",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5329,"PHASE3":5331,"PHASE4":5333,"NA":5335},{"trials":5312,"activeCount":101},[],{"trials":5314,"activeCount":101},[5315],{"nctId":5316,"briefTitle":5317,"status":952,"phases":5318,"primaryCompletion":309,"completion":309,"start":696,"enrollment":1234,"conditions":5319,"interventions":5327},"NCT03934827","MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour",[89],[5320,31,5321,4102,699,5322,5323,5324,5325,5326],"Melanoma","Uterine Cancer","Urethral Cancer","Bladder Cancer","Renal Cancer","Lung Cancer","Head and Neck Cancer",[5309,5328],"MRx0518\u002Fplacebo",{"trials":5330,"activeCount":101},[],{"trials":5332,"activeCount":101},[],{"trials":5334,"activeCount":101},[],{"trials":5336,"activeCount":101},[],{"intervention":5328,"totalTrials":143,"cells":5338},{"EARLY_PHASE1":5339,"PHASE1":5341,"PHASE2":5347,"PHASE3":5349,"PHASE4":5351,"NA":5353},{"trials":5340,"activeCount":101},[],{"trials":5342,"activeCount":101},[5343],{"nctId":5316,"briefTitle":5317,"status":952,"phases":5344,"primaryCompletion":309,"completion":309,"start":696,"enrollment":1234,"conditions":5345,"interventions":5346},[89],[5320,31,5321,4102,699,5322,5323,5324,5325,5326],[5309,5328],{"trials":5348,"activeCount":101},[],{"trials":5350,"activeCount":101},[],{"trials":5352,"activeCount":101},[],{"trials":5354,"activeCount":101},[],{"intervention":5356,"totalTrials":143,"cells":5357},"CN54ENV DNA",{"EARLY_PHASE1":5358,"PHASE1":5360,"PHASE2":5373,"PHASE3":5375,"PHASE4":5377,"NA":5379},{"trials":5359,"activeCount":101},[],{"trials":5361,"activeCount":101},[5362],{"nctId":5363,"briefTitle":5364,"status":111,"phases":5365,"primaryCompletion":5366,"completion":5367,"start":5368,"enrollment":1095,"conditions":5369,"interventions":5371},"NCT03663998","Optimising DNA Vaccinations in Healthy Volunteers",[89],"2017-05-10","2018-04-10","2015-08-15",[5370],"HIV-1-infection",[5356,5372],"GENEVAX® IL-12 DNA",{"trials":5374,"activeCount":101},[],{"trials":5376,"activeCount":101},[],{"trials":5378,"activeCount":101},[],{"trials":5380,"activeCount":101},[],{"intervention":5372,"totalTrials":143,"cells":5382},{"EARLY_PHASE1":5383,"PHASE1":5385,"PHASE2":5391,"PHASE3":5393,"PHASE4":5395,"NA":5397},{"trials":5384,"activeCount":101},[],{"trials":5386,"activeCount":101},[5387],{"nctId":5363,"briefTitle":5364,"status":111,"phases":5388,"primaryCompletion":5366,"completion":5367,"start":5368,"enrollment":1095,"conditions":5389,"interventions":5390},[89],[5370],[5356,5372],{"trials":5392,"activeCount":101},[],{"trials":5394,"activeCount":101},[],{"trials":5396,"activeCount":101},[],{"trials":5398,"activeCount":101},[],{"intervention":5400,"totalTrials":143,"cells":5401},"Penicillin G_1200mg",{"EARLY_PHASE1":5402,"PHASE1":5404,"PHASE2":5416,"PHASE3":5418,"PHASE4":5420,"NA":5422},{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[5406],{"nctId":5407,"briefTitle":5408,"status":111,"phases":5409,"primaryCompletion":113,"completion":113,"start":5410,"enrollment":320,"conditions":5411,"interventions":5413},"NCT04053140","Closed-loop Control of Penicillin Delivery",[89],"2019-11-05",[5412],"Healthy Volunteers",[5400,5414,5415],"Penicillin G_2400mg","Penicillin G_600mg\u002Fhr",{"trials":5417,"activeCount":101},[],{"trials":5419,"activeCount":101},[],{"trials":5421,"activeCount":101},[],{"trials":5423,"activeCount":101},[],{"intervention":5414,"totalTrials":143,"cells":5425},{"EARLY_PHASE1":5426,"PHASE1":5428,"PHASE2":5434,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5427,"activeCount":101},[],{"trials":5429,"activeCount":101},[5430],{"nctId":5407,"briefTitle":5408,"status":111,"phases":5431,"primaryCompletion":113,"completion":113,"start":5410,"enrollment":320,"conditions":5432,"interventions":5433},[89],[5412],[5400,5414,5415],{"trials":5435,"activeCount":101},[],{"trials":5437,"activeCount":101},[],{"trials":5439,"activeCount":101},[],{"trials":5441,"activeCount":101},[],{"intervention":5415,"totalTrials":143,"cells":5443},{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5452,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5445,"activeCount":101},[],{"trials":5447,"activeCount":101},[5448],{"nctId":5407,"briefTitle":5408,"status":111,"phases":5449,"primaryCompletion":113,"completion":113,"start":5410,"enrollment":320,"conditions":5450,"interventions":5451},[89],[5412],[5400,5414,5415],{"trials":5453,"activeCount":101},[],{"trials":5455,"activeCount":101},[],{"trials":5457,"activeCount":101},[],{"trials":5459,"activeCount":101},[],{"intervention":3572,"totalTrials":143,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5470,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":101},[],{"trials":5465,"activeCount":101},[5466],{"nctId":3565,"briefTitle":3566,"status":111,"phases":5467,"primaryCompletion":3568,"completion":3568,"start":1587,"enrollment":3569,"conditions":5468,"interventions":5469},[89],[19],[3572,3558],{"trials":5471,"activeCount":101},[],{"trials":5473,"activeCount":101},[],{"trials":5475,"activeCount":101},[],{"trials":5477,"activeCount":101},[],{"intervention":5479,"totalTrials":143,"cells":5480},"Ad4-EnvCN54",{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5496,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5482,"activeCount":101},[],{"trials":5484,"activeCount":101},[5485],{"nctId":5486,"briefTitle":5487,"status":111,"phases":5488,"primaryCompletion":5489,"completion":5489,"start":5490,"enrollment":3569,"conditions":5491,"interventions":5493},"NCT03408262","Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women",[89],"2020-02-10","2017-10-06",[5492],"Human Immunodeficiency Virus",[5479,5494,5495],"MVA-CN54","CN54gp140\u002FMPLA",{"trials":5497,"activeCount":101},[],{"trials":5499,"activeCount":101},[],{"trials":5501,"activeCount":101},[],{"trials":5503,"activeCount":101},[],{"intervention":5494,"totalTrials":143,"cells":5505},{"EARLY_PHASE1":5506,"PHASE1":5508,"PHASE2":5514,"PHASE3":5516,"PHASE4":5518,"NA":5520},{"trials":5507,"activeCount":101},[],{"trials":5509,"activeCount":101},[5510],{"nctId":5486,"briefTitle":5487,"status":111,"phases":5511,"primaryCompletion":5489,"completion":5489,"start":5490,"enrollment":3569,"conditions":5512,"interventions":5513},[89],[5492],[5479,5494,5495],{"trials":5515,"activeCount":101},[],{"trials":5517,"activeCount":101},[],{"trials":5519,"activeCount":101},[],{"trials":5521,"activeCount":101},[],{"intervention":5495,"totalTrials":143,"cells":5523},{"EARLY_PHASE1":5524,"PHASE1":5526,"PHASE2":5532,"PHASE3":5534,"PHASE4":5536,"NA":5538},{"trials":5525,"activeCount":101},[],{"trials":5527,"activeCount":101},[5528],{"nctId":5486,"briefTitle":5487,"status":111,"phases":5529,"primaryCompletion":5489,"completion":5489,"start":5490,"enrollment":3569,"conditions":5530,"interventions":5531},[89],[5492],[5479,5494,5495],{"trials":5533,"activeCount":101},[],{"trials":5535,"activeCount":101},[],{"trials":5537,"activeCount":101},[],{"trials":5539,"activeCount":101},[],{"intervention":5541,"totalTrials":143,"cells":5542},"GTU®-multiHIV B clade",{"EARLY_PHASE1":5543,"PHASE1":5545,"PHASE2":5555,"PHASE3":5557,"PHASE4":5559,"NA":5561},{"trials":5544,"activeCount":101},[],{"trials":5546,"activeCount":101},[5547],{"nctId":5548,"briefTitle":5549,"status":952,"phases":5550,"primaryCompletion":2639,"completion":5551,"start":5552,"enrollment":10,"conditions":5553,"interventions":5554},"NCT02075983","Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes",[89],"2015-12","2013-06",[34],[5541],{"trials":5556,"activeCount":101},[],{"trials":5558,"activeCount":101},[],{"trials":5560,"activeCount":101},[],{"trials":5562,"activeCount":101},[],{"intervention":5564,"totalTrials":143,"cells":5565},"ConM SOSIP",{"EARLY_PHASE1":5566,"PHASE1":5568,"PHASE2":5584,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5567,"activeCount":101},[],{"trials":5569,"activeCount":101},[5570],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5573,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5576,"interventions":5577},"NCT03816137","Modelling the Interaction Between Rationally-designed Synthetic Model Viral Protein Immunogens",[89],"2019-03-19",117,[5370],[5564,5578,5579,5580,5581,5582,5583],"EDC ConM SOSIP","ConS UFO","EDC ConS UFO","Mosaic SOSIPs","763 SOSIP","AMC011 SOSIP",{"trials":5585,"activeCount":101},[],{"trials":5587,"activeCount":101},[],{"trials":5589,"activeCount":101},[],{"trials":5591,"activeCount":101},[],{"intervention":5578,"totalTrials":143,"cells":5593},{"EARLY_PHASE1":5594,"PHASE1":5596,"PHASE2":5602,"PHASE3":5604,"PHASE4":5606,"NA":5608},{"trials":5595,"activeCount":101},[],{"trials":5597,"activeCount":101},[5598],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5599,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5600,"interventions":5601},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5603,"activeCount":101},[],{"trials":5605,"activeCount":101},[],{"trials":5607,"activeCount":101},[],{"trials":5609,"activeCount":101},[],{"intervention":5579,"totalTrials":143,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5620,"PHASE3":5622,"PHASE4":5624,"NA":5626},{"trials":5613,"activeCount":101},[],{"trials":5615,"activeCount":101},[5616],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5617,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5618,"interventions":5619},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5621,"activeCount":101},[],{"trials":5623,"activeCount":101},[],{"trials":5625,"activeCount":101},[],{"trials":5627,"activeCount":101},[],{"intervention":5580,"totalTrials":143,"cells":5629},{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5638,"PHASE3":5640,"PHASE4":5642,"NA":5644},{"trials":5631,"activeCount":101},[],{"trials":5633,"activeCount":101},[5634],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5635,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5636,"interventions":5637},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5639,"activeCount":101},[],{"trials":5641,"activeCount":101},[],{"trials":5643,"activeCount":101},[],{"trials":5645,"activeCount":101},[],{"intervention":5581,"totalTrials":143,"cells":5647},{"EARLY_PHASE1":5648,"PHASE1":5650,"PHASE2":5656,"PHASE3":5658,"PHASE4":5660,"NA":5662},{"trials":5649,"activeCount":101},[],{"trials":5651,"activeCount":101},[5652],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5653,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5654,"interventions":5655},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5657,"activeCount":101},[],{"trials":5659,"activeCount":101},[],{"trials":5661,"activeCount":101},[],{"trials":5663,"activeCount":101},[],{"intervention":5582,"totalTrials":143,"cells":5665},{"EARLY_PHASE1":5666,"PHASE1":5668,"PHASE2":5674,"PHASE3":5676,"PHASE4":5678,"NA":5680},{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[5670],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5671,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5672,"interventions":5673},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5675,"activeCount":101},[],{"trials":5677,"activeCount":101},[],{"trials":5679,"activeCount":101},[],{"trials":5681,"activeCount":101},[],{"intervention":5583,"totalTrials":143,"cells":5683},{"EARLY_PHASE1":5684,"PHASE1":5686,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5698},{"trials":5685,"activeCount":101},[],{"trials":5687,"activeCount":101},[5688],{"nctId":5571,"briefTitle":5572,"status":111,"phases":5689,"primaryCompletion":309,"completion":309,"start":5574,"enrollment":5575,"conditions":5690,"interventions":5691},[89],[5370],[5564,5578,5579,5580,5581,5582,5583],{"trials":5693,"activeCount":101},[],{"trials":5695,"activeCount":101},[],{"trials":5697,"activeCount":101},[],{"trials":5699,"activeCount":101},[],{"intervention":5701,"totalTrials":143,"cells":5702},"MDMA",{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5716,"PHASE3":5718,"PHASE4":5720,"NA":5722},{"trials":5704,"activeCount":101},[],{"trials":5706,"activeCount":101},[5707],{"nctId":5708,"briefTitle":5709,"status":952,"phases":5710,"primaryCompletion":5711,"completion":5711,"start":5712,"enrollment":417,"conditions":5713,"interventions":5715},"NCT04158778","Bristol Imperial MDMA in Alcoholism Study",[89],"2020-06-12","2018-04-18",[5714],"Alcohol Use Disorder",[5701],{"trials":5717,"activeCount":101},[],{"trials":5719,"activeCount":101},[],{"trials":5721,"activeCount":101},[],{"trials":5723,"activeCount":101},[],{"intervention":5725,"totalTrials":143,"cells":5726},"Pazopanib and paclitaxel",{"EARLY_PHASE1":5727,"PHASE1":5729,"PHASE2":5738,"PHASE3":5740,"PHASE4":5742,"NA":5744},{"trials":5728,"activeCount":101},[],{"trials":5730,"activeCount":101},[5731],{"nctId":5732,"briefTitle":5733,"status":111,"phases":5734,"primaryCompletion":2704,"completion":1401,"start":3027,"enrollment":379,"conditions":5735,"interventions":5737},"NCT01608009","[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer",[89],[5736],"Ovarian Neoplasm",[5725],{"trials":5739,"activeCount":101},[],{"trials":5741,"activeCount":101},[],{"trials":5743,"activeCount":101},[],{"trials":5745,"activeCount":101},[],{"intervention":5747,"totalTrials":143,"cells":5748},"Sildenafil and Boceprevir",{"EARLY_PHASE1":5749,"PHASE1":5751,"PHASE2":5761,"PHASE3":5763,"PHASE4":5765,"NA":5767},{"trials":5750,"activeCount":101},[],{"trials":5752,"activeCount":101},[5753],{"nctId":5754,"briefTitle":5755,"status":111,"phases":5756,"primaryCompletion":5757,"completion":3605,"start":1334,"enrollment":32,"conditions":5758,"interventions":5760},"NCT01499498","The Boceprevir and Sildenafil Pharmacokinetics Study",[89],"2013-04",[5759],"Hepatitis C",[5747],{"trials":5762,"activeCount":101},[],{"trials":5764,"activeCount":101},[],{"trials":5766,"activeCount":101},[],{"trials":5768,"activeCount":101},[],{"intervention":5770,"totalTrials":143,"cells":5771},"G3215",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5784,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5773,"activeCount":101},[],{"trials":5775,"activeCount":101},[5776],{"nctId":5777,"briefTitle":5778,"status":111,"phases":5779,"primaryCompletion":5780,"completion":5780,"start":2249,"enrollment":5781,"conditions":5782,"interventions":5783},"NCT02692040","Study of the Gut Hormone Analogue G3215 in Adult Subjects",[89],"2019-01",90,[5228,19],[5770],{"trials":5785,"activeCount":101},[],{"trials":5787,"activeCount":101},[],{"trials":5789,"activeCount":101},[],{"trials":5791,"activeCount":101},[],{"intervention":5793,"totalTrials":143,"cells":5794},"CN54gp140 mixed with GLA-AF",{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5807,"PHASE3":5809,"PHASE4":5811,"NA":5813},{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[5799],{"nctId":5800,"briefTitle":5801,"status":111,"phases":5802,"primaryCompletion":5803,"completion":5803,"start":5804,"enrollment":942,"conditions":5805,"interventions":5806},"NCT01966900","The Safety and Immunogenicity of a Potential HIV Vaccine",[89],"2015-11","2013-10",[1308],[5793],{"trials":5808,"activeCount":101},[],{"trials":5810,"activeCount":101},[],{"trials":5812,"activeCount":101},[],{"trials":5814,"activeCount":101},[],{"intervention":5816,"totalTrials":143,"cells":5817},"GTU-MultiHIV B clade vaccine1mg",{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5832,"PHASE3":5834,"PHASE4":5836,"NA":5838},{"trials":5819,"activeCount":101},[],{"trials":5821,"activeCount":101},[5822],{"nctId":5823,"briefTitle":5824,"status":264,"phases":5825,"primaryCompletion":1364,"completion":1364,"start":1306,"enrollment":1412,"conditions":5826,"interventions":5828},"NCT01130376","Novel Interventions in HIV-1 Infection",[89],[5827],"HIV-1 Infection",[5816,5829,5830,5831],"Interleukin-2","GM-CSF","Growth Hormone",{"trials":5833,"activeCount":101},[],{"trials":5835,"activeCount":101},[],{"trials":5837,"activeCount":101},[],{"trials":5839,"activeCount":101},[],{"intervention":5829,"totalTrials":143,"cells":5841},{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5850,"PHASE3":5852,"PHASE4":5854,"NA":5856},{"trials":5843,"activeCount":101},[],{"trials":5845,"activeCount":101},[5846],{"nctId":5823,"briefTitle":5824,"status":264,"phases":5847,"primaryCompletion":1364,"completion":1364,"start":1306,"enrollment":1412,"conditions":5848,"interventions":5849},[89],[5827],[5816,5829,5830,5831],{"trials":5851,"activeCount":101},[],{"trials":5853,"activeCount":101},[],{"trials":5855,"activeCount":101},[],{"trials":5857,"activeCount":101},[],{"intervention":5830,"totalTrials":143,"cells":5859},{"EARLY_PHASE1":5860,"PHASE1":5862,"PHASE2":5868,"PHASE3":5870,"PHASE4":5872,"NA":5874},{"trials":5861,"activeCount":101},[],{"trials":5863,"activeCount":101},[5864],{"nctId":5823,"briefTitle":5824,"status":264,"phases":5865,"primaryCompletion":1364,"completion":1364,"start":1306,"enrollment":1412,"conditions":5866,"interventions":5867},[89],[5827],[5816,5829,5830,5831],{"trials":5869,"activeCount":101},[],{"trials":5871,"activeCount":101},[],{"trials":5873,"activeCount":101},[],{"trials":5875,"activeCount":101},[],{"intervention":5831,"totalTrials":143,"cells":5877},{"EARLY_PHASE1":5878,"PHASE1":5880,"PHASE2":5886,"PHASE3":5888,"PHASE4":5890,"NA":5892},{"trials":5879,"activeCount":101},[],{"trials":5881,"activeCount":101},[5882],{"nctId":5823,"briefTitle":5824,"status":264,"phases":5883,"primaryCompletion":1364,"completion":1364,"start":1306,"enrollment":1412,"conditions":5884,"interventions":5885},[89],[5827],[5816,5829,5830,5831],{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"trials":5891,"activeCount":101},[],{"trials":5893,"activeCount":101},[],{"intervention":5895,"totalTrials":143,"cells":5896},"Rilpivirine",{"EARLY_PHASE1":5897,"PHASE1":5899,"PHASE2":5908,"PHASE3":5910,"PHASE4":5912,"NA":5914},{"trials":5898,"activeCount":101},[],{"trials":5900,"activeCount":101},[5901],{"nctId":5902,"briefTitle":5903,"status":111,"phases":5904,"primaryCompletion":5905,"completion":3568,"start":3499,"enrollment":942,"conditions":5906,"interventions":5907},"NCT01562886","The Rilpivirine Cerebrospinal-fluid (CSF) Study",[89],"2012-11",[34],[5895],{"trials":5909,"activeCount":101},[],{"trials":5911,"activeCount":101},[],{"trials":5913,"activeCount":101},[],{"trials":5915,"activeCount":101},[],{"intervention":5917,"totalTrials":143,"cells":5918},"PP 1420",{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5930,"PHASE3":5932,"PHASE4":5934,"NA":5936},{"trials":5920,"activeCount":101},[],{"trials":5922,"activeCount":101},[5923],{"nctId":5924,"briefTitle":5925,"status":111,"phases":5926,"primaryCompletion":5927,"completion":5927,"start":2044,"enrollment":32,"conditions":5928,"interventions":5929},"NCT01052493","A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects",[89],"2010-10-18",[19],[5917],{"trials":5931,"activeCount":101},[],{"trials":5933,"activeCount":101},[],{"trials":5935,"activeCount":101},[],{"trials":5937,"activeCount":101},[],{"intervention":5939,"totalTrials":143,"cells":5940},"DNA-C CN54ENV",{"EARLY_PHASE1":5941,"PHASE1":5943,"PHASE2":5953,"PHASE3":5955,"PHASE4":5957,"NA":5959},{"trials":5942,"activeCount":101},[],{"trials":5944,"activeCount":101},[5945],{"nctId":5946,"briefTitle":5947,"status":111,"phases":5948,"primaryCompletion":3510,"completion":3510,"start":5949,"enrollment":515,"conditions":5950,"interventions":5951},"NCT02589795","Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers",[89],"2016-08-11",[34],[5939,5952],"CN54gp140",{"trials":5954,"activeCount":101},[],{"trials":5956,"activeCount":101},[],{"trials":5958,"activeCount":101},[],{"trials":5960,"activeCount":101},[],{"intervention":5952,"totalTrials":143,"cells":5962},{"EARLY_PHASE1":5963,"PHASE1":5965,"PHASE2":5971,"PHASE3":5973,"PHASE4":5975,"NA":5977},{"trials":5964,"activeCount":101},[],{"trials":5966,"activeCount":101},[5967],{"nctId":5946,"briefTitle":5947,"status":111,"phases":5968,"primaryCompletion":3510,"completion":3510,"start":5949,"enrollment":515,"conditions":5969,"interventions":5970},[89],[34],[5939,5952],{"trials":5972,"activeCount":101},[],{"trials":5974,"activeCount":101},[],{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"intervention":5980,"totalTrials":143,"cells":5981},"DNA",{"EARLY_PHASE1":5982,"PHASE1":5984,"PHASE2":5995,"PHASE3":5997,"PHASE4":5999,"NA":6001},{"trials":5983,"activeCount":101},[],{"trials":5985,"activeCount":101},[5986],{"nctId":5987,"briefTitle":5988,"status":111,"phases":5989,"primaryCompletion":4539,"completion":5551,"start":5552,"enrollment":1612,"conditions":5990,"interventions":5991},"NCT01922284","Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses",[89],[34],[5980,5992,5993,5994],"MVA-C","CN54rgp140","GLA-AF",{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[],{"trials":6000,"activeCount":101},[],{"trials":6002,"activeCount":101},[],{"intervention":5992,"totalTrials":143,"cells":6004},{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6013,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6006,"activeCount":101},[],{"trials":6008,"activeCount":101},[6009],{"nctId":5987,"briefTitle":5988,"status":111,"phases":6010,"primaryCompletion":4539,"completion":5551,"start":5552,"enrollment":1612,"conditions":6011,"interventions":6012},[89],[34],[5980,5992,5993,5994],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"trials":6018,"activeCount":101},[],{"trials":6020,"activeCount":101},[],{"intervention":5993,"totalTrials":143,"cells":6022},{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6031,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6024,"activeCount":101},[],{"trials":6026,"activeCount":101},[6027],{"nctId":5987,"briefTitle":5988,"status":111,"phases":6028,"primaryCompletion":4539,"completion":5551,"start":5552,"enrollment":1612,"conditions":6029,"interventions":6030},[89],[34],[5980,5992,5993,5994],{"trials":6032,"activeCount":101},[],{"trials":6034,"activeCount":101},[],{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":101},[],{"intervention":5994,"totalTrials":143,"cells":6040},{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6049,"PHASE3":6051,"PHASE4":6053,"NA":6055},{"trials":6042,"activeCount":101},[],{"trials":6044,"activeCount":101},[6045],{"nctId":5987,"briefTitle":5988,"status":111,"phases":6046,"primaryCompletion":4539,"completion":5551,"start":5552,"enrollment":1612,"conditions":6047,"interventions":6048},[89],[34],[5980,5992,5993,5994],{"trials":6050,"activeCount":101},[],{"trials":6052,"activeCount":101},[],{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[],{"intervention":1367,"totalTrials":143,"cells":6058},{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6067,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6060,"activeCount":101},[],{"trials":6062,"activeCount":101},[6063],{"nctId":1359,"briefTitle":1360,"status":111,"phases":6064,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":32,"conditions":6065,"interventions":6066},[89],[34],[1344,1367,1368],{"trials":6068,"activeCount":101},[],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[],{"intervention":1368,"totalTrials":143,"cells":6076},{"EARLY_PHASE1":6077,"PHASE1":6079,"PHASE2":6085,"PHASE3":6087,"PHASE4":6089,"NA":6091},{"trials":6078,"activeCount":101},[],{"trials":6080,"activeCount":101},[6081],{"nctId":1359,"briefTitle":1360,"status":111,"phases":6082,"primaryCompletion":1362,"completion":1363,"start":1364,"enrollment":32,"conditions":6083,"interventions":6084},[89],[34],[1344,1367,1368],{"trials":6086,"activeCount":101},[],{"trials":6088,"activeCount":101},[],{"trials":6090,"activeCount":101},[],{"trials":6092,"activeCount":101},[],{"intervention":1310,"totalTrials":143,"cells":6094},{"EARLY_PHASE1":6095,"PHASE1":6097,"PHASE2":6103,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6096,"activeCount":101},[],{"trials":6098,"activeCount":101},[6099],{"nctId":1301,"briefTitle":1302,"status":111,"phases":6100,"primaryCompletion":1304,"completion":1305,"start":1306,"enrollment":942,"conditions":6101,"interventions":6102},[89],[1308],[1310,1294],{"trials":6104,"activeCount":101},[],{"trials":6106,"activeCount":101},[],{"trials":6108,"activeCount":101},[],{"trials":6110,"activeCount":101},[],{"intervention":6112,"totalTrials":143,"cells":6113},"Itacitinib",{"EARLY_PHASE1":6114,"PHASE1":6116,"PHASE2":6127,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6115,"activeCount":101},[],{"trials":6117,"activeCount":101},[6118],{"nctId":6119,"briefTitle":6120,"status":111,"phases":6121,"primaryCompletion":6122,"completion":6122,"start":6123,"enrollment":1336,"conditions":6124,"interventions":6126},"NCT04358185","Itacitinib in Advanced Hepatocellular Carcinoma",[89],"2023-04-07","2018-12-03",[6125],"Advanced Hepatocellular Carcinoma",[6112],{"trials":6128,"activeCount":101},[],{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"trials":6134,"activeCount":101},[],{"intervention":6136,"totalTrials":143,"cells":6137},"Tranilast",{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6149,"PHASE3":6151,"PHASE4":6153,"NA":6155},{"trials":6139,"activeCount":101},[],{"trials":6141,"activeCount":101},[6142],{"nctId":6143,"briefTitle":6144,"status":367,"phases":6145,"primaryCompletion":1306,"completion":1306,"start":2767,"enrollment":101,"conditions":6146,"interventions":6148},"NCT00717808","Effects of Tranilast on Pharmacokinetics of Methotrexate (MTX) in Patients With Rheumatoid Arthritis (RA)",[89],[6147],"Rheumatoid Arthritis",[6136],{"trials":6150,"activeCount":101},[],{"trials":6152,"activeCount":101},[],{"trials":6154,"activeCount":101},[],{"trials":6156,"activeCount":101},[],{"intervention":6158,"totalTrials":143,"cells":6159},"Phenoxymethyl Penicillin",{"EARLY_PHASE1":6160,"PHASE1":6162,"PHASE2":6172,"PHASE3":6174,"PHASE4":6176,"NA":6178},{"trials":6161,"activeCount":101},[],{"trials":6163,"activeCount":101},[6164],{"nctId":6165,"briefTitle":6166,"status":111,"phases":6167,"primaryCompletion":6168,"completion":6168,"start":6169,"enrollment":37,"conditions":6170,"interventions":6171},"NCT03847610","Minimally Invasive Sensing of Beta-lactam Antibiotics",[89],"2018-08-10","2018-04-12",[5412],[6158],{"trials":6173,"activeCount":101},[],{"trials":6175,"activeCount":101},[],{"trials":6177,"activeCount":101},[],{"trials":6179,"activeCount":101},[],{"intervention":6181,"totalTrials":143,"cells":6182},"NUC-1031",{"EARLY_PHASE1":6183,"PHASE1":6185,"PHASE2":6194,"PHASE3":6196,"PHASE4":6198,"NA":6200},{"trials":6184,"activeCount":101},[],{"trials":6186,"activeCount":101},[6187],{"nctId":6188,"briefTitle":6189,"status":111,"phases":6190,"primaryCompletion":2639,"completion":2639,"start":3644,"enrollment":3569,"conditions":6191,"interventions":6193},"NCT01621854","NUC-1031 in Patients With Advanced Solid Tumours",[89],[6192],"Cancer",[6181],{"trials":6195,"activeCount":101},[],{"trials":6197,"activeCount":101},[],{"trials":6199,"activeCount":101},[],{"trials":6201,"activeCount":101},[],{"intervention":6203,"totalTrials":143,"cells":6204},"1x10^9 vp AZD1222",{"EARLY_PHASE1":6205,"PHASE1":6207,"PHASE2":6220,"PHASE3":6222,"PHASE4":6224,"NA":6226},{"trials":6206,"activeCount":101},[],{"trials":6208,"activeCount":101},[6209],{"nctId":6210,"briefTitle":6211,"status":952,"phases":6212,"primaryCompletion":6213,"completion":6213,"start":6214,"enrollment":515,"conditions":6215,"interventions":6217},"NCT05007275","A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers",[89],"2024-06","2021-10-10",[466,6216],"SARS-CoV-2 Infection",[6203,6218,6219],"5x10^9 vp AZD1222","1x10^10 vp AZD1222",{"trials":6221,"activeCount":101},[],{"trials":6223,"activeCount":101},[],{"trials":6225,"activeCount":101},[],{"trials":6227,"activeCount":101},[],{"intervention":6218,"totalTrials":143,"cells":6229},{"EARLY_PHASE1":6230,"PHASE1":6232,"PHASE2":6238,"PHASE3":6240,"PHASE4":6242,"NA":6244},{"trials":6231,"activeCount":101},[],{"trials":6233,"activeCount":101},[6234],{"nctId":6210,"briefTitle":6211,"status":952,"phases":6235,"primaryCompletion":6213,"completion":6213,"start":6214,"enrollment":515,"conditions":6236,"interventions":6237},[89],[466,6216],[6203,6218,6219],{"trials":6239,"activeCount":101},[],{"trials":6241,"activeCount":101},[],{"trials":6243,"activeCount":101},[],{"trials":6245,"activeCount":101},[],{"intervention":6219,"totalTrials":143,"cells":6247},{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6256,"PHASE3":6258,"PHASE4":6260,"NA":6262},{"trials":6249,"activeCount":101},[],{"trials":6251,"activeCount":101},[6252],{"nctId":6210,"briefTitle":6211,"status":952,"phases":6253,"primaryCompletion":6213,"completion":6213,"start":6214,"enrollment":515,"conditions":6254,"interventions":6255},[89],[466,6216],[6203,6218,6219],{"trials":6257,"activeCount":101},[],{"trials":6259,"activeCount":101},[],{"trials":6261,"activeCount":101},[],{"trials":6263,"activeCount":101},[],{"intervention":6265,"totalTrials":97,"cells":6266},"Idazoxan",{"EARLY_PHASE1":6267,"PHASE1":6285,"PHASE2":6287,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6268,"activeCount":101},[6269,6278],{"nctId":6270,"briefTitle":6271,"status":111,"phases":6272,"primaryCompletion":6273,"completion":4516,"start":2249,"enrollment":417,"conditions":6274,"interventions":6276},"NCT02323217","I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers",[88],"2016-02",[5412,542,6275],"Molecular Imaging",[6265,6277],"Isocarboxazid",{"nctId":6279,"briefTitle":6280,"status":264,"phases":6281,"primaryCompletion":2364,"completion":6282,"start":4516,"enrollment":97,"conditions":6283,"interventions":6284},"NCT02874820","I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD",[88],"2017-07",[542],[6265],{"trials":6286,"activeCount":101},[],{"trials":6288,"activeCount":101},[],{"trials":6290,"activeCount":101},[],{"trials":6292,"activeCount":101},[],{"trials":6294,"activeCount":101},[],{"intervention":6296,"totalTrials":143,"cells":6297},"TRV027",{"EARLY_PHASE1":6298,"PHASE1":6309,"PHASE2":6311,"PHASE3":6313,"PHASE4":6315,"NA":6317},{"trials":6299,"activeCount":101},[6300],{"nctId":6301,"briefTitle":6302,"status":111,"phases":6303,"primaryCompletion":6304,"completion":6304,"start":6305,"enrollment":515,"conditions":6306,"interventions":6308},"NCT04419610","RAS and Coagulopathy in COVID19",[88],"2021-05-12","2020-10-09",[6307],"COVID",[6296],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[],{"trials":6314,"activeCount":101},[],{"trials":6316,"activeCount":101},[],{"trials":6318,"activeCount":101},[],{"intervention":6277,"totalTrials":143,"cells":6320},{"EARLY_PHASE1":6321,"PHASE1":6327,"PHASE2":6329,"PHASE3":6331,"PHASE4":6333,"NA":6335},{"trials":6322,"activeCount":101},[6323],{"nctId":6270,"briefTitle":6271,"status":111,"phases":6324,"primaryCompletion":6273,"completion":4516,"start":2249,"enrollment":417,"conditions":6325,"interventions":6326},[88],[5412,542,6275],[6265,6277],{"trials":6328,"activeCount":101},[],{"trials":6330,"activeCount":101},[],{"trials":6332,"activeCount":101},[],{"trials":6334,"activeCount":101},[],{"trials":6336,"activeCount":101},[],{"intervention":3490,"totalTrials":143,"cells":6338},{"EARLY_PHASE1":6339,"PHASE1":6345,"PHASE2":6347,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6340,"activeCount":101},[6341],{"nctId":3480,"briefTitle":3481,"status":952,"phases":6342,"primaryCompletion":3483,"completion":3484,"start":2273,"enrollment":3485,"conditions":6343,"interventions":6344},[88],[19,3487,3488],[3490,3491,3475],{"trials":6346,"activeCount":101},[],{"trials":6348,"activeCount":101},[],{"trials":6350,"activeCount":101},[],{"trials":6352,"activeCount":101},[],{"trials":6354,"activeCount":101},[],{"intervention":3491,"totalTrials":143,"cells":6356},{"EARLY_PHASE1":6357,"PHASE1":6363,"PHASE2":6365,"PHASE3":6367,"PHASE4":6369,"NA":6371},{"trials":6358,"activeCount":101},[6359],{"nctId":3480,"briefTitle":3481,"status":952,"phases":6360,"primaryCompletion":3483,"completion":3484,"start":2273,"enrollment":3485,"conditions":6361,"interventions":6362},[88],[19,3487,3488],[3490,3491,3475],{"trials":6364,"activeCount":101},[],{"trials":6366,"activeCount":101},[],{"trials":6368,"activeCount":101},[],{"trials":6370,"activeCount":101},[],{"trials":6372,"activeCount":101},[],{"intervention":6374,"totalTrials":143,"cells":6375},"VR588",{"EARLY_PHASE1":6376,"PHASE1":6387,"PHASE2":6389,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6377,"activeCount":101},[6378],{"nctId":6379,"briefTitle":6380,"status":111,"phases":6381,"primaryCompletion":6382,"completion":6382,"start":6383,"enrollment":6384,"conditions":6385,"interventions":6386},"NCT02740049","In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma",[88],"2016-10-19","2016-01-27",9,[16],[6374],{"trials":6388,"activeCount":101},[],{"trials":6390,"activeCount":101},[],{"trials":6392,"activeCount":101},[],{"trials":6394,"activeCount":101},[],{"trials":6396,"activeCount":101},[],{"intervention":3007,"totalTrials":393,"cells":6398},{"EARLY_PHASE1":6399,"PHASE1":6401,"PHASE2":6403,"PHASE3":6405,"PHASE4":6411,"NA":6413},{"trials":6400,"activeCount":101},[],{"trials":6402,"activeCount":101},[],{"trials":6404,"activeCount":101},[],{"trials":6406,"activeCount":101},[6407],{"nctId":2999,"briefTitle":3000,"status":111,"phases":6408,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":379,"conditions":6409,"interventions":6410},[90,91],[3005],[2988,3007],{"trials":6412,"activeCount":101},[],{"trials":6414,"activeCount":101},[6415,6424,6436],{"nctId":6416,"briefTitle":6417,"status":111,"phases":6418,"primaryCompletion":6419,"completion":6419,"start":6420,"enrollment":10,"conditions":6421,"interventions":6422},"NCT00180635","NO Donors and Inhibitors to Study Imbalance of Nitrogen Stress and Antioxidant Defense in COPD",[93],"2006-07","2003-10",[28],[6423,3007],"Aminoguanidine",{"nctId":6425,"briefTitle":6426,"status":111,"phases":6427,"primaryCompletion":6428,"completion":6428,"start":6429,"enrollment":6430,"conditions":6431,"interventions":6432},"NCT00159263","Effect of Symbicort on GR Localisation in Asthma",[93],"2006-11","2004-11",10,[16],[3007,6433,6434,6435],"Formoterol Inhalant Powder","Budesonide Powder","Budesonide and Formoterol Product",{"nctId":6437,"briefTitle":6438,"status":111,"phases":6439,"primaryCompletion":6440,"completion":6440,"start":6441,"enrollment":379,"conditions":6442,"interventions":6443},"NCT00159380","Nitric Oxide (NO) Donors and Inhibitors Study: Study to Evaluate L-Arginine and Aminoguanidine in Asthmatic Subjects",[93],"2005-03","2003-09",[16],[6423,3007],{"intervention":6445,"totalTrials":393,"cells":6446},"RSV A Memphis 37",{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6451,"PHASE3":6453,"PHASE4":6455,"NA":6457},{"trials":6448,"activeCount":101},[],{"trials":6450,"activeCount":101},[],{"trials":6452,"activeCount":101},[],{"trials":6454,"activeCount":101},[],{"trials":6456,"activeCount":101},[],{"trials":6458,"activeCount":101},[6459,6468,6477,6486],{"nctId":6460,"briefTitle":6461,"status":111,"phases":6462,"primaryCompletion":5804,"completion":3498,"start":2224,"enrollment":6463,"conditions":6464,"interventions":6467},"NCT01349543","The Development of a Human Model of Respiratory Syncytial Virus Infection",[93],58,[6465,6466],"Respiratory Syncytial Virus Infections","Respiratory Viral Infections",[6445],{"nctId":6469,"briefTitle":6470,"status":111,"phases":6471,"primaryCompletion":6472,"completion":6472,"start":6473,"enrollment":417,"conditions":6474,"interventions":6476},"NCT06274619","Novel Mucosal Correlates Of RSV Protection In Older Adults",[93],"2025-04-07","2024-03-13",[6475],"Respiratory Tract Infections",[6445],{"nctId":6478,"briefTitle":6479,"status":111,"phases":6480,"primaryCompletion":6481,"completion":6481,"start":6482,"enrollment":515,"conditions":6483,"interventions":6485},"NCT03728413","The Impact of Age on Adaptive Immunity in Adults Infected With Respiratory Syncytial Virus",[93],"2023-05-04","2018-11-12",[6484],"RSV Infection",[6445],{"nctId":6487,"briefTitle":6488,"status":111,"phases":6489,"primaryCompletion":6490,"completion":6490,"start":1587,"enrollment":6491,"conditions":6492,"interventions":6494},"NCT02755948","Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge",[93],"2020-02-01",75,[6465,6493],"Influenza, Human",[6445,6495,6496],"Influenza A\u002FCalifornia\u002F04\u002F2009-likw","Influenza A\u002FBelgium\u002F4217\u002F2015",{"intervention":6498,"totalTrials":268,"cells":6499},"Psilocybin",{"EARLY_PHASE1":6500,"PHASE1":6502,"PHASE2":6513,"PHASE3":6524,"PHASE4":6526,"NA":6528},{"trials":6501,"activeCount":101},[],{"trials":6503,"activeCount":101},[6504],{"nctId":6505,"briefTitle":6506,"status":111,"phases":6507,"primaryCompletion":6508,"completion":1259,"start":6509,"enrollment":1336,"conditions":6510,"interventions":6512},"NCT06258031","PsilOCD: A Pharmacological-Challenge Feasibility Study",[89],"2024-06-28","2022-10-28",[6511],"Obsessive-Compulsive Disorder",[6498],{"trials":6514,"activeCount":101},[6515],{"nctId":6516,"briefTitle":6517,"status":111,"phases":6518,"primaryCompletion":6519,"completion":6520,"start":4425,"enrollment":1520,"conditions":6521,"interventions":6523},"NCT04505189","Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study",[89,90],"2023-12-11","2024-06-12",[6522],"Anorexia Nervosa",[6498],{"trials":6525,"activeCount":101},[],{"trials":6527,"activeCount":101},[],{"trials":6529,"activeCount":101},[6530],{"nctId":6531,"briefTitle":6532,"status":952,"phases":6533,"primaryCompletion":6534,"completion":1051,"start":6535,"enrollment":417,"conditions":6536,"interventions":6538},"NCT05548075","Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action",[],"2024-01-10","2022-08-15",[6537],"Fibromyalgia",[6498],{"intervention":6540,"totalTrials":268,"cells":6541},"Next generation sequencing",{"EARLY_PHASE1":6542,"PHASE1":6544,"PHASE2":6546,"PHASE3":6548,"PHASE4":6550,"NA":6552},{"trials":6543,"activeCount":101},[],{"trials":6545,"activeCount":101},[],{"trials":6547,"activeCount":101},[],{"trials":6549,"activeCount":101},[],{"trials":6551,"activeCount":101},[],{"trials":6553,"activeCount":101},[6554,6563,6575],{"nctId":6555,"briefTitle":6556,"status":952,"phases":6557,"primaryCompletion":2157,"completion":2157,"start":6558,"enrollment":6559,"conditions":6560,"interventions":6562},"NCT03597958","Genetic Causes of Hypercholesterolaemia in the Emirati Population",[],"2017-01-17",1000,[6561],"Familial Hypercholesterolemia",[6540],{"nctId":6564,"briefTitle":6565,"status":952,"phases":6566,"primaryCompletion":6567,"completion":6567,"start":6568,"enrollment":6569,"conditions":6570,"interventions":6574},"NCT03607604","Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE",[],"2021-12-31","2015-04-01",778,[6571,6572,6573],"Diabetes Mellitus, Type 1","Diabetes Mellitus, Type 2","Maturity-onset Diabetes of the Young",[6540],{"nctId":6576,"briefTitle":6577,"status":952,"phases":6578,"primaryCompletion":2157,"completion":2157,"start":3782,"enrollment":642,"conditions":6579,"interventions":6583},"NCT03589092","Genetic Causes of Gestational Diabetes in the Emirati Population",[],[6580,6581,6573,6582],"Gestational Diabetes","GDM","MODY",[6540],{"intervention":6423,"totalTrials":97,"cells":6585},{"EARLY_PHASE1":6586,"PHASE1":6588,"PHASE2":6590,"PHASE3":6592,"PHASE4":6594,"NA":6596},{"trials":6587,"activeCount":101},[],{"trials":6589,"activeCount":101},[],{"trials":6591,"activeCount":101},[],{"trials":6593,"activeCount":101},[],{"trials":6595,"activeCount":101},[],{"trials":6597,"activeCount":101},[6598,6602],{"nctId":6416,"briefTitle":6417,"status":111,"phases":6599,"primaryCompletion":6419,"completion":6419,"start":6420,"enrollment":10,"conditions":6600,"interventions":6601},[93],[28],[6423,3007],{"nctId":6437,"briefTitle":6438,"status":111,"phases":6603,"primaryCompletion":6440,"completion":6440,"start":6441,"enrollment":379,"conditions":6604,"interventions":6605},[93],[16],[6423,3007],{"intervention":6607,"totalTrials":97,"cells":6608},"Insulin",{"EARLY_PHASE1":6609,"PHASE1":6611,"PHASE2":6613,"PHASE3":6615,"PHASE4":6617,"NA":6619},{"trials":6610,"activeCount":101},[],{"trials":6612,"activeCount":101},[],{"trials":6614,"activeCount":101},[],{"trials":6616,"activeCount":101},[],{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[6621,6628],{"nctId":6622,"briefTitle":6623,"status":111,"phases":6624,"primaryCompletion":6273,"completion":1496,"start":2450,"enrollment":429,"conditions":6625,"interventions":6627},"NCT01257087","Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery",[93],[6626,19],"Type 2 Diabetes Mellitus",[6607],{"nctId":6629,"briefTitle":6630,"status":111,"phases":6631,"primaryCompletion":6632,"completion":6632,"start":5367,"enrollment":29,"conditions":6633,"interventions":6634},"NCT04267770","Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion",[93],"2018-11-09",[5279],[6607,6607],{"intervention":6636,"totalTrials":143,"cells":6637},"l-ornithine l-aspartate",{"EARLY_PHASE1":6638,"PHASE1":6640,"PHASE2":6642,"PHASE3":6644,"PHASE4":6646,"NA":6648},{"trials":6639,"activeCount":101},[],{"trials":6641,"activeCount":101},[],{"trials":6643,"activeCount":101},[],{"trials":6645,"activeCount":101},[],{"trials":6647,"activeCount":101},[],{"trials":6649,"activeCount":101},[6650],{"nctId":6651,"briefTitle":6652,"status":111,"phases":6653,"completion":6654,"start":6655,"enrollment":611,"conditions":6656,"interventions":6657},"NCT00305591","Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.",[93],"2007-10","2006-03",[2644,2642],[6636],{"intervention":6659,"totalTrials":143,"cells":6660},"gastric bypass",{"EARLY_PHASE1":6661,"PHASE1":6663,"PHASE2":6665,"PHASE3":6667,"PHASE4":6669,"NA":6671},{"trials":6662,"activeCount":101},[],{"trials":6664,"activeCount":101},[],{"trials":6666,"activeCount":101},[],{"trials":6668,"activeCount":101},[],{"trials":6670,"activeCount":101},[],{"trials":6672,"activeCount":101},[6673],{"nctId":6674,"briefTitle":6675,"status":111,"phases":6676,"primaryCompletion":6677,"completion":6677,"start":2224,"enrollment":6678,"conditions":6679,"interventions":6680},"NCT01353118","The Effects of Glycemic Optimization Before Gastric Bypass Surgery",[93],"2016-12",41,[5280],[6659],{"intervention":6682,"totalTrials":143,"cells":6683},"Respiratory infections",{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6690,"PHASE4":6692,"NA":6694},{"trials":6685,"activeCount":101},[],{"trials":6687,"activeCount":101},[],{"trials":6689,"activeCount":101},[],{"trials":6691,"activeCount":101},[],{"trials":6693,"activeCount":101},[],{"trials":6695,"activeCount":101},[6696],{"nctId":6697,"briefTitle":6698,"status":264,"phases":6699,"primaryCompletion":6700,"completion":6700,"start":6701,"enrollment":452,"conditions":6702,"interventions":6707},"NCT04664075","Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)",[],"2022-04-30","2021-01-25",[1097,6703,6704,6475,5019,6705,466,6706],"SARS (Severe Acute Respiratory Syndrome)","Respiratory Viral Infection","Infection Viral","RNA Virus Infections",[6682],{"intervention":6709,"totalTrials":143,"cells":6710},"Lidocaine hydrochloride 2% for",{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6717,"PHASE4":6719,"NA":6721},{"trials":6712,"activeCount":101},[],{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":101},[],{"trials":6718,"activeCount":101},[],{"trials":6720,"activeCount":101},[],{"trials":6722,"activeCount":101},[6723],{"nctId":6724,"briefTitle":6725,"status":952,"phases":6726,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":611,"conditions":6729,"interventions":6732},"NCT05250791","Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome",[93],"2024-09-15","2023-02-02",[4707,6730,6731],"Quality of Life","Recurrent Cancer",[6709,6733],"0.9% sterile Sodium Chloride solution for",{"intervention":6733,"totalTrials":143,"cells":6735},{"EARLY_PHASE1":6736,"PHASE1":6738,"PHASE2":6740,"PHASE3":6742,"PHASE4":6744,"NA":6746},{"trials":6737,"activeCount":101},[],{"trials":6739,"activeCount":101},[],{"trials":6741,"activeCount":101},[],{"trials":6743,"activeCount":101},[],{"trials":6745,"activeCount":101},[],{"trials":6747,"activeCount":101},[6748],{"nctId":6724,"briefTitle":6725,"status":952,"phases":6749,"primaryCompletion":6727,"completion":6727,"start":6728,"enrollment":611,"conditions":6750,"interventions":6751},[93],[4707,6730,6731],[6709,6733],{"intervention":6753,"totalTrials":143,"cells":6754},"Rosiglitazone",{"EARLY_PHASE1":6755,"PHASE1":6757,"PHASE2":6759,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6756,"activeCount":101},[],{"trials":6758,"activeCount":101},[],{"trials":6760,"activeCount":101},[],{"trials":6762,"activeCount":101},[],{"trials":6764,"activeCount":101},[],{"trials":6766,"activeCount":101},[6767],{"nctId":6768,"briefTitle":6769,"status":367,"phases":6770,"primaryCompletion":3466,"completion":3466,"start":6771,"enrollment":101,"conditions":6772,"interventions":6773},"NCT00481429","Predictive Markers of Glitazone Efficacy in Diabetic Patients - Pilot Study",[],"2007-05",[6572],[6753],{"intervention":6775,"totalTrials":143,"cells":6776},"Best medical therapy",{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6781,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[],{"trials":6782,"activeCount":101},[],{"trials":6784,"activeCount":101},[],{"trials":6786,"activeCount":101},[],{"trials":6788,"activeCount":101},[6789],{"nctId":6790,"briefTitle":6791,"status":264,"phases":6792,"primaryCompletion":6793,"completion":6793,"start":6794,"enrollment":1412,"conditions":6795,"interventions":6801},"NCT05622500","Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease",[93],"2025-04-08","2022-09-03",[6796,6797,6798,6799,6800],"Chronic Venous Insufficiency","Chronic Venous Thrombosis","Iliac Vein Stenosis","Iliac Vein Obstruction","Post Thrombotic Syndrome",[6775],{"intervention":6803,"totalTrials":143,"cells":6804},"Nebulised hypertonic saline",{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6809,"PHASE3":6811,"PHASE4":6813,"NA":6815},{"trials":6806,"activeCount":101},[],{"trials":6808,"activeCount":101},[],{"trials":6810,"activeCount":101},[],{"trials":6812,"activeCount":101},[],{"trials":6814,"activeCount":101},[],{"trials":6816,"activeCount":101},[6817],{"nctId":6818,"briefTitle":6819,"status":111,"phases":6820,"primaryCompletion":6821,"completion":6822,"start":6823,"enrollment":989,"conditions":6824,"interventions":6826},"NCT03623698","Nebulised Hypertonic Saline in Children and Young People With Neuromuscular Disease and Cerebral Palsy",[],"2019-08-14","2019-09-26","2018-06-15",[6825],"Neuromuscular Diseases",[6803],{"intervention":6828,"totalTrials":143,"cells":6829},"Tenofovir disoproxil",{"EARLY_PHASE1":6830,"PHASE1":6832,"PHASE2":6834,"PHASE3":6836,"PHASE4":6838,"NA":6840},{"trials":6831,"activeCount":101},[],{"trials":6833,"activeCount":101},[],{"trials":6835,"activeCount":101},[],{"trials":6837,"activeCount":101},[],{"trials":6839,"activeCount":101},[],{"trials":6841,"activeCount":101},[6842],{"nctId":6843,"briefTitle":6844,"status":111,"phases":6845,"primaryCompletion":6846,"completion":6846,"start":1364,"enrollment":6847,"conditions":6848,"interventions":6850},"NCT02129829","PROLIFICA - West African Treatment Cohort for Hepatitis B",[],"2018-07-31",1079,[6849,4321],"Hepatitis B, Chronic",[6828],{"intervention":6852,"totalTrials":143,"cells":6853},"SARS-CoV-2 Virus 1x10^1 TCID50",{"EARLY_PHASE1":6854,"PHASE1":6856,"PHASE2":6858,"PHASE3":6860,"PHASE4":6862,"NA":6864},{"trials":6855,"activeCount":101},[],{"trials":6857,"activeCount":101},[],{"trials":6859,"activeCount":101},[],{"trials":6861,"activeCount":101},[],{"trials":6863,"activeCount":101},[],{"trials":6865,"activeCount":101},[6866],{"nctId":6867,"briefTitle":6868,"status":111,"phases":6869,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":1095,"conditions":6872,"interventions":6876},"NCT04865237","SARS-CoV-2 Human Challenge Characterisation Study",[93],"2022-07-11","2021-03-06",[466,6873,6874,465,6875],"SARS-CoV Infection","Corona Virus Infection","COVID-19",[6852,6877,6878,6879],"Remdesivir","SARS-CoV-2 Virus 1x10^2 TCID50","SARS-CoV-2 Virus 1x10^3 TCID50",{"intervention":6877,"totalTrials":143,"cells":6881},{"EARLY_PHASE1":6882,"PHASE1":6884,"PHASE2":6886,"PHASE3":6888,"PHASE4":6890,"NA":6892},{"trials":6883,"activeCount":101},[],{"trials":6885,"activeCount":101},[],{"trials":6887,"activeCount":101},[],{"trials":6889,"activeCount":101},[],{"trials":6891,"activeCount":101},[],{"trials":6893,"activeCount":101},[6894],{"nctId":6867,"briefTitle":6868,"status":111,"phases":6895,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":1095,"conditions":6896,"interventions":6897},[93],[466,6873,6874,465,6875],[6852,6877,6878,6879],{"intervention":6878,"totalTrials":143,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6906,"PHASE4":6908,"NA":6910},{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[],{"trials":6905,"activeCount":101},[],{"trials":6907,"activeCount":101},[],{"trials":6909,"activeCount":101},[],{"trials":6911,"activeCount":101},[6912],{"nctId":6867,"briefTitle":6868,"status":111,"phases":6913,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":1095,"conditions":6914,"interventions":6915},[93],[466,6873,6874,465,6875],[6852,6877,6878,6879],{"intervention":6879,"totalTrials":143,"cells":6917},{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6922,"PHASE3":6924,"PHASE4":6926,"NA":6928},{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[],{"trials":6923,"activeCount":101},[],{"trials":6925,"activeCount":101},[],{"trials":6927,"activeCount":101},[],{"trials":6929,"activeCount":101},[6930],{"nctId":6867,"briefTitle":6868,"status":111,"phases":6931,"primaryCompletion":6870,"completion":6870,"start":6871,"enrollment":1095,"conditions":6932,"interventions":6933},[93],[466,6873,6874,465,6875],[6852,6877,6878,6879],{"intervention":6935,"totalTrials":143,"cells":6936},"Hepatitis B",{"EARLY_PHASE1":6937,"PHASE1":6939,"PHASE2":6941,"PHASE3":6943,"PHASE4":6945,"NA":6947},{"trials":6938,"activeCount":101},[],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[],{"trials":6948,"activeCount":101},[6949],{"nctId":6950,"briefTitle":6951,"status":111,"phases":6952,"primaryCompletion":6953,"completion":6954,"start":6955,"enrollment":379,"conditions":6956,"interventions":6957},"NCT03535779","Characterisation of Human B Cell Maturation in Response to Vaccination",[],"2017-06-15","2018-03-13","2017-03-06",[6935],[6935,6958],"Tetanus Toxoid",{"intervention":6958,"totalTrials":143,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6967,"PHASE4":6969,"NA":6971},{"trials":6962,"activeCount":101},[],{"trials":6964,"activeCount":101},[],{"trials":6966,"activeCount":101},[],{"trials":6968,"activeCount":101},[],{"trials":6970,"activeCount":101},[],{"trials":6972,"activeCount":101},[6973],{"nctId":6950,"briefTitle":6951,"status":111,"phases":6974,"primaryCompletion":6953,"completion":6954,"start":6955,"enrollment":379,"conditions":6975,"interventions":6976},[],[6935],[6935,6958],{"intervention":6978,"totalTrials":143,"cells":6979},"Oestrogen Patches",{"EARLY_PHASE1":6980,"PHASE1":6982,"PHASE2":6984,"PHASE3":6986,"PHASE4":6988,"NA":6990},{"trials":6981,"activeCount":101},[],{"trials":6983,"activeCount":101},[],{"trials":6985,"activeCount":101},[],{"trials":6987,"activeCount":101},[],{"trials":6989,"activeCount":101},[],{"trials":6991,"activeCount":101},[6992],{"nctId":6993,"briefTitle":6994,"status":367,"phases":6995,"primaryCompletion":6996,"completion":6996,"start":3644,"enrollment":101,"conditions":6997,"interventions":6998},"NCT01691976","Mild Cognitive Impairment in Men Following Androgen Deprivation",[93],"2013-12",[699],[6978,6999],"LHRHa",{"intervention":6999,"totalTrials":143,"cells":7001},{"EARLY_PHASE1":7002,"PHASE1":7004,"PHASE2":7006,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":7003,"activeCount":101},[],{"trials":7005,"activeCount":101},[],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"trials":7011,"activeCount":101},[],{"trials":7013,"activeCount":101},[7014],{"nctId":6993,"briefTitle":6994,"status":367,"phases":7015,"primaryCompletion":6996,"completion":6996,"start":3644,"enrollment":101,"conditions":7016,"interventions":7017},[93],[699],[6978,6999],{"intervention":7019,"totalTrials":143,"cells":7020},"Sanger and\u002For Next Generation Sequencing",{"EARLY_PHASE1":7021,"PHASE1":7023,"PHASE2":7025,"PHASE3":7027,"PHASE4":7029,"NA":7031},{"trials":7022,"activeCount":101},[],{"trials":7024,"activeCount":101},[],{"trials":7026,"activeCount":101},[],{"trials":7028,"activeCount":101},[],{"trials":7030,"activeCount":101},[],{"trials":7032,"activeCount":101},[7033],{"nctId":7034,"briefTitle":7035,"status":952,"phases":7036,"primaryCompletion":7037,"completion":7037,"start":348,"enrollment":1157,"conditions":7038,"interventions":7046},"NCT03589079","Delineation of Novel Monogenic Disorders in the United Arab Emirates Population",[],"2021-01",[7039,7040,7041,7042,7043,7044,7045],"Mendelian Disorders","Genetic Disorder","Novel Mutation","Hereditary Disorder","De Novo Mutation","Inherited Disease","Single-Gene Defects",[7019],{"intervention":7048,"totalTrials":143,"cells":7049},"Aldosterone Antagonist",{"EARLY_PHASE1":7050,"PHASE1":7052,"PHASE2":7054,"PHASE3":7056,"PHASE4":7058,"NA":7060},{"trials":7051,"activeCount":101},[],{"trials":7053,"activeCount":101},[],{"trials":7055,"activeCount":101},[],{"trials":7057,"activeCount":101},[],{"trials":7059,"activeCount":101},[],{"trials":7061,"activeCount":101},[7062],{"nctId":7063,"briefTitle":7064,"status":367,"phases":7065,"primaryCompletion":7066,"completion":7067,"start":7037,"enrollment":101,"conditions":7068,"interventions":7072},"NCT04556279","Investigating Salt Taste Threshold in Patients Being Investigated for Primary Hyperaldosteronism Before and After Treatment.",[],"2022-02","2022-03",[7069,1565,7070,7071],"Hyperaldosteronism; Primary","Salt; Excess","Appetite Disorders",[7048],{"intervention":7074,"totalTrials":143,"cells":7075},"salbutamol + ipratropium bromide nebules",{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7080,"PHASE3":7082,"PHASE4":7084,"NA":7086},{"trials":7077,"activeCount":101},[],{"trials":7079,"activeCount":101},[],{"trials":7081,"activeCount":101},[],{"trials":7083,"activeCount":101},[],{"trials":7085,"activeCount":101},[],{"trials":7087,"activeCount":101},[7088],{"nctId":7089,"briefTitle":7090,"status":264,"phases":7091,"primaryCompletion":7092,"completion":7092,"start":3337,"enrollment":97,"conditions":7093,"interventions":7094},"NCT00180843","Assessment of Ventilation-perfusion Abnormalities in Patients With Stable Smoking-related Airways Disease",[93],"2008-02",[28],[7074,7095],"nebulized saline",{"intervention":7095,"totalTrials":143,"cells":7097},{"EARLY_PHASE1":7098,"PHASE1":7100,"PHASE2":7102,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7099,"activeCount":101},[],{"trials":7101,"activeCount":101},[],{"trials":7103,"activeCount":101},[],{"trials":7105,"activeCount":101},[],{"trials":7107,"activeCount":101},[],{"trials":7109,"activeCount":101},[7110],{"nctId":7089,"briefTitle":7090,"status":264,"phases":7111,"primaryCompletion":7092,"completion":7092,"start":3337,"enrollment":97,"conditions":7112,"interventions":7113},[93],[28],[7074,7095],{"intervention":7115,"totalTrials":143,"cells":7116},"Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon",{"EARLY_PHASE1":7117,"PHASE1":7119,"PHASE2":7121,"PHASE3":7123,"PHASE4":7125,"NA":7127},{"trials":7118,"activeCount":101},[],{"trials":7120,"activeCount":101},[],{"trials":7122,"activeCount":101},[],{"trials":7124,"activeCount":101},[],{"trials":7126,"activeCount":101},[],{"trials":7128,"activeCount":101},[7129],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7132,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7135,"interventions":7137},"NCT01935791","Investigating Brown Adipose Tissue Activation in Humans",[93],"2018-11-05","2013-07",[7136],"Metabolic Diseases",[7115,7138,7139,7140,7141,7142,7143],"Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control","Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control","Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon","Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control","Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control","Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon",{"intervention":7138,"totalTrials":143,"cells":7145},{"EARLY_PHASE1":7146,"PHASE1":7148,"PHASE2":7150,"PHASE3":7152,"PHASE4":7154,"NA":7156},{"trials":7147,"activeCount":101},[],{"trials":7149,"activeCount":101},[],{"trials":7151,"activeCount":101},[],{"trials":7153,"activeCount":101},[],{"trials":7155,"activeCount":101},[],{"trials":7157,"activeCount":101},[7158],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7159,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7160,"interventions":7161},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7139,"totalTrials":143,"cells":7163},{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7168,"PHASE3":7170,"PHASE4":7172,"NA":7174},{"trials":7165,"activeCount":101},[],{"trials":7167,"activeCount":101},[],{"trials":7169,"activeCount":101},[],{"trials":7171,"activeCount":101},[],{"trials":7173,"activeCount":101},[],{"trials":7175,"activeCount":101},[7176],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7177,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7178,"interventions":7179},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7140,"totalTrials":143,"cells":7181},{"EARLY_PHASE1":7182,"PHASE1":7184,"PHASE2":7186,"PHASE3":7188,"PHASE4":7190,"NA":7192},{"trials":7183,"activeCount":101},[],{"trials":7185,"activeCount":101},[],{"trials":7187,"activeCount":101},[],{"trials":7189,"activeCount":101},[],{"trials":7191,"activeCount":101},[],{"trials":7193,"activeCount":101},[7194],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7195,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7196,"interventions":7197},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7141,"totalTrials":143,"cells":7199},{"EARLY_PHASE1":7200,"PHASE1":7202,"PHASE2":7204,"PHASE3":7206,"PHASE4":7208,"NA":7210},{"trials":7201,"activeCount":101},[],{"trials":7203,"activeCount":101},[],{"trials":7205,"activeCount":101},[],{"trials":7207,"activeCount":101},[],{"trials":7209,"activeCount":101},[],{"trials":7211,"activeCount":101},[7212],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7213,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7214,"interventions":7215},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7142,"totalTrials":143,"cells":7217},{"EARLY_PHASE1":7218,"PHASE1":7220,"PHASE2":7222,"PHASE3":7224,"PHASE4":7226,"NA":7228},{"trials":7219,"activeCount":101},[],{"trials":7221,"activeCount":101},[],{"trials":7223,"activeCount":101},[],{"trials":7225,"activeCount":101},[],{"trials":7227,"activeCount":101},[],{"trials":7229,"activeCount":101},[7230],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7231,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7232,"interventions":7233},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7143,"totalTrials":143,"cells":7235},{"EARLY_PHASE1":7236,"PHASE1":7238,"PHASE2":7240,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7237,"activeCount":101},[],{"trials":7239,"activeCount":101},[],{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":101},[],{"trials":7245,"activeCount":101},[],{"trials":7247,"activeCount":101},[7248],{"nctId":7130,"briefTitle":7131,"status":111,"phases":7249,"primaryCompletion":7133,"completion":7133,"start":7134,"enrollment":37,"conditions":7250,"interventions":7251},[93],[7136],[7115,7138,7139,7140,7141,7142,7143],{"intervention":7253,"totalTrials":143,"cells":7254},"Aprotinin",{"EARLY_PHASE1":7255,"PHASE1":7257,"PHASE2":7259,"PHASE3":7261,"PHASE4":7263,"NA":7265},{"trials":7256,"activeCount":101},[],{"trials":7258,"activeCount":101},[],{"trials":7260,"activeCount":101},[],{"trials":7262,"activeCount":101},[],{"trials":7264,"activeCount":101},[],{"trials":7266,"activeCount":101},[7267],{"nctId":7268,"briefTitle":7269,"status":111,"phases":7270,"completion":7271,"start":7272,"enrollment":989,"conditions":7273,"interventions":7276},"NCT00131040","Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass",[93],"2005-06","2003-01",[7274,7275],"Ischemic Heart Disease","Angina Pectoris",[7253],{"intervention":7278,"totalTrials":143,"cells":7279},"Anti-Arrhythmic therapy",{"EARLY_PHASE1":7280,"PHASE1":7282,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7290},{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[],{"trials":7285,"activeCount":101},[],{"trials":7287,"activeCount":101},[],{"trials":7289,"activeCount":101},[],{"trials":7291,"activeCount":101},[7292],{"nctId":7293,"briefTitle":7294,"status":111,"phases":7295,"primaryCompletion":7296,"completion":7297,"start":7298,"enrollment":7299,"conditions":7300,"interventions":7302},"NCT02459574","Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation",[93],"2018-09-30","2018-11-27","2015-05-01",321,[22,7301],"Recurrent Atrial Fibrillation",[7278],{"intervention":7304,"totalTrials":143,"cells":7305},"Nebivolol",{"EARLY_PHASE1":7306,"PHASE1":7308,"PHASE2":7310,"PHASE3":7312,"PHASE4":7314,"NA":7316},{"trials":7307,"activeCount":101},[],{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[],{"trials":7313,"activeCount":101},[],{"trials":7315,"activeCount":101},[],{"trials":7317,"activeCount":101},[7318],{"nctId":7319,"briefTitle":7320,"status":111,"phases":7321,"primaryCompletion":7322,"completion":7322,"start":6419,"enrollment":1260,"conditions":7323,"interventions":7324},"NCT00125853","The Effect of Nebivolol on Insulin Sensitivity",[93],"2009-01",[1565],[7304,7325],"Atenolol",{"intervention":7325,"totalTrials":143,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7334,"PHASE4":7336,"NA":7338},{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[],{"trials":7333,"activeCount":101},[],{"trials":7335,"activeCount":101},[],{"trials":7337,"activeCount":101},[],{"trials":7339,"activeCount":101},[7340],{"nctId":7319,"briefTitle":7320,"status":111,"phases":7341,"primaryCompletion":7322,"completion":7322,"start":6419,"enrollment":1260,"conditions":7342,"interventions":7343},[93],[1565],[7304,7325],{"intervention":7345,"totalTrials":143,"cells":7346},"Baclofen 10mg",{"EARLY_PHASE1":7347,"PHASE1":7349,"PHASE2":7351,"PHASE3":7353,"PHASE4":7355,"NA":7357},{"trials":7348,"activeCount":101},[],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"trials":7356,"activeCount":101},[],{"trials":7358,"activeCount":101},[7359],{"nctId":7360,"briefTitle":7361,"status":111,"phases":7362,"primaryCompletion":3498,"completion":3498,"start":7134,"enrollment":452,"conditions":7363,"interventions":7366},"NCT01563224","GABA-B Receptor Function in Healthy Volunteers",[93],[7364,7365],"No Condition","Brain GABA-B Function",[7345,7367],"Baclofen 60mg",{"intervention":7367,"totalTrials":143,"cells":7369},{"EARLY_PHASE1":7370,"PHASE1":7372,"PHASE2":7374,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"trials":7377,"activeCount":101},[],{"trials":7379,"activeCount":101},[],{"trials":7381,"activeCount":101},[7382],{"nctId":7360,"briefTitle":7361,"status":111,"phases":7383,"primaryCompletion":3498,"completion":3498,"start":7134,"enrollment":452,"conditions":7384,"interventions":7385},[93],[7364,7365],[7345,7367],{"intervention":7387,"totalTrials":143,"cells":7388},"predisolone",{"EARLY_PHASE1":7389,"PHASE1":7391,"PHASE2":7393,"PHASE3":7395,"PHASE4":7397,"NA":7399},{"trials":7390,"activeCount":101},[],{"trials":7392,"activeCount":101},[],{"trials":7394,"activeCount":101},[],{"trials":7396,"activeCount":101},[],{"trials":7398,"activeCount":101},[],{"trials":7400,"activeCount":101},[7401],{"nctId":7402,"briefTitle":7403,"status":264,"phases":7404,"completion":7405,"start":7271,"enrollment":379,"conditions":7406,"interventions":7407},"NCT00159354","Measurement of Smoking-Induced Neutrophil Activation",[93],"2006-12",[25],[7387],{"intervention":7409,"totalTrials":143,"cells":7410},"anti-TNF therapy",{"EARLY_PHASE1":7411,"PHASE1":7413,"PHASE2":7415,"PHASE3":7417,"PHASE4":7419,"NA":7421},{"trials":7412,"activeCount":101},[],{"trials":7414,"activeCount":101},[],{"trials":7416,"activeCount":101},[],{"trials":7418,"activeCount":101},[],{"trials":7420,"activeCount":101},[],{"trials":7422,"activeCount":101},[7423],{"nctId":7424,"briefTitle":7425,"status":111,"phases":7426,"primaryCompletion":1334,"completion":1334,"start":2044,"enrollment":7427,"conditions":7428,"interventions":7430},"NCT01060098","T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade",[],48,[6147,4181,7429],"Psoriatic Arthritis",[7409],{"intervention":7432,"totalTrials":143,"cells":7433},"Beta-lactam antibiotic",{"EARLY_PHASE1":7434,"PHASE1":7436,"PHASE2":7438,"PHASE3":7440,"PHASE4":7442,"NA":7444},{"trials":7435,"activeCount":101},[],{"trials":7437,"activeCount":101},[],{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[],{"trials":7445,"activeCount":101},[7446],{"nctId":7447,"briefTitle":7448,"status":111,"phases":7449,"primaryCompletion":7450,"completion":7450,"start":2866,"enrollment":1637,"conditions":7451,"interventions":7455},"NCT03033394","Beta-lactam Pharmacokinetics in Secondary Care",[],"2019-08-01",[7452,7453,7454],"Pharmacokinetics","Beta Lactam Adverse Reaction","Penicillin Allergy",[7432],{"intervention":7457,"totalTrials":143,"cells":7458},"linezolid",{"EARLY_PHASE1":7459,"PHASE1":7461,"PHASE2":7463,"PHASE3":7465,"PHASE4":7467,"NA":7469},{"trials":7460,"activeCount":101},[],{"trials":7462,"activeCount":101},[],{"trials":7464,"activeCount":101},[],{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[7471],{"nctId":7472,"briefTitle":7473,"status":111,"phases":7474,"primaryCompletion":7475,"completion":7475,"start":3337,"enrollment":7476,"conditions":7477,"interventions":7480},"NCT00501150","Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections",[93],"2007-06",211,[7478,7479],"Gram-positive Bacterial Infections","Staphylococcal Infections",[7457],{"intervention":7482,"totalTrials":143,"cells":7483},"Ferrous sulphate",{"EARLY_PHASE1":7484,"PHASE1":7486,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7485,"activeCount":101},[],{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[],{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[7496],{"nctId":7497,"briefTitle":7498,"status":952,"phases":7499,"primaryCompletion":1334,"completion":5551,"start":3499,"enrollment":26,"conditions":7500,"interventions":7501},"NCT01590134","The Efficacy and Safety of Iron Supplementation",[93],[36],[7482],{"intervention":7503,"totalTrials":143,"cells":7504},"Genetic analysis",{"EARLY_PHASE1":7505,"PHASE1":7507,"PHASE2":7509,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7506,"activeCount":101},[],{"trials":7508,"activeCount":101},[],{"trials":7510,"activeCount":101},[],{"trials":7512,"activeCount":101},[],{"trials":7514,"activeCount":101},[],{"trials":7516,"activeCount":101},[7517],{"nctId":7518,"briefTitle":7519,"status":111,"phases":7520,"primaryCompletion":7521,"completion":7521,"start":7522,"enrollment":7523,"conditions":7524,"interventions":7527},"NCT03211507","Idiopathic Pulmonary Fibrosis Job Exposures Study",[],"2019-10-05","2017-05-01",960,[7525,7526],"IPF","Idiopathic Pulmonary Fibrosis",[7503],{"intervention":6495,"totalTrials":143,"cells":7529},{"EARLY_PHASE1":7530,"PHASE1":7532,"PHASE2":7534,"PHASE3":7536,"PHASE4":7538,"NA":7540},{"trials":7531,"activeCount":101},[],{"trials":7533,"activeCount":101},[],{"trials":7535,"activeCount":101},[],{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[],{"trials":7541,"activeCount":101},[7542],{"nctId":6487,"briefTitle":6488,"status":111,"phases":7543,"primaryCompletion":6490,"completion":6490,"start":1587,"enrollment":6491,"conditions":7544,"interventions":7545},[93],[6465,6493],[6445,6495,6496],{"intervention":6496,"totalTrials":143,"cells":7547},{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7552,"PHASE3":7554,"PHASE4":7556,"NA":7558},{"trials":7549,"activeCount":101},[],{"trials":7551,"activeCount":101},[],{"trials":7553,"activeCount":101},[],{"trials":7555,"activeCount":101},[],{"trials":7557,"activeCount":101},[],{"trials":7559,"activeCount":101},[7560],{"nctId":6487,"briefTitle":6488,"status":111,"phases":7561,"primaryCompletion":6490,"completion":6490,"start":1587,"enrollment":6491,"conditions":7562,"interventions":7563},[93],[6465,6493],[6445,6495,6496],{"intervention":7565,"totalTrials":143,"cells":7566},"Aspirin 75mg",{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7571,"PHASE3":7573,"PHASE4":7575,"NA":7577},{"trials":7568,"activeCount":101},[],{"trials":7570,"activeCount":101},[],{"trials":7572,"activeCount":101},[],{"trials":7574,"activeCount":101},[],{"trials":7576,"activeCount":101},[],{"trials":7578,"activeCount":101},[7579],{"nctId":7580,"briefTitle":7581,"status":264,"phases":7582,"primaryCompletion":7583,"completion":7583,"start":7584,"enrollment":7585,"conditions":7586,"interventions":7587},"NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.",[93],"2021-11-30","2020-04-03",320,[6875],[7565,7588,7589,7590,7591],"Clopidogrel 75mg","Rivaroxaban 2.5 MG","Atorvastatin 40mg","Omeprazole 20mg",{"intervention":7588,"totalTrials":143,"cells":7593},{"EARLY_PHASE1":7594,"PHASE1":7596,"PHASE2":7598,"PHASE3":7600,"PHASE4":7602,"NA":7604},{"trials":7595,"activeCount":101},[],{"trials":7597,"activeCount":101},[],{"trials":7599,"activeCount":101},[],{"trials":7601,"activeCount":101},[],{"trials":7603,"activeCount":101},[],{"trials":7605,"activeCount":101},[7606],{"nctId":7580,"briefTitle":7581,"status":264,"phases":7607,"primaryCompletion":7583,"completion":7583,"start":7584,"enrollment":7585,"conditions":7608,"interventions":7609},[93],[6875],[7565,7588,7589,7590,7591],{"intervention":7589,"totalTrials":143,"cells":7611},{"EARLY_PHASE1":7612,"PHASE1":7614,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7613,"activeCount":101},[],{"trials":7615,"activeCount":101},[],{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[7624],{"nctId":7580,"briefTitle":7581,"status":264,"phases":7625,"primaryCompletion":7583,"completion":7583,"start":7584,"enrollment":7585,"conditions":7626,"interventions":7627},[93],[6875],[7565,7588,7589,7590,7591],{"intervention":7590,"totalTrials":143,"cells":7629},{"EARLY_PHASE1":7630,"PHASE1":7632,"PHASE2":7634,"PHASE3":7636,"PHASE4":7638,"NA":7640},{"trials":7631,"activeCount":101},[],{"trials":7633,"activeCount":101},[],{"trials":7635,"activeCount":101},[],{"trials":7637,"activeCount":101},[],{"trials":7639,"activeCount":101},[],{"trials":7641,"activeCount":101},[7642],{"nctId":7580,"briefTitle":7581,"status":264,"phases":7643,"primaryCompletion":7583,"completion":7583,"start":7584,"enrollment":7585,"conditions":7644,"interventions":7645},[93],[6875],[7565,7588,7589,7590,7591],{"intervention":7591,"totalTrials":143,"cells":7647},{"EARLY_PHASE1":7648,"PHASE1":7650,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7649,"activeCount":101},[],{"trials":7651,"activeCount":101},[],{"trials":7653,"activeCount":101},[],{"trials":7655,"activeCount":101},[],{"trials":7657,"activeCount":101},[],{"trials":7659,"activeCount":101},[7660],{"nctId":7580,"briefTitle":7581,"status":264,"phases":7661,"primaryCompletion":7583,"completion":7583,"start":7584,"enrollment":7585,"conditions":7662,"interventions":7663},[93],[6875],[7565,7588,7589,7590,7591],{"intervention":6433,"totalTrials":143,"cells":7665},{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7672,"PHASE4":7674,"NA":7676},{"trials":7667,"activeCount":101},[],{"trials":7669,"activeCount":101},[],{"trials":7671,"activeCount":101},[],{"trials":7673,"activeCount":101},[],{"trials":7675,"activeCount":101},[],{"trials":7677,"activeCount":101},[7678],{"nctId":6425,"briefTitle":6426,"status":111,"phases":7679,"primaryCompletion":6428,"completion":6428,"start":6429,"enrollment":6430,"conditions":7680,"interventions":7681},[93],[16],[3007,6433,6434,6435],{"intervention":6434,"totalTrials":143,"cells":7683},{"EARLY_PHASE1":7684,"PHASE1":7686,"PHASE2":7688,"PHASE3":7690,"PHASE4":7692,"NA":7694},{"trials":7685,"activeCount":101},[],{"trials":7687,"activeCount":101},[],{"trials":7689,"activeCount":101},[],{"trials":7691,"activeCount":101},[],{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[7696],{"nctId":6425,"briefTitle":6426,"status":111,"phases":7697,"primaryCompletion":6428,"completion":6428,"start":6429,"enrollment":6430,"conditions":7698,"interventions":7699},[93],[16],[3007,6433,6434,6435],{"intervention":6435,"totalTrials":143,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7708,"PHASE4":7710,"NA":7712},{"trials":7703,"activeCount":101},[],{"trials":7705,"activeCount":101},[],{"trials":7707,"activeCount":101},[],{"trials":7709,"activeCount":101},[],{"trials":7711,"activeCount":101},[],{"trials":7713,"activeCount":101},[7714],{"nctId":6425,"briefTitle":6426,"status":111,"phases":7715,"primaryCompletion":6428,"completion":6428,"start":6429,"enrollment":6430,"conditions":7716,"interventions":7717},[93],[16],[3007,6433,6434,6435],{"intervention":7719,"totalTrials":143,"cells":7720},"Imatinib",{"EARLY_PHASE1":7721,"PHASE1":7723,"PHASE2":7725,"PHASE3":7727,"PHASE4":7729,"NA":7731},{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[],{"trials":7728,"activeCount":101},[],{"trials":7730,"activeCount":101},[],{"trials":7732,"activeCount":101},[7733],{"nctId":7734,"briefTitle":7735,"status":111,"phases":7736,"primaryCompletion":3546,"completion":3546,"start":3466,"enrollment":7737,"conditions":7738,"interventions":7740},"NCT00632255","Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment",[],88,[615,7739],"Newly Diagnosed",[7719],{"intervention":7742,"totalTrials":143,"cells":7743},"Ferrous sulphate 200mg oral",{"EARLY_PHASE1":7744,"PHASE1":7746,"PHASE2":7748,"PHASE3":7750,"PHASE4":7752,"NA":7754},{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[],{"trials":7751,"activeCount":101},[],{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[7756],{"nctId":7757,"briefTitle":7758,"status":264,"phases":7759,"primaryCompletion":1586,"completion":1586,"start":7134,"enrollment":268,"conditions":7760,"interventions":7762},"NCT01908543","Iron Deficiency and Hereditary Haemorrhagic Telangiectasia",[93],[7761],"Hereditary Haemorrhagic Telangiectasia",[7742],{"intervention":7764,"totalTrials":143,"cells":7765},"Immunization",{"EARLY_PHASE1":7766,"PHASE1":7768,"PHASE2":7770,"PHASE3":7772,"PHASE4":7774,"NA":7776},{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"trials":7771,"activeCount":101},[],{"trials":7773,"activeCount":101},[],{"trials":7775,"activeCount":101},[],{"trials":7777,"activeCount":101},[7778],{"nctId":7779,"briefTitle":7780,"status":111,"phases":7781,"primaryCompletion":7782,"completion":7782,"start":7783,"enrollment":1260,"conditions":7784,"interventions":7787},"NCT04515368","A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity",[93],"2020-09-03","2016-06-10",[7785,7786],"Positron-Emission Tomography","Immunization Reaction",[7764],{"intervention":7789,"totalTrials":143,"cells":7790},"Actrapid insulin+Gloucose",{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7795,"PHASE3":7797,"PHASE4":7799,"NA":7801},{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[],{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[],{"trials":7800,"activeCount":101},[],{"trials":7802,"activeCount":101},[7803],{"nctId":7804,"briefTitle":7805,"status":264,"phases":7806,"primaryCompletion":7807,"completion":7807,"start":7322,"enrollment":611,"conditions":7808,"interventions":7809},"NCT01213563","Management of Type 2 Diabetes After Gastric Bypass Surgery",[93],"2010-09",[6572],[7789,7810],"Actrapid insulin",{"intervention":7810,"totalTrials":143,"cells":7812},{"EARLY_PHASE1":7813,"PHASE1":7815,"PHASE2":7817,"PHASE3":7819,"PHASE4":7821,"NA":7823},{"trials":7814,"activeCount":101},[],{"trials":7816,"activeCount":101},[],{"trials":7818,"activeCount":101},[],{"trials":7820,"activeCount":101},[],{"trials":7822,"activeCount":101},[],{"trials":7824,"activeCount":101},[7825],{"nctId":7804,"briefTitle":7805,"status":264,"phases":7826,"primaryCompletion":7807,"completion":7807,"start":7322,"enrollment":611,"conditions":7827,"interventions":7828},[93],[6572],[7789,7810]]